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ABSTRACT 
 
Adiponectin is one of the most abundant circulatory hormone that plays an important role on 
homeostasis of glucose and lipid, oxidative stress, and inflammation by enhancing insulin sensitivity. 
It is highly implicated to pathogenesis of metabolic syndrome. This thesis examined: (study 1) 
glucocorticoids effect on adiponectin flux by regulation of permeability and its mechanism involved, 
(study 2) impact of high glucose on transendothelial movement of adiponectin and a whole-body 
biodistribution to understand functional significance, (study3) influence of iron overload on 
endothelial permeability of adiponectin to investigate the regulatory mechanism. 
Findings from study 1 indicated that glucocorticoids altered tight junction profiles that led 
to reduce endothelial paracellular permeability and to decrease adiponectin contents in rat skeletal 
muscle. In study 2, the data demonstrated that hyperglycemia decreased vascular permeability and 
resulted in increased adiponectin transendothelial movement, which observations were tested by 
multifaceted vasculature platforms in vivo, ex vivo and 2D & 3D in vitro with high glucose treatment. 
Lastly, study 3 showed that iron overload induced oxidative stress and altered tight junction 
expression to elevate permeability of endothelial monolayers. This increased adiponectin movement 
across the endothelial barrier. 
In summary, my studies demonstrated that adiponectin transendothelial movement was 
regulated by vascular permeability. The alteration of permeability relied on expression of tight 
junction and its regulatory mechanism resulted from diabetic conditions.   
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CHAPTER ONE: INTRODUCTION 
 
1.1 METABOLIC SYNDROME AND PATHOPHYSIOLOGY 
 Metabolic syndrome is defined by a combination of medical issues including insulin 
resistance, excessive visceral fat, high triglycerides, low HDL cholesterol, dyslipidemia, 
hypertension, and hyperglycemia, putting individuals at high risk to develop diabetes and/or 
cardiovascular disease. Furthermore, metabolic syndrome is also highly associated with vascular risk.   
 
1.1.1 DIABETES MELLITUS 
Diabetes Mellitus is described as a chronic metabolic disease characterized by a loss of 
glucose homeostasis due to a lack of or impaired insulin production, secretion or action. The 
terminology of ‘Diabetes Mellitus’ comes from the Greek diabainein (‘to pass through’) or diabetes  
(‘siphon’) and meli (‘honey (urine)’), and was first defined and named in 400-230 BCE (199). This 
name is rooted in the fact that untreated Diabetes Mellitus patients suffer from symptoms including 
experiencing extreme thirst, frequent urination, dehydration, weight loss without intent, ketone 
bodies in the urine, urine with a sweet smell, and decreased vision or blindness, all associated with 
high blood glucose levels. In addition, untreated Diabetes Mellitus leads further comorbidities, for 
example, neuropathy with tingling or numbness in the hands or feet, artery damage with high risk of 
atherosclerosis, cardiovascular disease (CVD) or heart failure, and damage to the microvasculature 
resulting in reduced circulation (80). For millennia, Diabetes Mellitus has been a challenging disease 
in terms of resolving the root causes. The discovery of insulin in 1921, followed by commercialized 
medications including insulin and other glucose-lowering agents allowed for treatment of the disease, 
but do not address prevention. As such, the population of diagnosed Diabetes Mellitus patients has 
increased exponentially in the current era. According to the most updated records from Statistics 
Canada (Diabetes, 2017), the number of Canadian Diabetes Mellitus patients is 2.3 million (around 
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7.3% of population aged 12 and older). Following the IDF (International Diabetes Federation), they 
estimate that more than 600 million of the global population will be Diabetes Mellitus patients by 
2040 (270).  
 
1.1.2 PATHOPHYSIOLOGY OF DIABETES MELLITUS 
Diabetes Mellitus is well known as the most common heterogeneous disease which has 
several etiologies (125). It has been reported that the Diabetes Mellitus is imputed by combination 
of risk factors including both genetic (e.g., family history) and environment (e.g., age, physical 
inactivity, dietary habits, BMI (obesity), stress, gender, hormonal changes, inflammation, 
complications associated with medications or surgery, etc) (39). In general, Diabetes Mellitus is 
categorized into three major types; Type 1 Diabetes Mellitus (T1DM), Type 2 Diabetes Mellitus 
(T2DM) and Gestational Diabetes Mellitus (GDM). The most prevalent type of diabetes is T2DM, 
which accounts for >90% of cases. T1DM follows as the second most common type, at 5-10% of the 
population of diabetic patients. GDM is distinct in that it is a temporary condition that occurs during 
pregnancy in approximately 5.5% of total births. Different physiological processes cause T1DM and 
T2DM. T1DM is an autoimmune disease. Pancreatic beta cells are destroyed by abnormal 
autoimmunity in T1DM, and subsequent insulinopenia eventually leads to hyperglycemia. On the 
other hand, T2DM is an endocrine disorder that results in a chronic imbalance of glucose homeostasis 
due to insulin resistance. At the early stages of T2DM development, blood glucose is observed to be 
in the normal range, and its metabolism looks undistorted. However, the circulating level of insulin 
increases to compensate for insulin resistance (hyperinsulinemia),. As the disease progresses, 
depending on the individual, genetic susceptibility and risk factors from the environment trigger 
pancreatic beta cell dysfunction. They often experience defects in insulin regulation due to beta cell 
damage, for example, producing insufficient insulin or delaying insulin secretion. Thus, the impaired 
insulin sensitivity in T2DM combined with insufficient insulin release impacts on glucose uptake 
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and leads patients to suffer chronic hyperglycemia, not only in the postprandial phase but also after 
fasting. 
 
1.2 MECHANISMS OF DIABETES MELLITUS 
1.2.1 INSULIN RESISTANCE 
Insulin resistance is defined as a condition of impaired cellular responses to insulin, a 
circulating hormone secreted from pancreatic beta cells. The cellular response is activated by insulin 
binding to its heterodimer receptor, insulin receptor (IR), in insulin-target tissues (166), and followed 
by activation of an intracellular signaling cascade. To determine change in insulin signaling, 
activation of Akt by phosphorylation (Ser473) is mainly quantified (262). Alterations in Akt activity 
have been experimentally observed in Diabetes Mellitus subjects, not only T2DM animal models, 
but also T1DM (236, 293, 320, 321). It has been well established that T2DM is tightly associated 
with obesity, metabolic syndrome and subsequent insulin resistance (88). The insulin resistance is 
observed in tissues in which glucose uptake is mediated by insulin, for example, brain, liver, skeletal 
muscle, and adipose tissue. Skeletal muscle is particularly important in this context, as it accounts 
for 75-80% of insulin-stimulated glucose uptake (60). However, insulin resistance is also associated 
with diabetic complications in numerous other tissues leading to various pathologies (264, 293). In 
the case of nephropathy, impaired insulin signaling leads to a decrease in glucose uptake by the 
kidney. Reduced insulin signaling and associated glucose uptake causes the liver to recognize the 
body as having low glucose availability, triggering aberrant glucose production via gluconeogenesis 
or glycogenolysis. Impaired insulin-mediated suppression of lipolysis also causes mobilization of 
free fatty acids (FFA) from adipose tissue. Systemic accumulation of FFAs and excess glucose 
(hyperglycemia) exacerbates the failing insulin secretion and response mechanisms, ultimately 
causing diabetes and its complications. Indeed, the loss of insulin action makes changes in molecular 
localization and expression level of GLUTs (glucose transporters) and SGLTs (sodium-glucose 
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linked transporters). (74, 167, 195, 284, 322) Thus, insulin resistance has been considered as an 
important mechanism in the development of Diabetes Mellitus. 
 
1.2.2 COMPENSATORY HYPERINSULINEMIA 
In 1966, the Fraser group observed significantly increased plasma insulin levels in 19 non-
diabetic patients who had essential hypertension as compared to a group of normotensive controls 
(292). Around 25 years later, these findings were replicated by other groups, which supported the 
observation of hyperinsulinemia along with hypertension, although there was no change in glucose 
levels. Intrestingly, plasma insulin highly increased during oral glucose tolerance test (OGTT) or 
intravenous glucose tolerance test (IVGTT) in hypertensive individuals as well (77, 162, 176, 206, 
237, 253). From the follow up studies, it was concluded that insulin resistance and compensatory 
hyperinsulinemia is a risk factor for CVD (120, 216, 240). As described above, we currently 
understand that insulin resistance can lead to compensatory hyperinsulinemia to control insulin-
mediated glucose uptake from the blood stream, and that ultimately insulin resistance can develop 
into overt Diabetes Mellitus without appropriate treatment (215). 
Glucocorticoids (GCs) are a medication widely used as the first line therapy for inflammation 
and autoimmune diseases. More than 1% of the population is prescribed glucocorticoids on any one 
day for the treatment of inflammation, cancer, or respiratory diseases. Older individuals (70-79yrs) 
have especially high rates of GC treatment, accounting for around 2.5% of this population (275). 
Unfortunately, this powerful medication shows detrimental effects on pre-diabetic patients, as it 
increases insulin resistance (105, 274). GCs are a class of steroid hormone. It was reported in rat and 
mouse animal models that excess GCs lowered insulin sensitivity and resulted in hyperinsulinemia 
(215). In addition, overexposure of GCs leads to increased adipose tissue at visceral and trunk sites 
(86). In adipose tissue, impaired insulin signaling cannot suppress lipolysis and cannot increase 
glucose uptake. Similarly, glucose uptake was downregulated in muscle. In the liver, GC overload 
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caused a failure of inhibition of gluconeogenesis and glycogenolysis. As a result of these alterations, 
circulating glucose and free fatty acids increased and energy metabolism shifted at a level of 
mitochondrial oxidation.(87) 
Dexamethasone is the primary prescribed drug for GC therapy, and some patients experience 
side effects from overexposure of this exogenous GC based on dose and/or duration of treatment. On 
the other hand, Cortisol is a steroid hormone that is produced de novo by the adrenal cortex under 
stress conditions. Although endogenous GC overexposure is rare, it is categorized as a chronic 
endocrine disorder (209). Overall, GCs overexposure by either endogenous or exogenous GCs is 
named Cushing Syndrome. Without treatment, Cushing Syndrome alters cortisol circadian rhythm, 
activates the hypothalamic-pituitary-adrenal (HPA) axis, and increases adipose tissue (obesity) with 
the development of insulin resistance. (16, 87, 228, 250) 
 
1.2.3 HYPERGLYCEMIA; FAILURE OF GLUCOSE CONTROL 
Hyperglycemia, a chronic elevation of blood glucose due to a failure of glucose control, is 
seen in the major two types of diabetes patients. In the progression of diabetes, the most effective 
way to reduce the risk of vascular complications is by controlling glucose levels (1, 62). Because 
T1DM is a condition of systemic insulin deficiency, patients have insulin dependency. Additionally, 
half of T2DM patients eventually require insulin therapy. Studies show the importance of glucose 
control with exogenous insulin therapy in experimental diabetic models. In a study of insulin infusion 
into T1DM subjects to improve glucose control (203), the therapy prevented microvascular and 
macrovascular complications (62, 256, 302). Further, pancreatic islet transplants also have a 
protective effect against the development of complications (94). 
There are some clinical intervention strategies for hyperglycemia. Before starting 
medications, life style modification and setting the individual hemoglobin A1C (HbA1c) target are 
required for patients because the most urgent clinical goal is lowering plasma glucose levels. The 
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lifespan of red blood cell is around 2~3 months (varying between 70 and 140 days) (49), and the 
HbA1c measures the glycated hemoglobin within red blood cells, thus reflecting the glucose levels 
over the previous 2 - 3 months (224, 225). The normal range of HbA1c is 4 - 5.6%, while an HbA1c 
of 6.5% is the diagnostic threshold (232). If the HbA1c is above the threshold, there are numerous 
pharmaceutical agents to reduce glycemia though various targets and mechanisms; (1) Agents for 
enhancing insulin secretion from the pancreas (e.g., sulfonylureas (1), glucagon-like peptide-1 
receptor (GLP-1R) agonist (97), dipeptidyl peptidase-IV (DPP-IV) inhibitor (207)). (2) Insulin 
sensitizing agents, which are commonly peroxisome proliferator-activated receptor gamma (PPARg) 
activators or agonists (e.g., Thiazolidinediones (TZD) (150), metformin (115)). (3) Anti-
hyperglycemic drugs that directly eliminate glucose from the bloodstream (e.g., Inhibitors of sodium-
dependent glucose transporter 2 (SGLT2) (164, 273)). 
 
1.2.4 REDOX IMBALANCE AND OXIDATIVE STRESS 
1.2.4.1 ABERRANT ENERGY PRODUCTION; MITOCHONDRIAL DAMAGE 
In general, once cells uptake glucose, energy production starts from the process of glycolysis 
that produces two pyruvate and two net ATP per one molecule of glucose via anaerobic metabolism 
(33). The pyruvate then moves into the mitochondria and is processed through oxidative 
decarboxylation to generate Acetyl-CoA for running the Kreb’s cycle. This if followed by oxidative 
phosphorylation via the electron transport chain (ETC) on the inner mitochondrial membrane. The 
mitochondrial ETC is composed of complexes I, II, III, IV, and V, as well as electron transporters 
coenzyme Q10 (CoQ10)/ubiquinone and cytochrome c (Cyt C). The electron flow tightly coupled 
via complexes I/III/IV or complex II/III/IV, which use NADH, FADH2 and oxygen to produce a 
proton gradient across the inner membrane. The built-up proton gradient is then used by complex 
V/ATP synthase to make ATP and H2O (328). When the cell uses fatty acids (FAs) or amino acids 
(AAs) as an energy source, the sources go through beta-oxidation and oxidative phosphorylation to 
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generate large amounts of chemical energy (eg. ~130 ATP/1 FA). The energy production in healthy 
cells is well managed, however, the cells in diabetes fail to control this energetic flux, resulting in 
impaired cellular energy generation (101).  
Many studies have demonstrated that hyperglycemia induces mitochondrial dysfunction by 
promoting fragmentation. Mitochondrial fragmentation is facilitated by DRP1 (GTPase Dynamin-
Related Protein 1, for fission) activation and MFN2 downregulation (GTPase Mitofusin 2, for fusion) 
regulated by signaling related to intracellular Ca2+ concentrations, CaMKII (calmodulin-dependent 
kinase II) and ERK 1/2 (extracellular signal-regulated kinase 1/2) activation (28, 246, 317). The 
induction of mitochondrial fragmentation, and prevention of fission, is closely associated with ROS 
(reactive oxygen species) overproduction that enhances DRP1-mediated fission (9). In the 
progression of diabetic complications, superoxide generation from the mitochondria is an early stage 
event, along with electron leakage to produce H2O2 instead of ATP, which usually happens at 
complex I (NADH dehydrogenase) and in between CoQ10 and complex III (36, 46, 52, 186, 221, 
238, 261, 272, 330). Importantly, uncoupling of the ETC not only generates excess ROS, but the loss 
of mitochondrial membrane potential also stops ATP production and generates heat instead of ATP 
in diabetic heart. This also slows intracellular glucose transport. In contrast, free fatty acid uptake is 
increased, which is postulated to be a compensatory mechanism for the loss of glucose metabolism. 
This has been repeatedly observed to be associated with vascular complications (2, 7, 35, 52, 78, 
220).  
 
1.2.4.2 OXIDATIVE STRESS 
Oxidative stress relies on the imbalance of cellular ROS production versus the capacity for 
cellular detoxification. The detoxification includes removing reactive intermediates from oxidative 
metabolism and repairing cellular damage from excessive ROS. In diabetes, especially in 
hyperglycemia, the causes of cellular oxidative stress are up-regulation of the sorbitol/polyol 
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pathway, protein glycosylation, and glucose autoxidation (290). Hexokinase plays an important role 
in glucose utilization by most cells and it is regulated by glucose-6-phosphate dehydrogenase 
(G6PDH), the rate limiting step for the pentose phosphate pathway (PPP) (33). The products of the 
PPP are the sources for the synthesis of nucleotides and aromatic amino acids, as well as NADPH, 
which gives the cell reducing power (69, 327). Under high glucose conditions, the flux of glucose 
metabolism is shifted to generate more NADPH via PPP activation, while at the same time the flux 
of the sorbitol pathway is increased. Sorbitol accumulates by activation of aldose reductase to convert 
NADPH to NADP+. Then, excess NADH by the following reaction of sorbitol dehydrogenase (SDH) 
would be the bundle for the mitochondrial ETC. Furthermore, the accumulated sorbitol also provides 
osmotic stress in cells. (69, 205) 
In addition to increases in NADPH and sorbitol under hyperglycemic conditions, because 
mitochondrial ROS inhibits GADPH activity, the reaction from frunctose-6-phosphate to UDP N-
acetylglucosamine by glutamine:fructose-6-phosphate amidotransferase (GFAT) is increased 
preferentially as compared to glycolysis (68). This enhances O-linked N-acetylglucosamine (O-
GlcNAc), which competes with serine/threonine phosphorylation of transcription factors to alter gene 
expression in diabetes. (68, 137, 227) 
 
1.2.5 IRON OVERLOAD  
Iron overload is one of the risk factors for diabetes, observed in clinical hereditary 
hemochromatosis (HH) cases. Among HH patients, approximately 60% of patients have a high risk 
of developing diabetes. (70, 297) The leading cause of HH is a homozygous HFE (human factors 
engineering) mutation at C282Y, followed by other less common mutations in iron metabolism-
related proteins, for example, TfR2 (transferrin receptor 2), HJV (hemojuvelin), and hepcidin (75, 
204). The mutation in HFE increases iron accumulation in several tissues. The alteration in iron 
metabolism due to excess iron uptake by tissues leads to a change in glucose homeostasis by affecting 
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insulin action and secretion. T2DM patients have been shown to have increased serum ferritin levels, 
which plays roles in iron storage, as well as acting as an iron carrier in plasma. Multiple animal 
studies have demonstrated the association between serum ferritin level and diabetes risk (41, 83, 116, 
117, 239). In addition, iron depletion by deferoxamine, an iron chelator, improved insulin resistance 
by increasing glucose uptake and insulin sensitivity (67).  
This close correlation between iron overload and diabetes risk is not fully understood. 
However, there are some suggested mechanisms. Iron overload may lead to diabetes by 1) causing 
insulin deficiency by inducing pancreatic beta cell failure, 2) promoting insulin resistance, and 3) 
inducing hepatic dysfunction mediated by insulin resistance.  Firstly, iron overload induces 
intracellular oxidative stress. Pancreatic beta cells are particularly susceptible to oxidative stress as 
there is a comparably weak antioxidative defense system in beta cells as compared to other tissues 
(151). The central role of beta cells is focused on glucose metabolism, including mitochondrial 
oxidative phosphorylation and glucose-induced insulin secretion. As energy is produced via 
mitochondrial metabolism in the beta cell, the occurrence of a redox imbalance from excess ROS 
leads to beta cell dysfunction, ultimately resulting in the reduction of insulin secretion (263). Next, 
iron overload is associated with insulin resistance in adipocytes and hepatocytes. A population study 
showed that increasing plasma ferritin levels correlate with insulin resistance of adipose tissue. In 
vitro, decreased glucose transport and adiponectin expression (a marker of an insulin sensitizer) was 
observed in adipocytes treated with iron. (66, 298) Above all, however, the strongest correlations 
with elevated serum ferritin levels are the induction of hepatic insulin resistance, increase in hepatic 
iron accumulation, as well as plasma levels of adiponectin (223). Cells have a compensatory 
mechanism to respond to high iron levels, in order to avoid the insulin resistance associated with 
systemic iron overload. This mechanism involves the upregulation of the iron hormone hepcidin via 
the iron-sensing pathway. Enhanced hepcidin production contributes to the control of up-taking 
nutritional iron, as well as releasing stored intracellular iron by inhibition of ferroportin (an iron 
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exporter). However, in the case of advanced liver injury, the hepatic dysfunction prevents the rapid 
regulation of hepcidin, and ultimately results in loss of iron control, resulting in hepatic iron 
accumulation (138). Overall, iron overload is thought to contribute to Diabetes Mellitus by impairing 
systemic insulin secretion and action. 
 
1.3 ADIPONECTIN 
Adiponectin is known as a circulating hormone derived from adipocytes. It is one of a series 
of adipokines such as leptin, interleukin-6, TNF-alpha, retinol-binding protein 4 (RBP4), and so on 
that are secreted into the bloodstream. Adiponectin is one of the most abundant proteins in the 
circulation of normal humans (3~30ug/mL), accounting for 0.01% of all plasma proteins (13). 
Adiponectin plays a pivotal role in the regulation of metabolism, especially in the conditions of 
obesity and diabetes. Previous research has shown that the level of adiponectin in serum has a 
negative correlation with aspects of metabolic syndrome (obesity and insulin resistance) and is 
associated with an increased risk of cardiovascular disease and diabetes. This section will review the 
current understanding of signaling mechanisms mediated by adiponectin, including its receptors and 
other downstream intracellular signaling proteins. Also, it will review the specific effects of 
adiponectin in target tissues. 
 
1.3.1 STRUCTURE OF ADIPONECTIN 
Adiponectin is a highly conserved protein which is encoded by the gene located on 
chromosome 3q27, which has been identified through genome-wide association studies as a diabetes 
susceptibility locus (133, 255). Adiponectin is composed of 244 amino acids has three main domains; 
a signal peptide, an N-terminal collagen-like fibrose region and C-terminal globular domain. The 
adiponectin sequence shares similarities with collagens X and VIII, and complement factor C1q. In 
addition, the C-terminal globular domain structure resembles the crystal structure of TNF- α, even 
 11 
though there is no similarity of primary sequences (235). There are two different types of functional 
adiponectin; full-length adiponectin (fAd) and globular adiponectin (gAd). The gAd is liberated by 
cleavage of fAd by leukocyte derived elastase to generate a C-terminal globular fragment of 
adiponectin which mediates important functional effects. Despite gAd being a shorter sequence of 
amino acids and structurally smaller than fAd, its potent metabolic effects are similar to fAd. But, 
importantly, the specific affinities for the two different adiponectin receptors are different. In animal 
studies to examine the role of gAd in the context of genetic obesity (leptin-deficient ob/ob), even 
though no change on the body weight of mice was observed, gAd overexpression ameliorated insulin 
resistance, beta cell degranulation, and diabetes by enhancing fatty acid oxidation (309). The 
adiponectinemia also raised lipid clearance and lipoprotein lipase activity and suppressed insulin-
mediated endogenous glucose production (51). Before secretion into bloodstream, adiponectin 
undergoes post-translational modification (PTM). A previous mass spectrometry (MS)-based study 
has mapped the PTM sites for adiponectin. Four proline residues are conserved for hydroxylation in 
the collagen domain, and five lysine residues are also conserved for hydroxylation and glycosylation 
subsequently (four sites in the collagen region and one site in the hyper-variable region) (286, 288). 
The PTM steps are involved in the binding to the putative adiponectin receptor T-cadherin, which is 
a glycosylphosphatidylinositol-linked cell-surface molecule (109). 
 
1.3.2 ADIPONECTIN OLIGOMERS  
Full-length adiponectin exists in the body as three oligomeric forms; LMW (low-molecular 
weight), MMW (medium-molecular weight) and HMW (high-molecular weight) isoforms. 
Monomeric adiponectin has not been detected in circulation under physiological conditions. (Fig 1.1) 
The LMW form is an adiponectin trimer, and is the basic building block for higher molecular 
weight forms. LMW adiponectin is formed by hydrophobic interactions between the globular regions 
of adiponectin and is stabilized by non-covalent interactions of the collagenous domains in a triple-
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helix stalk. The structure of the trimer is a ball-and-stick-like shape including a large globular sphere 
(269). The crystal structure of the globular domain was determined at a resolution of 2.1 Å (1 Å = 
0.1 nm) (235). 
The MMW form is hexameric adiponectin. MMW adiponectin is formed by two 
homotrimers by disulfide bond-mediated self-association. The cysteine residue in the adiponectin N-
terminal variable domain plays an essential role in the formation of a disulfide bond (Cys36 in human, 
Cys39 in mouse) (196, 268, 269, 285). MMW adiponectin was visualized by high-resolution electron 
microscopy as being Y shaped in structure (252). 
The HMW form is oligomeric adiponectin, though the structure is still poorly characterized. 
Through TEM (transmission electron microscopy), bovine HMW adiponectin was reported to be 
asymmetric bouquet-like in shape within a tight ring of octadecamers (13, 252). But the composition 
of human HMW adiponectin oligomers differs from those of rodents and cows. Human HMW 
adiponectin shows the range of oligomers as 18 – 30-mers or even larger (280) . 
Oligomerization of adiponectin is important not only for the structural properties, but also 
functional activity. For example, MMW and HMW forms from adiponectin mutants lacking the 
cysteine residue in N-terminal domain did not bind to the T-cadherin receptor. (109)  
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Figure 1.1. Adiponectin structure and oligomers 
The full-length adiponectin (fAd) gene encodes 244 AAs. The polypeptide is composed of several 
domains; a collagen-like fibrous domain (N-term) and a C1q-like globular domain (C-term). fAd 
has three different isoforms; LMW (trimer), MMW (hexamer) and HMW (oligomer). On the other 
hand, gAd (globular adiponectin) has only the globular domain (191).  
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1.3.3. RECEPTORS OF ADIPONECTIN 
Secreted and circulating adiponectin is distributed to target tissues. In target tissues, 
intracellular adiponectin signaling is mediated through adiponectin binding to receptors AdipoR1 
and AdipoR2, which are 7-transmembrane adiponectin receptor isomers with an internal N-terminus 
and an external C-terminus (307). AdipoR1 is found in several types of tissues, but especially 
abundant in skeletal muscle, whereas AdipoR2 is found commonly in liver (306). These adiponectin 
receptors show different affinities for the ligand types. Based upon the results of RNA interference 
of the receptor genes and affinity tests, AdipoR1 is high-affinity receptor for globular adiponectin, 
while AdipoR2 is low-affinity receptor for globular adiponectin. Conversely, AdipoR2 binds full-
length adiponectin with high affinity (123). The adiponectin receptors are highly conserved between 
human and mouse, with 96.8% of AdipoR1 and 95.3% of AdipoR2 sequence similarity (307) 
AdipoR1 and AdipoR2 are key players in the functional role of adiponectin with 
physiological and pathophysiological significance. Adiponectin receptors are involved in the 
regulation of several metabolic processes such as glucose and lipid metabolism, inflammation and 
oxidative stress. A functional study of adiponectin receptors showed that the mRNA expression level 
of AdipoR1 and AdipoR2 decreased in obese transgenic mice compared with wild type mice (310). 
Also, disruption of AdipoR1 and AdipoR2 inhibits aidponectin binding to these receptors, and 
eliminates the metabolic actions of adiponectin. Specifically, AMPK activation was decreased in the 
AdipoR1 KO mice, and in the AdipoR2 KO mice, PPARα signaling was reduced. Additionally, 
disruption of both adiponectin receptors increased tissue triglyceride accumulation, inflammation 
and oxidative stress markers at both mRNA and protein levels. It also induced insulin resistance and 
glucose intolerance. (310) 
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1.3.4 ADIPONECTIN SIGNALING 
Previous studies have shown (Fig 1.2) that adiponectin binding via AdipoR1 and AdipoR2 
mediated signal transduction, mainly through AMPK and PPARα pathways, resulting in increased 
insulin sensitivity (34, 59, 123), stimulation of fatty acid oxidation and glucose utilization (173), and 
mitochondria biogenesis (51, 114). Adiponectin also suppressed hepatic glucose production (173). It 
has also been reported that adiponectin has AdipoR1- and AdipoR2-activated ceramidase activity 
leading to antiapoptotic function (107, 122).  
After binding of adiponectin to its receptors, the very next molecule involved in signaling is 
APPL. APPL1 (phosphotyrosine interaction, PH domain, and leucine zipper containing 1) is an 
adaptor protein for adiponectin receptors (168). The phosphotyrosine binding domain (PTB) of 
APPL1 in its C-terminal site interacts with the N-terminal intracellular domain of AdipoR1 and 
AdipoR2. In contrast, APPL2 negatively regulates adiponectin signaling, producing a so-called Yin-
Yang regulation by APPL1-APPL2. In the basal condition, APPL2 occupies the intracellular N-
terminal of AdipoR1, at the same time, it interacts with APPL1 as an APPL1-APPL2 heterodimer. 
Thus, it interrupts the interaction between AdipoR1 and APPL1 as an adaptor protein, so adiponectin 
signaling is inhibited. However, once adiponectin signaling is stimulated by binding adiponectin to 
its receptors, APPL1 and APPL2 dissociate from each other and APPL1 is released. Then AdipoR1 
recruits APPL1, which is a limiting step for adiponectin signaling. APPL1 can activate several 
proteins involved in different signaling pathways by phosphorylation. For example, APPL1 regulates 
the LKB1/AMPK, MAPK, and PI3K/Akt pathways. PI3K/Akt are also components of the insulin 
signaling pathway. During the time that APPL1 is bound to APPL2 and inactivated, insulin signaling 
is inhibited by the active form of dephosphorylated S6K (217, 281). Other adaptor proteins for 
adiponectin receptors exist, but are not discussed here. 
AMPK (5'-AMP-activated protein kinase) belongs to a family of energy sensing enzymes 
and is a principal mediator of many of the effects of adiponectin. AMPK is activated in response to 
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and increase in the AMP/ATP ratio and by phosphorylation (98, 282). Upon activation of adiponectin 
signaling, the activity of AMPK is also directly regulated by adiponectin or adiponectin receptors in 
an APPL1-mediated manner. When extracellular adiponectin binds its cell surface receptors, Ca2+ 
influx increases and Ca2+/calmodulin-dependent protein kinase kinase β (CaMKK β) is activated to 
phosphorylate AMPK at the T172 site (114). LKB1 is also a kinase that activates AMPK, and 
adiponectin also promotes AMPK activation through promoting APPL1-dependent LKB1 cytosolic 
translocation (331). LKB1 deletion in the liver leads to increased blood glucose levels and impaired 
glucose tolerance (173). Additionally, AICAR is a small molecule that also can be used to increase 
pAMPK as a cell permeable activator (308). 
Activated AMPK cascades the signal to various downstream targets. Based on the ratio of 
NAD+/NADH, pAMPK activates SIRT1 to facilitate deacetylation of the transcription factor PGC-
1α to enhance mitochondrial biogenesis and related target gene expression (114). Furthermore, 
pAMPK induces phosphorylation of ACC (acetyl-CoA carboxylase) at site S79 and it leads to inhibit 
the ACC activation by cytosolic citrate, as an allosteric activator of ACC (129). This inactivation 
causes lowering concentration of malonyl-CoA, the product of ACC activity, which inhibits CPT1, 
the enzyme responsible for converting fatty acyl-CoA to acylcarnitine. Acylcarnitine is the first 
molecule involved in mitochondrial β-oxidation. In addition, pAMPK is also able to increase 
suppression of gluconeogenesis-related genes such as PEPCK (phosphoenolpyruvate carboxykinase) 
and G6Pase (glucose-6-phosphatase) downstream of adiponectin cues. Decreased gluconeogenesis 
affects both the AMP/ATP ratio as well as NAD+/NADH ratio (265). Thus, elevation in pAMPK 
leads to increased fatty acid oxidation, glucose uptake (51) and mitochondrial biogenesis (114). In 
contrast, blocking AMPK activation by dominant negative mutation shows opposite effects on these 
metabolic parameters (308).  
PPARs (peroxisomal proliferator-activated receptors) are a group of nuclear receptor 
proteins that act as transcription factors, regulating the expression of numerous genes, including the 
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adiponectin gene (171, 329). Adiponectin gene expression is regulated by binding of PPARs to PPRE 
(PPAR-responsive element) (329). Agonist treatment to activate PPARα leads to increased 
expression of both adiponectin and adiponectin receptors at the mRNA level. The effects on 
carbohydrate and lipid metabolism are also associated with elevated expression of PPARγ 
(peroxisomal proliferator-activated receptor gamma), caveolin-1, and mitochondrial markers in 
white adipose tissue (51).  
Finally, adiponectin signaling has different effects depending on the target tissue type. For 
instance, in skeletal muscle, both types of adiponectin (full-length and globular) can activate AMPK, 
but only full-length adiponectin is able to activate AMPK effectively in the liver (308). 
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Figure 1.2. Adiponectin Signaling via AdipoR1 and AdipoR2  
Adiponectin signaling is mediated by activation of two known receptors, AdipoR1 and AdipoR2. 
Uplon receptor activation, APPL1 is recruited to AdipoR1 and activates downstream signaling 
including PPARα, AMPK, AMPK/SIRT1, p38-MAPK, ERK1/2-MAPK, and Akt. APPL1 and 
APPL2 are controlled by Yin-Yang regulation. (281), (217) 
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1.4 ENDOTHELIAL MOVEMENT OF HORMONES 
1.4.1 STRUCTURE AND FUNCTION OF ENDOTHELIUM 
A monolayer of endothelial cells lines the entire circulatory system of the body. This 
endothelium acts as a barrier, which regulates the exchange of hormones, proteins and small 
molecules between the vascular compartment and the interstitial space (89, 208). The actions of a 
hormone or nutrient on a target tissue is implicitly dependent upon the ability of these factors to gain 
access to the tissue, and numerous studies have indicated that hormone and nutrient concentrations 
in blood differ from those surrounding cells on the tissue side of the blood vessel endothelium (18, 
30, 44, 45, 102, 136, 165, 245, 312). In this regard, it is our contention that the significance of the 
endothelium as a regulator of hormone and substrate access to target tissues is often underappreciated. 
Endothelial permeability can be regulated by two distinct pathways: 1) the transcellular pathway 
where solutes are actively transported across the endothelium, primarily via caveolae-mediated 
transcytosis; or 2) the paracellular pathway where solutes passively move through the intercellular 
space between adjacent endothelial cells. (Fig 1.3) 
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Figure 1.3. Routes of transendothelial transport. A schematic representation of paracellular and 
transcellular routes for transport of blood-borne hormones and solutes to interstitial space of 
underlying tissue. 
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1.4.2 TRANSCELLULAR TRANSPORT 
The transcellular movement of solutes involves energy-dependent trafficking of vesicles 
across the endothelium (89). This often requires their recognition by receptors in caveolae on the 
luminal surface of the endothelium, and may involve vesiculo-vacuolar organelles or occur via 
transcellular channels (89). Caveolae, cholesterol- and sphingolipid-rich non-clathrin-coated pits are 
abundant in endothelial cells. After ligand binding to receptors in caveolae, dynamin-mediated 
endocytosis occurs followed by vectorial transport and fusion of the vesicle with the basolateral 
membrane, resulting in the release of contents by exocytosis (89). As a general concept, transcellular 
vesicle trafficking is important in the transport of larger macromolecules across the endothelium 
since the paracellular route is typically capable of restricting passage of solutes larger than 3 nm in 
radius (95, 96). 
 
1.4.3 PARACELLULAR TRANSPORT 
The paracellular mode of transport across endothelia depends upon concentration gradients 
between blood and interstitial fluid. One regulatory mechanism of paracellular movement involves 
tight junctions (TJs), which are composed of strands of transmembrane and cytosolic proteins that 
closely control paracellular flux and have been established to be important in regulating hormone 
transport (96, 134, 136). As a component of the cell-cell junction of endothelia, the TJ provides a 
selective barrier to solute movement between cells (95). The permselectivity of the TJ barrier is 
dependent on the variable assemblage of TJ proteins that comprise the complex. Proteins such as 
occludin, tricellulin, and claudins directly establish the TJ barrier and form the backbone of TJ strands, 
while the cytosolic proteins, such as ZO-1, provide structural support to the TJ complex. The 
incorporation of specific TJ protein isoforms can enhance TJ barrier function (i.e., make TJs tighter) 
or form channels to increase TJ permeability (i.e., make TJs leakier) (95). Importantly, skeletal 
muscle and heart vasculature have a continuous endothelium with TJs between cells (5, 6). However, 
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the liver and spleen have a discontinuous endothelium with large holes, which allow rapid 
equilibration of plasma with the underlying tissue (5, 6). It was suggested that this expedited exposure 
of the liver to plasma solute changes may partly explain its earlier susceptibility to insulin resistance 
(132). Indeed, the precise architecture of TJs varies between different vascular beds, with TJs being 
either dominant at the apical point of intercellular space or intermingled with adherence junctions 
(AJs). Therefore, there is no doubt that transendothelial paracellular flux in certain vascular beds is 
more susceptible to changes in TJ composition and structure. Furthermore, changes in paracellular 
transport leading to endothelial hyperpermeability is a significant problem in vascular inflammation 
associated with diabetes, cancer, ischemia-reperfusion injury, thrombosis, trauma, sepsis, and T-
respiratory distress syndrome (144). Importantly, despite the tremendous interest in adipokines over 
recent years, very few studies have examined the critical step whereby factors secreted by adipose 
tissue, or other tissues, must enter the circulation via capillaries or lymph. Paracellular movement is 
very likely to be a major regulatory step in this process. Indeed, it has been demonstrated that 
lymph/capillary partitioning of adipokines is dependent upon their molecular size, and it has been 
proposed that this will have important ramifications for their regional and systemic distribution and 
subsequent physiological effects (172). 
It is also important to realize that crosstalk exists between 1) transcellular and paracellular 
routes of transport across endothelia and 2) TJs and AJs of endothelia. An example of the former is 
that in caveolin-1 knockout mice, or upon siRNA-mediated reduction of caveolin-1, altered TJ 
assembly in small capillaries and veins increased paracellular transport of albumin (175, 214, 230). 
In the latter case, it has been shown that vascular endothelial (VE)-cadherin mediated signaling can 
regulate the expression of TJ proteins and consequently alter barrier function (89). 
Indeed, evidence suggests that AJs also play a crucial role in regulating vascular permeability. 
They are comprised of calcium-dependent VE-cadherin in complex with a range of interacting 
partners, such as β-catenin and p120-catenin (89), and the expression of VE-cadherin is a specific 
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early developmental marker for the endothelial lineage. Deletion of the VE-cadherin gene induces 
embryonic lethality due to early collapse of the vasculature (92), and increased vascular permeability 
occurs when VE-cadherin homophilic binding is inhibited. AJ stability is also critically regulated by 
phosphorylation (89). More specifically, phosphorylation of VE-cadherin at catenin binding sites 
induced internalization and thus alterations in vascular permeability. Interestingly, recent work 
demonstrated that phosphorylation of these residues (Y658 and Y685 of VE-cadherin) occurs 
constitutively in veins but not arteries, correlating with enhanced leakiness in venous vessels (194). 
Furthermore, single point mutations in VE-cadherin (Y658F and Y685F) reduce paracellular 
permeability by blocking internalization of VE-cadherin (194). 
 
1.4.4 ENDOTHELIAL DYSFUNCTION IN DIABETES 
The concept of endothelial dysfunction in diabetes is well established (63). However, this 
typically refers to vascular functions independent of transendothelial solute flux. The endothelium is 
also a dynamic interface that responds to various stimuli and synthesizes and liberates vasoactive 
molecules such as nitric oxide, prostaglandins and endothelin. Accordingly, vascular complications 
in diabetes include outcomes occurring in large (atherosclerosis, cardiomyopathy) and small 
(retinopathy, nephropathy, neuropathy) vessels (254). Diabetes-induced deleterious alterations in 
paracellular solute movement also represents a form of endothelial dysfunction which should be fully 
characterized to establish its physiological significance. 
 
1.4.5 STUDIES ON TRANSENDOTHELIAL TRANSPORT OF HORMONES 
Transport of insulin has been perhaps the best studied example of transendothelial hormone 
transport. The concentration of insulin at the target cell surface has been shown to be very different 
from that in plasma by approaches including microdialysis (102, 245), direct interstitial sampling 
(30), and lymph measurements (45, 312). Furthermore, early temporal studies have demonstrated 
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that insulin-mediated glucose up-take in muscle lags behind increases in plasma insulin (81), In 
contrast, when using cultured skeletal muscle cells, the addition of recombinant insulin has been 
shown to stimulate glucose uptake almost immediately (maximal at ~10 minutes) (247). The time 
delay seen in vivo has led to the suggestion that reaching the interstitial space is the limiting factor 
for insulin-mediated glucose uptake (134). Thus, modification of access to skeletal muscle can have 
major effects on insulin action and subsequent metabolism (17, 134). Indeed, the efficiency and 
extent of insulin delivery to the interstitial space can be inhibited physiologically by diet (143). The 
mechanism via which insulin crosses the endothelium is at least in part via the paracellular pathway, 
and for more information on this topic readers are referred to recent excellent review articles by 
Kolka and Bergman (134, 135). 
Recent years have seen great interest in the role of adiponectin in the pathophysiology of 
diabetic complications (161, 229, 313). Numerous studies have now established that adiponectin can 
act on various targets to mediate antidiabetic, anti-inflammatory, anti-atherosclerotic, and 
cardioprotective effects (200, 229, 313). Thus, enhancing adiponectin action is considered as a 
therapeutically beneficial strategy. As described above, adiponectin circulates in the blood as three 
multimeric complexes; LMW (trimer), MMW (hexamer) and HMW (oligomer), and in obese and 
diabetic patients reduced circulating levels of adiponectin have been observed. It is likely that 
delivery of adiponectin to the interstitial space is a major, yet underestimated, determinant of its 
function. Given the size range of the biologically active forms of adiponectin (16 kDa for globular 
form and >500 kDa for HMW) there is considerable potential for selective paracellular transport of 
adiponectin, particularly in different vascular beds. HMW adiponectin is often considered to be the 
most biologically active and most relevant form with respect to the metabolic syndrome, and we 
speculate that given the large size of the HMW form, transendothelial movement may prove to be a 
significant rate-limiting step in its physiological actions (Fig 1.5). Indeed, it has been proposed that 
HMW adiponectin mediates beneficial metabolic effects primarily by acting on the liver (313), 
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whereas the globular form is thought to have more potent metabolic effects in skeletal muscle (161). 
These observations of tissue specificity could be explained by the leaky and moderately tight 
paracellular barriers, respectively, present in the vascular beds of these respective tissues, although 
this is likely an oversimplification (Fig. 1.4). As far as we are aware, no studies have directly 
examined the paracellular movement of adiponectin in skeletal muscle and liver. 
Studies of adiponectin movement across the blood-brain barrier (BBB) have indicated that 
only LMW and MMW, but not HMW forms were found in cerebral spinal fluid (142, 145, 185). 
Surprisingly, there are only a few studies examining interstitial adiponectin levels. One found that 
interstitial concentrations of adiponectin in human adipose tissue were ~25-fold lower than plasma 
(39) while the other found that exercise increased interstitial adiponectin levels, which were around 
20% of plasma concentration (106). We hypothesize that the magnitude of gradient between plasma 
and interstitial levels of adiponectin in skeletal muscle may be higher due to the existence of a tighter 
endothelial barrier within the muscle vasculature. Indeed, this may be highly significant as it has 
been shown that hyperinsulinemia differentially affects the compartmental (interstitial and 
circulating) distribution of the adiponectin complexes in lean and insulin-resistant, obese individuals 
(179). We have recently shown that adiponectin moves across cultured endothelial monolayers via a 
paracellular route and that this movement was reduced by hormonal or physical manipulation of TJs. 
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Figure 1.4. Diversity of paracellular transport characteristics in different vascular beds. The 
size and structure of tight junctions varies significantly between different tissues and in this figure 
we summarize this by defining three arbitrary categories of leaky, moderately tight and tight 
endothelia. The typical resistance values associated with these definitions and examples of tissues 
where each category of endothelium is characteristic is shown. N/A, not applicable. 
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1.4.6 TJ COMPOSITION AND PROTEIN EXPRESSION IN DIABETES 
Studies examining changes in TJ composition and protein expression in diabetes have not 
been extensive but have so far yielded numerous consistent observations in the study of diabetic 
complications. For example, reductions in ZO-1 have been observed in kidney glomeruli, the retina, 
BBB and intestine of various diabetic models (23, 158, 192, 234, 242). Localization of ZO-1 in 
glomeruli was also investigated by electron microscopy and found to redistribute from the podocyte 
membrane to the cytoplasm in the diabetic kidney (218). Several reports have indicated that both 
occludin and claudin-5 were reduced in the diabetic retina and BBB (12, 15, 23, 158, 242). Hence, 
expression or localization of TJ proteins appears to be susceptible to a diabetic environment and 
contribute to complications such as retinopathy and nephropathy. More widespread analysis is now 
needed, particularly in metabolically active tissues. Knockout mouse models have been generated 
for various TJ proteins, including occludin and claudin-1, 2, 4, 5, 7, 9, 11, 14, 15, 16, 18, and 19 (22, 
82, 85, 93, 100, 174, 180, 182, 187, 226, 257, 260, 279, 295). While little to no information is 
available regarding the metabolic phenotype of most of these models, one study using 
Cldn2−/−Cldn15−/− double-KO mice demonstrated that the animals died from malnutrition related 
to defective absorption of glucose, amino acids and fats (279). These models may prove valuable in 
elucidating the significance of alterations in transendothelial hormone flux in determining metabolic 
dysfunction in diabetes. 
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Figure 1.5. Paracellular movement of adiponectin. A conceptual model showing the potential 
significance of paracellular transendothelial movement of adiponectin. When vascular endothelium 
is leaky (left side) there is significant flux of all forms of adiponectin from bloodstream to interstitial 
space. However, as endothelium becomes tighter there is likely to be a gradient of decrease in high 
molecular weight or other multimeric forms of adiponectin whereas the smaller globular fragment of 
adiponectin may still be able to access underlying target tissue such as skeletal muscle. TJ, tight 
junctions; fAd, full length adiponectin; gAd, globular adiponectin. 
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1.4.7 THERAPEUTIC POTENTIAL OF TARGETING ENDOTHELIAL TRANSPORT 
Based on the above description of the importance of endothelial transport in diabetes, it is 
evident that developing therapeutic strategies that manipulate paracellular flux may prove useful. 
Indeed, a literature review indicates that various agents are already available; such as peptides which 
bind to integral TJ proteins, siRNA and antisense oligonucleotides targeting TJ proteins, various 
toxins, lipids, and activators or inhibitors of kinases and phosphatases that regulate junction assembly 
and function have all been shown to regulate paracellular permeability (91). Nevertheless, there is an 
innate risk in therapeutics which globally alter transendothelial permeability, and so it will be 
desirable to elicit changes in a localized or tissue specific manner, or to target specific components 
of TJs which allow more controlled and selective changes in permeability (61). One example of a 
current therapeutic approach targeting TJs is the use of glucocorticoids as a locally applied treatment 
for diabetic retinopathy. The mechanism of action is thought to involve, at least in part, restoration 
of barrier function in the retinal vasculature by modifying TJ composition and structure (76). 
Therefore, it is attractive to speculate that controlled manipulation of paracellular transport may be 
applicable to improving metabolic dysfunction in diabetes. 
 
1.5 MONITORING MODALITIES OF HORMONE MOVEMENT  
1.5.1 IN VIVO IMAGING AND APPLICATION 
Imaging technologies in biological research are increasingly becoming a keystone, which 
provide the chance to understand biological phenomena by bridging or closing the gap between 
research performed in vitro and in vivo. Modern approaches have surpassed the anatomical or 
functional imaging in conventional visualized manners by, for example, using radiological or 
illuminological tools. 
Tomography is imaging by sections or sectioning, through the use of any kind of penetrating 
wave. A device used in tomography is called a tomograph, while the image produced is a tomogram. 
 30 
After imaging and gathering the data projected from detectors, tomographic reconstruction is 
performed using a software algorithm processed by computer. There are several types of tomogram 
produced using different physical phenomena such as FMT, CT/SPECT, PET and MRI, etc. Here I 
will review the basic principles and applications in the biological research. 
 
1.5.1.1 FLUORESCENCE MOLECULAR TOMOGRAPHY / 
NEAR INFRA-RED FLUOROCHROME 
Fluorescence molecular tomography (FMT) is a non-invasive optical quantitative technique. 
FMT functions as a functional and molecular imaging modality to take volumetric two- or three-
dimensional images of the targeted fluorescent signals (188). 
The basic principle of FMT involves scanning an object and calculating the data from the 
object to digitally reconstruct it (189). The light sources of the object on the surface, and detectors 
used for each measured excitation/emission set (light source-detector pairs) provide a number of 
independent data samples. In 2D imaging mode, wide-field illumination corresponds to an infinite 
number of points of light sources because it is not mathematically possible to deconvolve the 
contribution of individual sources. Thus, it prevents 3D reconstruction of probe distribution on the 
object (188). However, a sequential scan of focal light sources in FMT makes it possible to measure 
each individual light source-detector pair, even though it also increases the expense of a prolonged 
measurement time (189, 190).  
FMT has shown advantages for use in in vivo imaging.  It is possible to perform time-course 
imaging in live animals without tissue depth limitations in small animals like mice and rats. At the 
time of imaging, small animals are anesthetized with a mixture of isoflorane and oxygen (276). FMT 
has a high sensitivity for detecting fluorescent signal, thus it is able to take images of the desired 
fluorescent probe at low concentrations, down to the picomolar level (46). Furthermore, the intensity 
of the fluorescent signal can be visualized systemically. In addition, using FMT it is also possible to 
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perform scans using multichannel lasers in the near infrared (NIR) spectrum (276). Because many 
fluorescent materials absorb in the visible region, but fewer do in the NIR region, NIR lasers are 
effective to prevent background fluorescence in many cases. Also NIR probes provide greater and 
more versatile access to fluorescent-imaging biomarkers (276).  
Recently, FMT has been applied to various biological research questions, because it 
functions in the assessment of disease progression and drug response at the molecular, cellular and 
target levels. These can be assessed by blood volume quantification, angiogenesis measurements, 
and tumor burden tracking, as examples. In tumor research, tumor size and angiogenesis level can be 
monitored and compared with anti-tumor or tumor-targeting drug carrier treatments to demonstrate 
efficacy (153, 178, 323). As a screening tool for assessing biodistribution of biologicals rapidly and 
cost effectively, FMT has powerful potential for use in the determination of pharmacokinetics, 
pharmacodynamics, targeting and clearance times and pathways (156, 276). To perform such 
research and visualize images through FMT, there are some commercial markers, such as fluorescent 
macromolecules, that are used to monitor specific processes. For example, probes that remain 
localized to the vasculature during angiogenesis, an apoptosis marker (annexin) which selectively 
binds phosphatidylserine exposed in the outer leaflet of the cell membrane during the early stages of 
apoptosis, cathepsins as a marker for a variety of disease states including inflammation and cancer 
(like autophagy), and matrix metalloproteinases (MMPs) as a marker of inflammation diseases and 
cancer. 
FMT equipment used to be liquid-based, and the sample had to be forced into a regular 
geometrical configuration of an index-matching cylinder filled with fluid because the liquid-based 
set up offered high sensitivity and high signal-to noise ratios. However, due to difficulties in handling 
of the liquid-based system, and non-natural positioning of the animal, a so-called non-contact scanner 
system was developed. In the non-contact system, an advanced theoretical framework and modeling 
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capacities were implemented, therefore, gantry based (149) and horizontal positioning of animal can 
now be performed (249). 
However, the performance of FMT is limited by the strong scattering of near-infrared 
photons (10, 177). It perturbs the ability of the information from the FMT to match the real signal 
from the body perfectly. Using extra anatomical information derived from the same orientation of 
animal positioning, it is possible to improve the reconstruction accuracy. Recently, these challenges 
have been addressed by developing additional tomography techniques to complement FMT and 
increase anatomical accuracy, such as MRI, X-ray CT and PET (10, 111, 152, 177). For instance, 
there are now 360 degree rotating scanning FMT approaches (147, 149), hybrid technology with 
FMT-MRI (152) and FMT-PCCT (177) which have been developed and applied to research. 
 
1.5.1.2 SINGLE-PHOTON EXCITATION COMPUTED TOMOGRAPHY 
X-ray Computed Tomography (CT or XCT) is a nondestructive technique for visualizing 
interior features within solid objects, and for obtaining digital information on their 3D geometries 
and properties.  
The fundamental theory of XCT consists of directing X-rays at an object from multiple 
orientations and measuring the decrease in intensity along a series of linear paths. Following Beer’s 
Law, intensity is reduced by a function of X-ray energy, path length, and the material linear 
attenuation coefficient. Using a specialized algorithm, reconstruction of the distribution of X-ray 
attenuation in the imaged volume is performed. In addition, the most CT X-ray detectors utilize 
scintillators. In general, smaller detectors provide better resolution for the image, but exhibit reduced 
count rates because of their reduced area compared to larger detectors. But, when acquisition time is 
extended to compensate, it is possible to reduce the noise levels. Common scintillation materials are 
cesium iodide, gadolinium oxysulfide, and sodium metatungstate (127).  
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In the case of hybrid implementations based on X-ray CT and FMT, a major limitation is the 
low soft-tissue contrast offered. In particular, bone, lung, and the tissue outline can be visualized 
with good contrast. But other internal organs and tissues are not visible with high contrast in X-ray 
CT images as they do not exhibit considerable absorption differences of X-ray photons (324).  
In single-photon emission computed tomography (SPECT), there have been recent 
improvements not only in the reliability and resolution, but also the construction of compact and 
novel detector geometries (110). It also offers reduced acquisition time or radiation dose and 
extended application (110). Thus, SPECT can be applied for organ-specific imaging of a broader 
range of tissues (29).  
 
1.5.1.3 POSITRON EMISSION TOMOGRAPHY 
Positron Emission Tomography (PET) is a modality used for the functional or metabolic 
assessment of tissue, which has been applied for research and diagnostics in the fields of neurology, 
cardiology and oncology. PET scanners utilize a combination of a scintillator and a photomultiplier 
to generate images (231). To take images with PET, it is necessary to introduce a labeled positron-
emitting radiotracer that is taken up by the tissues that are to be imaged. The PET scanner then detects 
the location of labeled molecules like glucose, thymidine, methionine, estradiol, annexin V, etc. in 
the body as the tracer decays. FDG (18F-fluorodeoxyglucose), which is glucose analog, is the most 
commonly used radiotracer for oncology applications imaged with PET (124).  
Recent studies have shown that the PET system not only allows for the detection of 
bioluminescence, but also fluorescence using the same setup (181). For example, PET/FMT is used 
to validate FMT as a surrogate for the nuclear imaging modality. Because of the longer half-life of 
fluorescent signals as compared to positron emitters, the PET/FMT system provides a more stable 
signal. Hybrid PET also offers the spatial information for tracer signal distribution by correlation 
(181). In addition, PET can also be used inside the high magnetic field of an MR system, as a hybrid 
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PET/MR, which was previously considered impossible due to the use photomultiplier tubes in a 
combined system (291, 315).  
 
1.5.1.4 MAGNETIC RESONANCE IMAGING 
The basic principle of magnetic resonance imaging (MRI) is that it relies on the properties 
of subatomic spin to obtain images. Protons, neutrons and electrons all spin around a central axis. 
Under conditions where protons and neutrons are balanced within an atom, then it could lead to a 
zero spin nucleus. Unbalanced atoms like hydrogen create a small magnetic field. This small 
magnetic field is a magnetic moment. These tiny magnetic moments are balanced against each other 
to generate a neutral magnetic field under normal conditions. However, these magnetic moments can 
be influenced by an external magnetic field. A directional magnetic field, or moment, is associated 
with charged particles in motion. Nuclei containing an odd number of protons or neutrons have a 
characteristic motion or precession. Because nuclei are charged particles, this precession produces a 
small magnetic moment that can be distinctly detected by MRI (248, 311, 326). 
MRI has superb contrast between different soft tissue structures in the body such as cartilage 
and soft organs like the brain or the heart with 3D acquisition. There is no involvement of any kind 
of ionizing radiation in MRI, but the resolution of MRI is higher than CT (248). MRI scanning also 
can provide information about blood circulation throughout the blood vessels (157). 
 
1.5.2 IN VITRO MICROVASCULATURE 
Although many disease models have been utilized to elucidate the underlying mechanisms 
of vascular complications, and the advanced imaging technologies described above have been 
developed to monitor the response of pathological conditions in these models, in most cases the 
studies are limited to animal models, especially rodents. To find direct pathological relevance to 
vascular impact in human diseases, inevitably we should use human endothelial cells. In vitro 
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vascular cell culture systems with human cells allows us to overcome the confounding effects 
associated with complex in vivo conditions related to disease. Currently, even though many 
researchers aim to rebuild the complicated vascular environment on a lab scale (e.g., blood vessel on 
a chip (130)), this in vitro culture system is still useful in terms of being able to measure the response 
to only a few selective factors from many vascular components.  
To mimic vasculature in vitro with endothelial cells, we should consider the aspects of both 
structural and functional properties. The most important structural feature of blood vessels is that 
they are composed of a monolayer of endothelium. The endothelial barrier compartmentalizes the 
area of the bloodstream lumen from the outside of vessels, while at the same time, it plays a role in 
controlling molecular transfer in between those two areas (72). In addition, there is the fluidity of 
bloodstream (146). In this part, I will cover the two types of microvascular systems used in vitro with 
descriptions of notable features and their applications. 
 
1.5.2.1 2D MONOLAYER OF ENDOTHELIUM 
There are two different types of 2D endothelial monolayer cell culture systems; 1) the static 
transwell system and 2) the dynamic in vitro system. Firstly, the static transwell system is a 
conventional way of 2D microvasculature culturing, which has transmembrane inserts hanging on 
the top of a multi-well plate. The transwell system allows cells to be cultured in a monolayer 
representative of the endothelial barrier by attaching the cells to the polycarbonate transmembrane 
of the insert. The insert has a high pore density, with micropores 0.3-0.4μm in size. The insert (apical 
side) represents the vessel lumen and the well (basolateral side) mimics the interstitial space. This 
transwell setting lets the system exchange the small molecules across the porous membrane by active 
or inactive transport mechanisms, but prevents the loss of endothelial cells by migration over the 
membrane (58, 283). The static model, however, does not reflect systemic fluidity. Thus, there have 
been attempts to dynamically apply fluid on the in vitro 2D vasculature cell culture system. To 
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provide endothelial shear stress with external medium flow, a microfluidic platform was applied 
(210). The endothelial monolayer with flow more accurately simulated normal physiology due to 
allowing for endothelial rearrangement mediated by shear stress (43, 72). Furthermore, long term 
culture is permissible in this system (301). Using these platforms, there are many options to 
investigate endothelial barrier function and response, for example, permeability testing of 
fluorochrome-conjugated target molecules, cell migration assays with a cancer cells or neutrophils, 
shear stress assay with iPSCs derived brain ECs, and so on. 
 
1.5.2.2 3D PERFUSABLE MICROVASCULATURE 
Reconstitution of vascular 3D structure is important not only for studying the behavior of 
endothelial cells, but also for determining cell fate and other physiologically relevant functions (25). 
Even though 2D in vitro vasculature models consider the fluidic environmental factor, it is difficult 
to say that this is relevant to the conditions in vivo because they are missing major structural 
properties. The vasculature in vivo is an enclosed system of tubular structures, having numerous 
branches. This feature allows fluid to be circulated throughout the whole body to exchange molecules. 
Therefore, the application of perfusibility on a 3D in vitro system allowed us to understand 
underlying mechanisms of vasculature better, especially vessel permeability. 
From that point of view, there was the important finding that endothelial cells can 
spontaneously assemble themselves to generate capillary structures (79). When endothelial cells are 
exposed to an environment with balanced growth factors and a favorable extracellular matrix (ECM), 
within a few days, the cells will self-assemble into a tubular shaped 3D microvasculature in an in 
vitro system. This endothelial feature can be applied to a PDMS microfluidics platform. The device 
has open-ended vessels connected to medium channels, making this platform useful to infuse any 
circulating molecules into the 3D vessel lumen. The platform is used to mimic the brain blood barrier 
to aid in understand the role of pericytes and astrocytes, and its alteration in permeability under 
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pathological conditions (314). This system can also be applied in a co-culturing system with other 
cell types that are also found in endogenous vascular structures, such as smooth muscle cells, 
pericytes, astrocytes and endothelial cells (103). 
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1.6 HYPOTHESIS AND RESEARCH AIMS 
I hypothesized that altered endothelial permeability in diabetes can regulate the physiological 
effects of adiponectin. Based upon this hypothesis, I designed the following specific objectives: 
 
Aim 1: To examine adiponectin flux in endothelial cell monolayers treated with glucocorticoids to 
reduce endothelial permeability and determine the mechanisms involved. My specific hypothesis was 
that by using glucocorticoids to alter tight junction protein profiles, and thus reduce paracellular 
permeability, that adiponectin flux would be attenuated. 
 
Aim 2: To investigate the effect of high glucose on transendothelial adiponectin flux, its 
biodistribution in mice, and the functional significance. This was based on the hypothesis that 
hyperglycemia in a mouse model of diabetes increases vascular permeability and regulate the extent 
of adiponectin movement from circulation to the interstitial space in target tissues. The hypothesis 
was further tested using isolated vessels ex vivo, in endothelial monolayers, and a 3D 
microvasculature network exposed to high glucose. 
 
Aim 3: To determine if iron overload, which is commonly observed in diabetes, influences the 
endothelial permeability of adiponectin, and to examine the underlying mechanisms. My hypothesis 
was that iron overload decreases endothelial permeability by elevating oxidative stress and altering 
the expression of tight junction proteins. 
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2.1. SUMMARY 
Altered permeability of the endothelial barrier in a variety of tissues has implications both in 
disease pathogenesis and treatment. Glucocorticoids are potent mediators of endothelial permeability 
and this forms the basis for their heavily-prescribed use as medications to treat ocular disease. 
However, the effect of glucocorticoids on endothelial barriers elsewhere in the body is less well-
studied. Here we investigated glucocorticoid-mediated changes in endothelial flux of Adiponectin 
(Ad), a hormone with a critical role in diabetes. First, we used monolayers of endothelial cells in 
vitro and found that the glucocorticoid dexamethasone increased transendothelial electrical 
resistance and reduced permeability of polyethylene glycol (PEG, molecular weight 4000kDa). 
Dexamethasone reduced flux of Ad from the apical to basolateral side, measured both by ELISA and 
Western blotting. We then examined a diabetic rat model induced by treatment with exogenous 
corticosterone, which was characterized by glucose intolerance and hyperinsulinemia. There was no 
change in circulating Ad but less Ad protein in skeletal muscle homogenates, despite slightly higher 
mRNA levels, in diabetic versus control muscles. Dexamethasone-induced changes in Ad flux across 
endothelial monolayers were associated with alterations in the abundance of select claudin (CLDN) 
tight junction (TJ) proteins. shRNA-mediated knockdown of one such gene, claudin-7, in HUVEC 
resulted in decreased TEER and increased adiponectin flux, confirming the functional significance 
of Dex-induced changes in its expression. In conclusion, our study identifies glucocorticoid-mediated 
reductions in flux of Ad across endothelial monolayers in vivo and in vitro. This suggests that 
impaired Ad action in target tissues, as a consequence of reduced transendothelial flux, may 
contribute to the glucocorticoid- induced diabetic phenotype. 
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2.2. INTRODUCTION 
As the primary barrier to the movement of circulating endocrine factors from the 
bloodstream to the interstitial space, the endothelium plays a critical role in hormone action (134, 
316). Endothelial permeability can significantly impact hormone action by preventing or delaying 
access of the hormone to target tissues (134, 299). Transendothelial solute movement can occur via 
the transcellular pathway where solutes are transported across the endothelium cell membrane or via 
the paracellular pathway where solutes passively move through the intercellular space between 
adjacent endothelial cells (316). Previous work has shown that hormone and nutrient concentrations 
in blood differ from surrounding cells on the tissue side of the blood vessel endothelium  (18, 102, 
312). Of note, this has been best documented in the case of insulin where concentrations of the 
hormone are significantly lower in the target tissue than in the circulation (134). 
Glucocorticoids are among the most commonly prescribed anti-inflammatory and 
immunosuppressive medications worldwide (47). They are also commonly used in oncology 
treatment (155) and for the treatment of macular edema and, more recently, retinopathy (4, 325). 
However, glucocorticoids have been shown to have potent effects on restricting endothelial transport 
(76, 296)  and they contribute to the development of diabetes at least in part by increasing hepatic 
glucose production and reducing GLUT4 translocation in muscle (20). Yet despite these observations, 
the potential importance of glucocorticoid-induced alterations in the transendothelial flux of 
circulating glucoregulatory hormones such as Ad is unclear. 
Ad is one of the most abundant plasma proteins and exists in three different isoforms: low 
molecular weight (LMW; trimer), medium molecular weight (MMW; hexamer) and high molecular 
weight (HMW; oligomer) (54). Ad has important and beneficial anti-diabetic, anti-inflammatory and 
cardioprotective actions (13, 54). Ad levels, in particular HMW, are decreased in obese individuals 
and this correlates with development of associated complications, including diabetes and 
cardiovascular disease (123, 202). Transendothelial movement of Ad across the blood-brain barrier 
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(BBB) into cerebrospinal fluid (CSF) was studied and only LMW and MMW were found in the CSF, 
suggesting that passage of HMW complexes were restricted (142, 145, 185). This may be 
functionally significant since HMW Ad is often considered to be the most biologically active and 
physiologically relevant form (54) (184). A recent study calculated the Stokes radii for the Ad 
oligomers and found that endothelial barriers controlled Ad transport in a cell- and tissue-specific 
manner (222). Thus, emerging evidence suggests that Ad action may be at least in part mediated by 
endothelial transport, although whether this is influenced by glucocorticoid-induced changes in 
transendothelial permeability remains unknown. 
Given the large size of Ad multimers it seem likely that transendothelial Ad movement is an 
important variable in determining it presence within, and action on, target tissues. Therefore we 
hypothesized that glucocorticoid-induced alterations in transendothelial permeability will modulate 
the transendothelial movement of Ad. In this regard, the objective of this study was to examine how 
glucocorticoid treatment of a cultured endothelium influences Ad flux in association with changes in 
permeability and apical junction protein abundance as well as investigate Ad content within the 
skeletal muscle in a diabetic rat model induced by exogenous glucocorticoid treatment. The overall 
goal of this work was to significantly advance our understanding of the glucocorticoid-induced 
diabetic phenotype by determining whether Ad movement out of the circulatory system might play 
a role in its pathogenesis. 
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2.3. MATERIALS AND METHODS  
2.3.1. HUVEC cell culture and treatments 
Normal primary human umbilical vein endothelial cells (HUVECs; Pooled, PCS-100–013) 
were obtained from ATCC (Manassas, VA, USA) and grown at 37°C and 5% CO2 on uncoated T75 
flasks in vascular cell basal medium (ATCC, PCS-100–030) containing 10% fetal bovine serum 
(FBS), VEGF endothelial cell growth kit (ATCC, PCS-100–041) and treated with DEX using 2% 
FBS (both medium were prepared without hydrocortisone hemisuccinate), 100 units/mL penicillin 
and 100 μg/mL streptomycin. Cells were kept frozen in medium containing 10% DMSO (Bio-Rad 
Laboratories Canada Ltd., Mississauga, ON, Canada). For experiments, passage 3 was used. Cells 
were counted using a haemocytometer and seeded onto permeable polyethylene terephthalate (PET) 
filters at the base of BD Falcon cell culture inserts (BD Biosciences, Mississauga, ON, Canada) at a 
density of 0.5 × 106 cells/insert. 
Dexamethasone (DEX) was obtained from Sigma-Aldrich (Oakville, ON, Canada), and full- 
length Ad was produced in-house using a mammalian expression system (i.e. HEK 293 cells) 
according to methods described by (288, 303). HUVECs were treated for 5 days with DEX (1 μM) 
starting 24 h after seeding cells into inserts, HUVECs were treated with DEX added to both apical 
and basolateral sides of inserts at concentrations indicated above 
 
2.3.2. shRNA-mediated knockdown of claudin 7 in HUVEC 
We used pGPU6/Neo-claudin-7 shRNA vector with target sequence (5’- 
GGCCATCAGATTGTCACAGAC-3’) (GenePharma Co., Ltd., Shanghai, China). These were 
transfected into HUVEC using Lipofectamine™ 3000 Reagent (Invitrogen, Carlsbad, CA, USA) 
exactly according to manufacturer’s protocol. Non-specific scrambed target sequence shRNA vector 
was used as control. Following selection with 50 μg/ml Neomycin (Sigma-Aldrich, Oakville, ON, 
 44 
CA) for 24 hours, cells were seeded onto inserts for analysis of TEER, examining adiponectin flux 
or preparation of cell lysates to confirm claudin 7 knock-down. 
 
2.3.3. Transendothelial electrical resistance (TEER),and [3H]PEG4000 and Adflux 
TEER was measured daily using chopstick electrodes (STX-2) connected to an EVOM 
voltohmmeter (World Precision Instruments, Sarasota, FL, USA). As a measure of paracellular 
permeability, apical to basolateral flux rates of [3H] polyethylene glycol at 1 μCi; 1 h flux (molecular 
mass 4000 Da; PEG-4000; PerkinElmer, Woodbridge, ON, Canada) or Ad (10 μg/mL; 24 h flux) to 
apical culture medium were determined across HUVEC endothelia. [3H] PEG-4000 in basolateral 
culture medium was detected using a liquid scintillation counter, Ad was detected using a mouse Ad 
ELISA kit (Antibody Immunoassay Services, Hong Kong) or Western blot. Permeability 
measurements were expressed according to calculations previously outlined by (300). 
 
2.3.4. L6 and H9C2 cell culture and treatment with HUVEC-conditioned medium 
Rat myoblasts and cardiomyocytes at passage 22–30 were grown in α_AMEM(Life 
Technologies Inc., Manassas, MA, USA) and DMEM containing 10% FBS and 1% antibiotic-
antimycotic (Wisent Inc., St- Bruno QC, Canada). Culture media from the basolateral compartment 
of HUVEC inserts were collected and applied. L6/ H9C2 cells were starved with medium containing 
0.5% FBS and 1% antibiotic-antimycotic for 3 h prior to treatment with HUVEC-conditioned 
medium. 
 
2.3.5. Quantitative real-time PCR analysis 
Total RNA was isolated from control and DEX-treated HUVECs and from soleus skeletal 
muscle using TRIzol Reagent . Extracted RNA was then treated with DNase I and first- strand cDNA 
was synthesized using SuperScript III reverse transcriptase and oligo(dT)12–18 primers (Life 
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Technologies Inc.,Manassas MA, USA). Quantitative real-time PCR (qRT- PCR) analyses were 
conducted using gene specific primers. SYBR Green I Supermix (Bio- Rad Laboratories Canada 
Ltd.Mississauga, ON, Canada) and a Chromo4 Detection System (CFB-3240; Bio-Rad Laboratories 
Canada Ltd.) Samples were run in duplicate. For all qRT- PCR analyses, TJ protein mRNA 
expression was normalized to GAPDH transcript abundance. For the expression profile, TJ protein 
transcripts were expressed relative to occludin mRNA. For TJ protein transcripts that were not 
detected in HUVECs, normal human adult kidney cDNA was obtained (BioChain Institute, Inc., 
Newark, CA, USA) and used as a positive control in qRT-PCR reactions. Agarose gel electrophoresis 
verified single qRT-PCR products at predicted amplicon sizes from positive control reactions. 
 
2.3.6. Animal model of diabetes induced by exogenous corticosterone treatment 
We used a well-established hyperinsulinemic/hyperglycemic rodent model of chronic 
glucocorticoid treatment (19, 20, 53, 241, 244). Upon experiment cessation, the tibialis anterior (TA) 
and soleus skeletal muscles were excised and immediately frozen in liquid N2 and kept at −80oC until 
future analysis. 
 
2.3.7. Oral glucose tolerance test 
Animals were fasted overnight (16 hours), 11 days after pellet implantation, and were 
administered an oral glucose tolerance test (OGTT, 1.5 g/kg body mass) on day 12 using glucometer 
(Bayer One Touch), additional fasted plasma was collected for later analysis of insulin concentrations 
via an ELISA 96-well kit (Crystal Chem, USA). Plasma for measurement of Ad concentration was 
obtained 7 days after pellet implantation at 0800 h and assessed using a mouse Ad ELISA kit (AIS, 
Hong Kong). 
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2.3.8. Measurement of hydraulic conductivity (Lp) in individually perfused rat mesenteric 
microvessel 
Female Sprague-Dawley rats of 220 to 250 g (2 to 3 mo old, Sage Laboratory Animal, PA) 
were used for the experiments. All procedures and animal use were approved by the Animal Care 
and Use Committee at Pennsylvania State University. Inactin hydrate (Sigma) was used for 
anesthesia and given subcutaneously at 170 mg/kg body weight. Microvessel permeability was 
assessed by measuring Lp in individually perfused microvessels, which measures the volume of 
water flux across the microvessel wall. Details have been described previously (318, 319). 
 
2.3.9. Staining for metachromatic myosin ATPase 
To identify skeletal muscle fiber type, a metachromatic myosin ATPase stain was performed 
using a modified protocol (Ogilvie and Feeback 1990). Sections were pre-incubated in an acidic 
buffer (pH=4.25) to differentially inhibit myosin ATPase within the different fiber types. In this 
protocol, type I fibers appear dark blue, type IIa appear light blue and type IIb and IIx are not apparent 
from each other and are classfied as IIb/x. These fibers appear almost white and are the largest. 
Images were acquired with a Nikon Eclipse 90i microscope and Q-imaging MicroPublisher with Q-
Capture software at 10x magnification. 
 
2.3.10. Immunohistochemistry of Ad and dystrophin in skeletal muscle 
Tibialis anterior (TA) from Control and CORT treated rats were cryostat sectioned (10 µm 
thick) for analysis of muscle Ad content. Sections were stained as previously described (139). 
Quantification was performed using Zen 2.0 software. The total Ad and dystrophin signal was 
determined by the sum of red/green signal intensity obtained arbitrary values in the field of view. 
Diagram view intensity was recorded by the software in form of histograms. Intracellular 
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quantification was done on Ad images (without dystrophin), images were changed to 8-bits on Image 
and the arbitrary intensity was calculated as mean intensity per area. 
 
2.3.11. Western blot analysis 
Control and DEX-treated HUVECs, and L6 or H9C2 cells treated with HUVEC-conditioned 
medium and soleus skeletal muscle were lysed in sample buffer (80 mM Tris-HCl (pH 6.8), 2% (w/v) 
SDS, 20% glycerol, 3.3% (v/v) β-mercaptoethanol 0.01% w/v bromophenol blue) containing 
protease and phosphatase inhibitors (3 mM EDTA, 10 uM E64, 1 mM Na3VO4, 1 μM leupeptin, 1 
μM pepstatin A, 1 μM okadaic acid and 200 μM PMSF). Apical and basolateral HUVEC-conditioned 
media collected from Ad flux experiments were concentrated with Amicon Ultra-4 Centrifugal Filter 
Units with Ultracel-30 membranes (EMD Millipore, Billerica, MA, USA) and subjected to 
nondenaturing, nonreducing conditions to allow the analysis of the different forms of Ad (HMW 
>250 kDa, MMW ~180 kDa, and LMW ~90 kDa). Primary antibodies specific for the following 
proteins: T-cadherin (1:1000, R&D Systems), occludin (OCLN, 1:3000), tricellulin (TRIC, 1:3000), 
claudin-7 (CLDN-7, 1:500), CLDN-10 (1:800), CLDN-11 (1:1000), phospho-AMPKα (Thr172) 
(1:1000), phospho-p38 MAPK [pT180/pY182] (1:1000), Ad (1:1000),β-actin (1:1000). 
OCLN, TRIC, CLDN-7, CLDN-10 and phospho-p38 MAPK [pT180/pY182] antibodies 
were obtained from Life Technologies, CLDN-11 and Ad antibodies were purchased from EMD 
Millipore and Signalway Antibody (College Park, MD, USA) respectively, and phospho-AMPKα 
(Thr172) and β-actin antibodies were obtained from Cell Signaling Technology (New England 
Biolabs Ltd., Whitby, ON, CA). Protein detection using enhanced chemiluminescence (Bio-Rad) and 
quantification by densitometry using ImageJ analysis software. TJ protein expression was 
normalized to β-actin, Tubulin protein abundance. 
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2.3.12. Statistical analysis 
All data are expressed as mean values ± SEM. A one-way analysis of variance (ANOVA) 
followed by a Student-Newman-Keuls test was used to determine significant differences (P ≤ 0.05) 
between groups. When appropriate, a Student’s t-test was also used. All statistical analyses were 
conducted using Prism 5, Excel SigmaStat 3.5 softwares. 
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2.4. RESULTS 
2.4.1. Dexamethasone induces endothelial tightening and inhibits Ad movement across 
endothelial cell monolayers 
We first investigated the effect of dexamethasone (DEX), a synthetic glucocorticoid, on 
tightness of an endothelial monolayer of HUVECs. Addition of DEX to culture media significantly 
elevated TEER (Fig.2.1.A) and correspondingly reduced the endothelial permeability of the 
paracellular transport marker [3H] PEG-4000 (Fig.2.1.B). Similar trends regarding permeability were 
observed in microvessels of DEX-treated rats. DEX treatment (n = 4) did not cause a significant 
reduction in baseline Lp compared to normal control group (n = 6), but lowered the mean value from 
1.5 ± 0.1 to 1.1 ± 0.2 (× 10-7 cm/s/cm H2O). When each vessel was exposed to platelet activating 
factor (PAF, 10 nM) that is known to cause transient increases in Lp (332), microvessels in DEX-
treated rats showed significantly attenuated Lp response. The mean peak Lp value was reduced from 
11.1 ± 1.8 (normal control) to 6.0 ± 0.4(× 10-7 cm/s/cm H2O, Fig.2.1.C). We then assessed flux of 
Ad from the apical to basolateral side of HUVEC monolayer and found a reduced total amount of 
Ad in basolateral media after DEX treatment (Fig.2.1.D-F). When monitoring absolute flux rates in 
control cells, Ad flux rate was 4.4 ± 0.12 cm s-1 × 10-9 which significantly decreased after DEX 
treatment to 3.2 ± 0.30cm s-1 × 10-9 (Fig.2.1.D). Following a 24 h flux period, Ad levels detected in 
basolateral media were 64.8 ± 5.7 ng/mL. Using Western blotting to examine various oligomeric 
forms of Ad LMW (~90 kDa), MMW (~180 kDa) and HMW (>250 kDa), we found that flux of all 
forms was reduced by DEX (Fig.2.1.E,F). Additionally, the functional activity of Ad appearing in 
basolateral media was confirmed by using this media to treat L6 skeletal muscle cells and H9C2 cells 
derived from rat heart ventricle. In both cell types the media increased AMPK phosphorylation 
(supplementary Fig.2.1.A,B). 
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2.4.2. Dexamethasone treatment alters transcript and protein abundance of select TJ proteins 
in HUVEC monolayers 
A tissue expression profile of transcripts encoding 26 TJ proteins in HUVECs revealed the 
presence of 15 (Fig.2.2.A). The most abundant transcript was found to be CLDN-11, while CLDN-
7, CLDN-12 and ZO-1 exhibited relatively high abundance and OCLN, TRIC, CLDN-10 and CLDN-
15 exhibited moderate levels of abundance (Fig.2.2.A). Transcripts not detected in HUVECs 
included CLDN-3, −4, −5, −8, −9, −16, −17, −18, −19, −23 and −25 (Fig.2.2.A & Supplementary 
Fig.2.1.C). Human kidney cDNA was used as a positive control for transcripts that were not detected 
in HUVECs (Supplementary Fig.2.1.C). To explore the response of TJ proteins to DEX- treatment, 
we first compared mRNA abundance of expressed target genes in HUVECs. DEX increased CLDN-
6 mRNA abundance while CLDN-2, −20, −22, −24 and ZO-1 mRNA showed significant decreases 
(Fig.2.2.B). DEX treatment had no significant effect on mRNA encoding OCLN, TRIC, CLDN-1, 
−7, −10, −11, −12 and −15(Fig.2.2.B). Following DEX treatment, the protein abundance of CLDN-
1, −7, −11 and ZO-1 was examined and found to be significantly upregulated following DEX 
treatment when compared to the control group (Fig.2.2C, D). On the other hand, CLDN-10 protein 
levels were significantly decreased when compared with the expression in control conditions 
(Fig.2.2.C, D). In order to validate the functional significance of Dex-induced changes in expression 
of tight juntion proteins we used shRNA to target claudin-7 and this effectively reduced its expression 
by 71% on average (Fig.2.3.A). Furthermore, HUVEC with reduced levels of claudin-7 showed 
reduced TEER and a small but significant increase in flux of adiponectin from apical to basolateral 
side (Fig.2.3.B-D). 
 
2.4.3. Examination of changes in transcellular endothelial flux 
The possible contribution of transcellular receptor-mediated Ad movement across HUVEC 
monolayers was then investigated by analysis of expression levels of three identified Ad receptors. 
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Intracellular Ad content in these cells was detected, although at low level, and expression levels did 
not change significantly with DEX treatment (Fig.2.4.A). However, DEX significantly increased T-
cadherin protein abundance (Fig.2.4.B), but had no effect on protein abundance of AdipoR1 and 
AdipoR2 (Fig.2.4.C). 
 
2.4.4. Skeletal muscle Ad content in a rat model of exogenous glucocorticoid-induced diabetes 
We then examined whether the increased endothelial cell barrier tightness observed after 
DEX treatment would be paralleled in a diabetic rodent model of chronic glucocorticoid exposure. 
As expected based on previously published work (53, 241, 244), two weeks of exogenous 
corticosterone (CORT) treatment resulted in severe fasting hyperinsulinemia and impaired glucose 
tolerance (supplementary Fig.2.2.A). In addition, CORT treatment caused mild/moderate elevations 
in fasted blood glucose concentrations (5.12± 0.2 mM to 8.3 ± 1.88 mM, supplementary Fig.2.2.B) 
despite the significantly increased fasted insulin concentrations (0.76±0.25 ng/ml to 4.68±0.72 ng/ml , 
supplementary Fig.2.2.C). CORT treatment also caused a change in skeletal muscle fibre type 
composition; a switch from predominantly slow to fast-twitch skeletal muscle fibers, within the 
tibialis anterior muscle (supplementary Fig.2.2.D). 
To explore whether CORT-treatment affects circulating Ad levels, we measured plasma Ad 
levels in these animals before CORT pellet implantation and at 7 days post pellet implantation, at 
0800h. Circulating Ad levels were unaffected by CORT treatment (Fig.2.5.A). Interestingly, there 
was an apparent elevation in skeletal muscle Ad mRNA levels (Fig.2.5.B), yet Ad protein content 
was significantly reduced (Fig.2.5.C,D). Upon immunohistochemical analyses, we also observed that 
the total amount of Ad was decreased in skeletal muscle from the COR-treated rats versus control 
rats (Fig.2.5.E-H). Dystrophin, was used to assess the structural integrity of the skeletal muscle and 
was unaffected by CORT treatment. Representative images are shown (Fig.2.5.E) with quantification 
of the total and intracellular Ad signal (Fig.2.5.G-H). Since CORT-treatment is known to 
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preferentially target fast-twitch skeletal muscle (20), representative images accordingly depict 
smaller IIb/x fiber area (Fig.2.4.D) within the CORT-treated rats. CORT-treatment was also found 
to cause a significant reduction in individual myocyte size (Fig.2.5.F). 
 
2.4.5. AdipoR abundance in a rat model of exogenous glucocorticoid-induced diabetes 
Both Ad receptor isoforms (AdipoR1 and AdipoR2) genes were expressed in rat soleus 
skeletal muscle and although an apparent increase in AdipoR1 mRNA abundance was seen in the 
diabetic rat model, neither was significantly altered (Fig.2.6.A,B). However, a significantly increased 
level of ADIPO-R1 protein (approximately 3.4 fold compared to the control) was seen (Fig.2.6.F). 
There were no changes in ADIPO- R2 nor in T- Cadherin protein levels (Fig.2.6.E,G). 
 
2.4.6. CORT treatment altered Tight Junction genes in rat soleus skeletal muscle after 2 weeks 
We then measured changes in mRNA abundance of tight junction, Cldn-1, −2, −3, −4,−5,−6, 
−7, −9, −10, −11, −12, −24,−14, −15, −19, −20, −22, −23 and Ocln, Tricand Z0–1 were found to be 
no significant changes with in diabetic rat skeletal muscle (Fig.2.6.C), with only Cldn −5, −10, −11, 
−22 significantly decreased (Fig.2.6.D). 
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Figure 2.1. Effects of DEX on permeability. HUVECs (Human Umbilical Vein Endothelial Cell) 
were seeded onto permeable polyethylene terephthalate (PET) filters and treated with or without 
1µM of DEX every other day in both top and bottom of compartments. Tightness of the monolayer 
was measured on the 5th day of DEX treatment. A) Transendothelial Electrical Resistance (TEER). 
B) [3H]PEG-4000 permeability across HUVEC monolayer. C) Measurements of hydraulic 
conductivity (Lp) in individually perfused mesenteric venulesfrom normal (n = 6) and Dex-treated 
(n = 4) rats. DEX treatment significantly attenuated the Lp responses to PAF that was known to cause 
transient increases in Lp. D–F) 10 µg of full-length Ad was added onto the apical side. After 24 hrs, 
the medium on basolateral was collected. D) Total Ad amount was quantified using ELISA. E) The 
collected basolateral medium was concentrated and separated by PAGE. 3 forms of Ad are labeled 
as LMW (~90 kDa), MMW (~180 kDa), HMW (>250 kDa). F) Representative Western blot for full-
length Ad flux across control and Dex-treated monolayers. Data are expressed as mean values ± SEM 
(n=4-8). *Significant difference (P£0.05) from control (Con) group. 
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Figure 2.2. Effect of DEX on Tight Junction Components. A) mRNA abundance by qRT-PCR 
analysis. HUVECs grown to confluence on permeable PET inserts. Total RNA was isolated from 
control cells on the 5th day. Transcript abundance was normalized to GAPDH and each gene 
examined was expressed relative to OCLN transcript abundance. B) TJ transcript levels in DEX-
treated cells were normalized to GAPDH, and expressed relative to the control group (Blue-
increasing compared to control; Green-decreasing compared to control). Data are expressed as mean 
values ± SEM (n = 3-5). C) Protein abundance in HUVECs grown on 
cell culture inserts. Protein abundance were normalized toβ-ACTIN, and expressed relative to the 
control group. D) Representative Western blots of CLDN- 1, -7, -10, -11, -15, TRI, OCC, Z0-1. Data 
are expressed as mean values ± SEM (n = 3-8). * indicates significant difference (P ≤ 0.05) from 
control (Con) group. 
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Figure 2.3. Knockdown of claudin-7 alters transendothelial electrical resistance and 
adiponectin flux. We used shRNA to reduce levels of claudin-7 in HUVEC and average efficiency 
of knockdown was 71% with a representative Western blot shown in A. In cells transfected with 
scrambled (Control) or claudin-7 shRNA we then tested TEER (B) and flux of adiponectin with 
representative Western blot shown in C and quantitation in D. In B and D values are mean ± SEM (n 
= 3) and *indicates significant difference (P ≤ 0.05) from control group. 
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Figure 2.4. Expression of Ad and its receptors in HUVEC. A) Ad expression in HUVECs 
treated with DEX after 5 days. B) T- CADHERIN expression in HUVECs with DEX treatment. C) 
ADIPO -R1/ -R2 expression in HUVECs. Data are expressed as mean values ± SEM (n = 3– 6). 
*indicates significant difference (P ≤ 0.05) from control (Con) group. 
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Figure 2.5. Ad level in CORT treated animals. A) Using ELISA, circulating Ad was calculated in 
1 week treated rat serum. B) Ad mRNA expression after 14 days of CORT. C&D) Representative 
Western blotting and quantitation of reduced Ad (~30 kDa) in soleus skeletal muscle. E) 
Immunohistochemical detection of dystrophin (green), Ad (red) in skeletal muscle isolated from rats 
after 2 weeks of CORT treatment, together with quantitation in F. G) Quantification of changes in 
intracellular Ad levels and H) cell number. Quantification of Ad shown as the intensity expressed 
per cell in arbitrary units and are expressed as mean values ± SEM (n = 3–5).* indicates significant 
difference (P ≤ 0.05) from control (Con) group. 
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Figure 2.6. Ad receptor expression in skeletal muscle. Rats were treated with CORT for 2 weeks. 
A,B) mRNA expression of Ad and its receptors after 14 days of CORT. Data are expressed as mean 
values ± SEM (n = 4–5). C–D) mRNA profile of tight junction in soleus skeletal muscle isolated 
from 2 weeks CORT- treated rats. mRNA abundance by qRT-PCR analysis. Transcript abundance 
was normalized to GAPDH mRNA abundance, and mRNA abundance for each gene examined was 
expressed relative to control group transcript abundance. 
Control group gene transcript were normalized to 1. C) mRNA profile of TJ that are increased after 
2 weeks CORT treatment compared to control. Blue- CORT- treated, Red- Control. D) TJ genes that 
are decreased after 2 weeks of CORT treatment. . E–G) Protein expression in soleus. E) T- 
CADHERIN. F) Ad receptor 1. G) Ad receptor 2. Data are expressed as mean values ± SEM (n = 3). 
* indicates significant difference (P ≤ 0.05) from control group. 
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Supplementary Figure 2.1. Validation of Ad functionality and basal level of HUVEC tight 
junctions A) Effect of treatment with HUVEC-conditioned basolateral medium from Ad flux 
experiments on p-AMPK and p-p38 MAPK phosphorylation in rat L6 and H9C2. Phosphorylated 
AMPK and p-p38 MAPK protein abundance was normalized to b-actin, and expressed relative to the 
corresponding time-matched control group. In (C), Western blots of p-AMPK, phospho-p38 
MAPKare shown. Data are expressed as mean values  SEM (n = 3). B) Non-detected genes in figure 
1(C) was ran on 1% gel in order to confirm the absence. Human kidney was used as positive control.  
Data are expressed as mean values  SEM (n = 3 - 16). *Significant difference (P £0.05) from control 
(Con) group. 
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Supplementary Figure 2.2. Circulation of metabolites in CORT treated rats. A) Glucose 
tolerance in response to an oral glucose tolerance test (OGTT). B) Fasted blood glucose and C) fasted 
insulin concentrations measured at the onset of the OGTT after 12 days of CORT treatment. D) 
Representative images of the tibialis anterior (TA) depicting fiber type staining with Metachromatic 
myosin ATPase. Data are expressed as mean values  SEM (n =5). *Significant difference (P£0.05) 
from control (Con) group. 
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2.5. DISCUSSION 
Glucocorticoids are potential mediators of endothelium permeability. Our study was 
designed investigate the its influence on endothelium permeability and consequently the changes in 
Ad movement across the endothelium barrier and the underlying mechanism. More recently, a similar 
proposed mechanism for regulation of Ad action was suggested both by us and others (222, 316). To 
the best of our knowledge, the regulation of this process by glucocorticoids had not been studied 
before. Our vitro model using DEX treated HUVEC and CORT treated rats to integrate the 
established observations that glucocorticoids can restrict paracellular transport across various 
endothelia (126, 212, 219) with the fact that glucocorticoids, commonly prescribed medications, have 
numerous side effects, including insulin resistance and diabetes (20). Furthermore, we examined 
whether the emerging phenomenon that transendothelial movement of Ad may regulate the anti-
diabetic effects of this hormone and whether this was regulated by glucocorticoids (222, 316). 
Specifically, our approach involved the use of endothelial cell monolayers and individually perfused 
intact microvessels to examine whether glucocorticoid altered Ad flux was through reduced 
microvessel permeability. We also used a rat model of diabetes induced by exogenous glucocorticoid 
treatment to determine changes in Ad content in muscle as well as peripheral insulin sensitivity. 
As indicated in the introduction, strong rationale for this work comes from previous studies 
with other circulating hormones, most notably insulin. Concentrations of insulin at the cell surface 
have been shown to be very different from those observed in plasma in microdialysis experiments 
(102, 245), direct interstitial sampling (30) and lymph measurements (45) (312). It was noted that 
insulin-mediated glucose uptake lagged behind the increase in plasma insulin (81), whereas in 
cultured skeletal muscle cells, insulin-mediated glucose uptake occurs within 10 min (247). The time 
delay seen in vivo (81) reflects a delay in insulin access to the myocyte which is mediated in part via 
altered paracellular or transcellular endothelial transport. Thus, modification of access to skeletal 
muscle can have major effects on insulin action and metabolism, suggesting that reaching the 
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interstitial space is the limiting factor for insulin-mediated glucose uptake (134). Indeed, delivery of 
insulin to the interstitial space has been shown to be altered by diet (143). 
We confirmed the ability of the synthetic glucocorticoid DEX to alter endothelial transport 
properties, in this case of HUVEC monolayers, as indicated by changes in TEER and PEG-4000. 
Similar effects were observed in DEX-treated rats, where we saw a significant reduction of 
permeability in rat mesenteric venules. We then showed that DEX reduced Ad flux across cultured 
endothelial monolayers by ELISA detection of total Ad content. 
Western blotting of Ad isoforms indicated that all three oligomeric forms of Ad (trimer, 
hexamer and oligomer) were reduced in basolateral media from DEX-treated cells, and although the 
magnitude of change was more evident in the case of LMW adiponectin, all isoforms were 
significantly altered and we do not believe this data infers a preferential restriction of LMW flux. 
This demonstration of restricted flux is important to establish from several perspectives. First, many 
studies have suggested that oligomeric high molecular weight complexes of Ad are most tightly 
correlated with insulin resistance (160, 197). Second, the concept that endothelial transport regulated 
Ad action was also proposed by a recent study which estimated the size of different Ad forms by 
calculating a Stokes radius (222). The Stokes radii were 3.96 nm for trimeric Ad, 6.01 nm for 
hexameric Ad and 10.1 nm for various HMW oligomeric forms (222) and these sizes are likely to be 
in the range that can be physically obstructed or facilitated by changes in endothelial cell tight 
junction size. Indeed, it was concluded that Ad bioavailability and action in target cells was 
attenuated under stressed conditions due to reduced trans-endothelial transport (222). We concur that 
regulation of Ad flux across endothelium is particularly relevant since the target tissues where Ad 
mediates its physiological effects have a wide-range of endothelial permeability. Liver, for example 
has highly fenestrated endothelium that may permit the passage of HMW Ad, which has potent 
effects on hepatic metabolism. In contrast, the central effects of HMW Ad may be limited by its 
transport across the comparatively tighter blood brain barrier (316). 
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The well-established effect of glucocorticoids to restrict endothelial transport has been 
proposed to be mediated via regulation of TJ and adherens junction (AJ) proteins (27, 76). Strands 
of transmembrane and cytosolic proteins form TJ and AJ complexes that regulate permeability 
between endothelial cells (95). Functional characteristics of the vertebrate TJ complex are dependent 
on the variable assemblage of TJ proteins such as occludin (OCLN), tricellulin (TRIC) and in 
particular, claudins (CLDNs) which directly establish the TJ barrier and form the backbone of TJ 
strands, while cytosolic ZO-1 and other cortical TJ proteins provide structural support to the TJ 
complex (95). The CLDN superfamily consists of at least 27 isoforms in mammals and the 
incorporation of specific CLDN isoforms in TJs can modulate TJ barrier function by making the 
paracellular pathway tighter or leakier (96). The main observations in our study were increased 
CLDN-7 and decreased CLDN-10 protein abundance in HUVEC in response to DEX and these 
changes may underlie the functional properties of paracellular transport limiting Ad flux. Little is 
known about CLDN-7, although CLDN-7 knockout is lethal in murine models and it seems that 
CLDN-7 most likely facilitates anion movement across vertebrate epithelia. CLDN-7 was previously 
found to form a complex with the epithelial cell adhesion molecule (EpCAM) which enhanced cell-
cell interaction (140, 277). We suggested that the functional role of CLDN-7 in our model is 
tightening of the endothelium in association with an increase in abundance, and that this may help to 
explain, in part, the restricted movement of Ad in DEX-treated HUVEC as well CORT-treated rats. 
Further supporting this idea, a reprevious studies which have found that CLDN-7 (−/−) can cause 
colonic inflammation and enhance the paracellular flux of small organic solutes (258), as well as 
observations that CLDN-7 (−/−) results in the presence of intercellular gaps below TJs and cell matrix 
loosening (64). Thus, we used shRNA to target claudin-7 in HUVEC and observed that this caused 
a decrease in TEER and increase in adiponectin flux across monolayers, further indicating an 
important mechanistic role for Dex-mediated changes in claudin-7 expression. Interestingly, another 
group found that NLRP3 inflammasome promoted endothelial disruption via production of HMGB1 
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to disrupt the junctions and increased paracellular permeability (42). Finally, (260) reported that urine 
Na(+), Cl(−), and K(+) were significantly increased in CLDN-7(−/−) mice compared with that of 
CLDN-7(+/+) mice. Taken together, the studies outlined above and our data indicate an important 
functional consequence for CLDN-7 reduction and compromised epithelial permeability as the result 
of tight junction disruption, and this supports the view that increased CDLN-7 abundance, as seen in 
these experiments, may contribute to endothelial tightening and reduced Ad flux. 
In contrast, CLDN-10 isoforms in vertebrate epithelia have been described to impart both 
charge and size selective properties to the paracellular pathway. Previous studies investigated the 
role of CLDN-10 deficient mice using Cre-Lox found that serum phosphate concentration was 28% 
higher and serum Mg2+ concentration was almost two-fold higher in cKO mice compared with 
controls. However, the same study also found that CLDN-10 transports molecules in a charged 
selective manner (31). To the best of our knowledge, Ad is uncharged. Therefore, the transport of 
Ad is less likely to be affected by CLDN-10. Nevertheless, it would be very interesting to explore 
whether the consistent decrease in CLDN-10 observed in this study has a functional role in the 
modulation of Ad transport across the endothelium barrier.  
In the glucocorticoid-induced diabetic rodent model used here, a decrease in CLDN-10 
mRNA expression in skeletal muscle was also observed. Although changes in expression profiles of 
other tight junction proteins do not entirely match the changes in HUVEC treated directly with DEX, 
this is not entirely surprising since there are multiple factors impinging upon tight junction protein 
expression in skeletal muscle tissue in vivo.  
We believe that reduced paracellular transport is the main mechanism of reduced Ad flux 
observed, yet we also tested possible indicators of altered transendothelial flux (316). In DEX-treated 
endothelial cells, there was no major change in ADIPO-R1 or ADIPO-R2 mRNA and protein 
expression, although in skeletal muscle homogenates, ADIPO-R1 protein expression levels increased 
significantly in CORT-treated animals. This may reflect a compensatory mechanism to reduced Ad 
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availability in order to increase sensitivity to available Ad. We also observed that DEX increased 
expression of T-cadherin in HUVEC. T-cadherin has been identified as a non-functional receptor for 
Ad (109). This is in agreement with a previous study showing that DEX enhanced T-cadherin 
expression in human osteosarcoma cells (32). One possible interpretation of our finding is that 
binding to endothelial T-cadherin may trap Ad in the vasculature, as has recently been proposed 
(169).  
We also investigated potential alterations in endothelial transport of Ad in a rodent model of 
glucocorticoid-induced diabetes (244). In these rats, we found normal circulating Ad levels but 
significantly reduced total Ad protein content within skeletal muscle without an accompanying 
decrease in muscle Ad gene expression. This suggests less flux of Ad from circulation could be a 
contributory mechanism. Indeed, upon immunohistochemical analysis we found reduced Ad content 
in the interstitial space. 
Although not a direct comparison to the in vitro studies we used here, it suggests that skeletal 
muscle Ad availability, and thus action, may be limited in this animal model possibly contributing to 
its diabetic phenotype (19-21, 244, 316).  
In conclusion, our study indicates that glucocorticoid-mediated tightening can reduce flux of 
Ad across endothelial monolayers, and that this may be due to alterations in the expression profile of 
tight junction proteins. Furthermore, in a rat model of diabetes induced by exogenous glucocorticoids, 
we observed reduced interstitial and intracellular levels of Ad in skeletal muscle. Thus, we propose 
that reduced Ad action in target tissues, as a consequence of reduced endothelial flux from circulation 
to interstitial space, may contribute to the diabetic phenotype occurring after glucocorticoid treatment. 
Since glucocorticoids are one of the most commonly prescribed medications, our discovery of 
reduced Ad transport in response to glucocorticoids is a particularly important and novel finding with 
potentially far- reaching consequences. 
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3.1. SUMMARY 
Adiponectin, a highly abundant polypeptide hormone in plasma, plays an important role in 
the regulation of energy metabolism in a wide variety of tissues as well as showing important 
beneficial effects in diabetes, inflammation and cardiovascular disease. To act on target tissues, 
adiponectin must move from the circulation to the interstitial space, suggesting that vascular 
permeability plays an important role in regulating adiponectin action. To test this hypothesis, 
fluorescently labelled adiponectin was used to monitor its biodistribution in mice with streptozotocin-
induced diabetes (STZD). Adiponectin was indeed found to have increased sequestration in the 
highly fenestrated liver and other tissues within 90 min in STZD mice. In addition, increased 
myocardial adiponectin was detected and confirmed using Computed Tomography (CT) co-
registration. This provided support of adiponectin delivery to affected cardiac tissue as a 
cardioprotective mechanism. A higher adiponectin content in the STZD heart tissues was further 
examined by ex vivo fluorescence molecular tomography (FMT) imaging, immunohistochemistry 
and Western blot analysis. In vitro mechanistic studies using an endothelial monolayer model 
cultured on permeable polyethylene terepthalate inserts further confirmed that adiponectin flux was 
increased by high glucose. However, in this in vitro model and mouse heart tissue, high glucose 
levels did not change adiponectin receptor levels. An examination of the tight junction (TJ) complex 
revealed a decrease in the TJ protein claudin (CLDN)-7 in high glucose-treated endothelial cells and 
the functional significance of this change was underscored by increased endothelium permeability 
upon siRNA-mediated knockdown of CLDN-7. Our data support the idea that glucose-induced 
effects on permeability of the vascular endothelium contribute to the actions of adiponectin by 
regulating its transendothelial movement from blood to the interstitial space. These observations are 
physiologically significant and critical when considering ways to harness the therapeutic potential of 
adiponectin for diabetes. 
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3.2. INTRODUCTION 
Extensive research on adiponectin has validated this hormone as a biomarker for 
cardiometabolic diseases and as a therapeutic target with enormous potential (289). In order to 
harness the numerous beneficial effects of adiponectin, it is essential to fully understand the 
mechanisms governing adiponectin action (161, 200, 271). To date, the vast majority of studies have 
focused on correlating changes in circulating adiponectin levels and disease markers (11). As a result, 
reduced adiponectin levels are well established to inversely correlate with diabetes and 
cardiovascular diseases (289). Adiponectin acts via binding to membrane receptors AdipoR1, 
AdipoR2 and T-cadherin (113, 306), and reductions in their expression or post-translational 
modification in disease states has been proposed to lead to adiponectin resistance (71, 233, 287). 
However, another critical factor that likely determines adiponectin action is vascular permeability 
(134, 135, 316). More specifically, to directly elicit a response in a target tissue adiponectin must 
transit from the circulation to interstitial space across the endothelial barrier (316). 
The monolayer of endothelial cells lining the circulatory system acts as a barrier that 
regulates the movement of blood borne factors to the interstitial space. In turn, the barrier properties 
of the endothelium are regulated by the transcellular pathway (i.e. solute transport across endothelial 
cells) as well as the paracellular pathway (i.e. solute movement between adjacent endothelial cells) 
(316). In general, larger macromolecules move via facilitated transcellular trafficking while the 
paracellular route typically restricts solutes in the range of 3 nm radius (96). Tight junctions (TJ) 
provide a selective barrier to solute movement between cells and altered expression of components 
including ZO-1, occludin, tricellulin and claudins alter TJ structure to make a leakier or tighter barrier 
for paracellular movement of solutes (95). Numerous previous studies, particularly focusing on 
insulin, have shown that vascular permeability can play an important role in contributing to the 
development of diabetes and heart failure (134, 316). It is important to note that endothelial 
permeability varies widely throughout the body in a tissue (and intra-tissue)-specific manner (316). 
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It has also been shown that endothelial barriers control adiponectin transport in a cell- and tissue-
specific manner (222) and we have reported that transendothelial movement of adiponectin was 
reduced by glucocorticoids (58). 
We believe that the role of endothelial permeability as an important determinant of 
adiponectin action has been somewhat underappreciated. In this study, we further considered a link 
between vascular permeability, adiponectin flux, and hyperglycaemia/diabetes by producing 
recombinant adiponectin, which we then conjugated with a near infra-red probe in order to track its 
biodistribution in live wild type and diabetic mice using fluorescence molecular tomography (FMT). 
We also examined the effects of high glucose levels on adiponectin flux across isolated arteries and 
cultured monolayers of endothelial cells. Finally, since the cardioprotective actions of adiponectin 
are currently the focus in our lab (54-56, 198, 201), we considered the role of the vascular barrier 
and diabetes on adiponectin access and action in the heart. These studies provide a novel and 
integrated view on the movement of adiponectin across the endothelial barrier under conditions that 
relate to diabetes and new insight into the impact that vascular permeability has on the actions of 
adiponectin on key organs. 
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3.3. MATERIALS AND METHODS  
3.3.1. Experimental animal model 
Male Nu/Nu homozygous mice and C57BL6 aged 8-13 weeks were utilized for assessing 
adiponectin biodistribution. All mice were maintained with access to water and low-fluorescent chow 
(Teklad global 18% Protein Rodent Diet (Irradiated), Harlan Laboratories, Indianapolis, IN, USA) 
throughout each experimental period. Age and weight-matched pairs were grouped for each injection 
(averaging 23~25g). After 12 h starvation, diabetes was induced by single intraperitoneal injection 
of 150mg kg-1 (body weight) STZ (Sigma-Aldrich, St. Louis, MI, USA). Experiments were 
performed 4 days after STZ injection and diabetes was diagnosed when mice exhibited a blood 
glucose level > 14mmol/L at this time, whilst all control mice had only saline injection. Circulating 
adiponectin was detected in serum before and after infusion of VivoTag-750 conjugated adiponectin 
using a mouse adiponectin ELISA kit (Immunodiagnostics Ltd, Hong Kong) which detects all 
adiponectin oligomeric forms. 
 
3.3.2. Fluorescence Molecular Tomography (FMT) to Detect VivoTag-750- adiponectin 
Recombinant adiponectin prepared in our laboratory was labeled with VivoTag-S 750 
(NEV10123, Perkin Elmer, Boston, MA, USA). Importantly, this recombinant protein formed 
oligomeric forms in a ratio which closely mirror those found in circulation (see supplementary figures 
1&2). Labeling efficiency was assessed by running labeled full-length adiponectin on a SDS-PAGE 
gel then scanned on a LI-COR Odyssey infrared imaging system to visualize the 3 adiponectin 
isoforms. Labeled proteins were transferred from the gels onto nitrocellulose membranes before 
probing with adiponectin-specific antibodies to assess fluorescence-to-total protein ratio. Labeled 
adiponectin was infused into lightly anesthetized mice (1-2% isoflurane) via a surgically placed 
permanent jugular vein cannula. For cannulation insertion, the mice were first anesthetized with 5% 
isoflurane then maintained at 2% isoflurane. The surgical site was cleaned with iodine solution and 
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alcohol before a longitudinal incision of about 15 mm was made in the skin at the neck of the animal, 
just above the right front leg. Connective tissue surrounding the jugular vein was carefully separated 
before two sutures of 6-0 Ethilon surgeon’s silk (Johnson & Johnson Intl, Brussels, Belgium) were 
placed ~5-10mm apart on the vein. A fine lateral incision was made between the sutures using micro-
scissors, which allowed insertion of a saline-filled polyethylene tube (PE10) into the vein between 
the sutures. When placement was confirmed, the caudal suture was released and the cannula slowly 
fed caudally ~ 5mm into the vein towards (but not entering) the heart. To confirm correct placement, 
50 µl saline was delivered through the cannula using a 31G insulin needle. The cannula was then 
securely tied to the jugular vein with silk suture and 85 µg of adiponectin conjugated with VivoTag-
S was administered followed by a 50 µl saline flush. The cannula was sealed using a heated haemostat, 
the skin incision was closed using silk suture, and a serum sample was collected from the tail vein 
within 2 min of adiponectin infusion. Mice were maintained at 2% isoflurane while being positioned 
in a glass mouse imaging cassette, then scanned 10, 30, 60, and 90min post-adiponectin infusion with 
a FMT 2500 LX Quantitative Tomography system (VisEn Medical, Perkin Elmer, Downers Grove, 
IL, USA) using the 750nm near infra-red channel (750/800nm excitation/emission). Once FMT 
scanning was completed, mice in the imaging cassette were immediately taken for a computed 
tomography (CT) scan (Locus eXplore MicroCT, GE Healthcare, London, ON, Canada and XRAD 
225Cx, Precision X-Ray, North Banford, CT, USA) under constant anesthesia to ensure identical 
mouse positioning and accurate alignment between CT and FMT. FMT software (TrueQuant, Perkin 
Elmer) reconstructs a quantitative 3D dataset in which fluorescence/voxel is expressed in nmol/L. 
FMT and CT datasets (dicom format) were imported into Inveon Research Workplace (Siemens 
Healthcare, Germany) or AMIDE (http://amide.sourceforge.net) for FMT-CT co-registration to 
permit accurate localization of the fluorescent signal. 
 
 
 77 
3.3.3. FMT analysis of tissues ex vivo 
To avoid potential scatter from adjacent tissue, heart, liver, kidney, pancreas and skeletal 
muscle, those tissues were excised from mice after cervical dislocation immediately following FMT 
and CT scanning (~100-120min post-adiponectin infusion). 2D epifluorescence FMT images were 
taken of these tissues on an opaque resin imaging block in the FMT imaging cassette. Quantitative 
analysis of the fluorescent signal was performed using the FMT software (TrueQuant, Perkin Elmer, 
Downers Grove, IL, USA). 
 
3.3.4. Ex vivo vascular permeability of adiponectin assay 
Five weeks old Wistar rats were used. After two weeks of standard diet in the animal facility, 
rats were fasted 5 hours before induction of diabetes by a single intraperitoneal injection of 
streptozocin (STZ, Sigma-Aldrich, St. Louis, MI, USA) at a dose of 100 mg.kg-1 bodyweight (~200 
µl/rat). Diabetes was diagnosed when hyperglycemia was higher than 10 mmol/L (180 mg/dL). Rats 
developed diabetes within 7 days of STZ injection. A control group of rats was injected with an 
equivalent volume of the vehicle solution (citrate buffer 0.5M, pH 4.5). Rats that failed to respond to 
STZ injection were not used for the study. Control or diabetic rats were anesthetized with isoflurane 
and a mid-line laparotomy was performed to expose and remove the mesenteric bed. Isolated 
mesenteric arteries were mounted on a glass cannula immerged in a 2-ml organ bath filled with a 
physiological salt solution (PSS; mmol/L: 130 NaCl; 4.7 KCl; 1.18 KH2PO4; 1.17 MgSO4; 14.9 
NaHCO3; 1.6 CaCl2; 0.023 EDTA; 10 glucose; pH 7.4) aerated with 12% O2; 5% CO2; 83 % N2 at 
37oC following a method previously described (211). Arterial segments were pressurized at 80 mm 
Hg in no-flow conditions and equilibrated for 30 min before starting experiments. 10 µg/mL 
adiponectin (200 µl) was added to the arterial perfusate which circulated at a flow rate of 2 µl/min 
for 90 min at a constant pressure of 80 mm Hg. At 0, 30, 60, 90 min, 100 µl samples of the extra-
vascular bath containing transported adiponectin were collected, and an equivalent volume of 
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physiological solution was added into the bath. Adiponectin levels were quantitatively determined 
by ELISA kit (Immunodiagnostics Ltd, Hong Kong). 
 
3.3.5. Cell culture 
Human Dermal Microvascular Endothelial Cells HDMEC (ATCC, Manassas, VA, USA) 
were grown in vascular cell basal medium (ATCC) supplemented with 10% fetal bovine serum (FBS) 
at 37°C, 5% CO2. All cells were used at passages 3–4 from the supplier. 500K HDMECs were seeded 
onto trans-well inserts (Corning, Tewksbury, MA, USA) sized for 12-well plates having 3.0 μm pore 
sizes. Hyperglycemia was induced with 25 mM glucose in vascular cell basal medium supplemented 
with 2% FBS for 6 days. To adjust for osmotic pressure differences, control cells were treated with 
5.5 mM glucose and 19.5 mM mannitol. 
 
3.3.6. Measurement of Transendothelial Electric Resistance (TEER) 
Measurements of TEER were conducted using STX-2 chopstick electrodes attached to an 
epithelial voltohmmeter (EVOM; World Precision Instruments, Sarasota, FL, USA). All TEER 
measurements were corrected for background by subtracting TEER recorded across a blank 
membrane primed with appropriate cell culture medium. Resistance measurements were taken at day 
0 and day 6 of treatment with 25 mM glucose and control (5.5 mM glucose + 19.5 mM mannitol). 
 
3.3.7. Permeability Assay using Endothelial Monolayers 
HDMECs were seeded onto trans-well inserts and treated with 25mM glucose and 5.5 mM 
glucose with 19.5 mM mannitol for 5 days prior to the start of experiments. At the start of the 
experiment, 10μg/mL of adiponectin with the 25mM glucose or 5.5 mM glucose with 19.5 mM 
mannitol including 2% FBS vascular cell basal medium (ATCC PCS-100-030, Cedarlane, Burlington, 
ON, CA) was applied to the apical chamber only. After 24 h, apical and basolateral media were 
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assessed for adiponectin concentration by gel electrophoresis after concentrating with 10,000Da 
MWCO(molecular weight cutoff) filter (EMD Millipore, Billerica, MA, USA) or by fluorescence 
intensity reader, respectively, and concentrations calculated by comparison to standard curves 
prepared in culture medium. 
 
3.3.8. Quantitative RT-PCR 
Using aliquots of total extracted RNA, cDNA was synthesized. And pRT-PCR reactions 
were performed using the SYBR Green PCR Master Mix (Lifetechnologies). Gene-specific primer 
sets were designed. human CLDN7, F: 5’ GGAGACGACAAAGTGAAGAAGG 3’, R: 5’ 
GGACAGGAACAGGAGAGCAG 3’, human GAPDH, F: 5’ AACATCATCCCTGCCTCTACTG 
3’, R: 5’ CCTGCTTCACCACCTTCTTG 3’, murine AdipoR1, F: 5’ 
ACGTTGGAGAGTCATCCCGTAT 3’, R: 5’ CTCTGTGTGGATGCGGAAGAT 3’, murine 
AdipoR2, F: 5’ TCCCAGGAAGATGAAGGGTTTAT 3’, R: 5’ 
TTCCATTCGTTCCATAGCATGA 3’, murine Adiponectin, F: 5’ 
TGTTCCTCTTAATCCTGCCCA 3’, R: 5’ CCAACCTGCACAAGTTCCCTT 3’, murine CLDN7, 
F: 5’ GGACCTGCCATCTTTATCGGC 3’, R: 5’ AGCTTTGCTTTCACTGCCTGG 3’, murine ZO-
1, F: 5’ GTCCCTGTGAGTCCTTCAGCTG 3’, R: 5’ ACTCAACACACCACCATTGCTG 3’, 
murine 18s RNA, F: 5’ AGTGAAACTGCGAATGGCTCA 3’, R: 5’ 
CGAGCGACCAAAGGAACCA 3’. 
 
3.3.9. Claudin-7 Knockdown by shRNA in HDMEC 
Claudin-7 gene expression was knocked-down in HDMECs using a pGPU6/Neo-claudin-7 
plasmid as shown previously (58) using the following shRNA target sequence: 5′-GGCCATCAG 
ATTGTCACAGAC-3′ (GenePharma Co., Ltd., Shanghai, China). Lipofectamine 3000 reagent (Life 
Technologies, Carlsbad, CA, USA) was used for all transfections following manufacturer 
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instructions. A non-targeted control (NTC) shRNA plasmid was designed with a non-specific 
scrambled sequence. The transfected cells were stabilized for 24h with 10% FBS medium and 
subjected to antibiotic selection (500 μg/mL G418 (Sigma-aldrich, Saint Louis, MO, USA)) for 2 
days. During antibiotic selection, transfected cells were seeded on trans-well inserts or 6 well-plates 
for further experiments.  
 
3.3.10. Western Blotting 
Proteins from mouse tissues were homogenized by TissueLyser II (QIAGEN, Hilden, 
Germany) in RIPA buffer with 80mM Tris–HCl (pH 6.8), 2% (w/v) SDS, 20% glycerol, 3.3% (v/v) 
β-mercaptoethanol and 0.01% (w/v) bromophenol blue, 30mM Hepes (pH 7.4), 2.5mM EGTA, 3mM 
EDTA, 70mM KCl, 20mM β-glycerolphosphate, 20mM NaF, 1mM Na3VO4, 200μM PMSF, 10μM 
E64, 1μM leupeptin, 1μM pepstatin A, 0.1% NP40, and 0.1μM okadaic acid. To detect the 3 forms 
of adiponectin, samples were prepared without β-mercaptoethanol or heating. For detection of other 
protein targets, samples were lysed in complete RIPA buffer and denatured at 95°C for 10min. 
Transported adiponectin was collected from basolateral HDMEC medium and concentrated using 
Amicon Ultra-4 Centrifugal Filter Units with Ultracel-10K (EMD Millipore, Billerica, MA, USA). 
To detect the 3 adiponectin oligomers, concentrated adiponectin samples were prepared without 
denaturation or reduction. Prepared samples were run on SDS-PAGE gels then transferred onto 
PVDF membranes (Bio-Rad Laboratories, Hercules CA, USA), before incubation with primary 
antibody, and detection by chemiluminescence. Polyclonal primary antibody of rabbit anti-
Adiponectin (dilution 1:1000) is produced in-house (159). Rabbit anti-AdipoR1/2 antibodies were 
from Phoenix Biotech (Toronto, ON, CA) (201). Mouse anti-FLAG M2 (dilution 1:1000, F1804, 
Sigma, Oakville, ON, CA), rabbit anti-Claudin-7 (dilution 1:500, Cat#34-9100, Thermo Fisher, 
Rockford, Illinois, USA), rabbit anti-a/β-Tubulin (dilution 1:1000, Cat#2148, Cell Signaling, 
Danvers, MA, USA), rabbit anti-GAPDH(14C10) (dilution 1:1000, Cat#2118, Cell Signaling, 
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Danvers, MA, USA) were purchased. And the appropriate HRP-conjugated secondary antibody (anti-
rabbit IgG-HRP (dilution 1:5000, Cat#7074), anti-mouse IgG-HRP (dilution 1:5000, Cat#7076)) was 
used from Cell Signaling (Danvers, MA, USA). Bands were quantified by densitometry using Fiji 
software and normalized to relevant loading controls as indicated. 
 
3.3.11. Immunofluorescence 
Mouse hearts were isolated following isoflurane anesthesia and the ventricles excised then 
cross-sectioned at the mid-line with a surgical blade before being embedded into a mold with Optimal 
Cutting Temperature compound (O.C.T) (Sakura Finetek USA Inc., Torrance, CA, USA) and frozen 
on dry ice. 5 μm thick cryosections were made using a cryostat and mounted onto positively charged 
glass slides (Superfrost, ThermoFisher, CA). Mounted slides were fixed in 4% PFA solution for 
10min to stain adiponectin or fixed in 100% ice-cold acetone, air-dried at room temperature, and 
rehydrated in distilled water followed by washing with phosphate-buffered saline (PBS) buffer. And 
permeabilization was followed by 0.5% TritonX-100. Before permeabilization, cell border staining 
was performed by incubating with 5 µg/mL Alexa488 conjugated wheat germ agglutinin (Thermo 
Fisher, Eugene, OR, USA) for 10min in adiponectin staining. Sections were then incubated with 
Adiponectin primary antibody (1:100) and Texas-Red secondary antibody (1:250) and DAPI for 
nuclear visualization. For vasculature staining, primary antibodies directed against Claudin-7 
(dilution 1:50, Cat#34-9100, Thermo Fisher, Rockford, Illinois, USA), VE-Cadherin (dilution 1:100, 
Cat#PA5-17401, Thermo Fisher, Rockford, Illinois, USA), PECAM-1 (dilution 1:50, Cat#SC-
376764, Santa Cruz Biotech, Mississauga, CA), ZO-1 (dilution 1:100, Cat#61-7300, ThermoFisher 
Scientific, Rockford, Illinois, USA), α-SMA (1:100, α-SM1, a kind gift from Dr. Giulio Gabbiani, 
University of Geneva, Switzerland), and desmin (1:30, Cat#M076029, Dako, Burlington, ON, CA) 
were used. Isotype-specific secondary antibodies anti-rabbit IgG-TRITC (1:100, Sigma, St. Louis, 
Missouri, USA), Alexa 568-conjugated IgG (1:100, Abcam, Carlsbad, CA, USA), Alexa647-
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conjugated IgG2a (1:100, Molecular Probes, LifeTechnologies Inc., Rockford, Illinois, USA), and 
anti-mouse IgG1-FITC (1:200, SouthernBiotech, Birmingham, Alabama, USA), and DAPI 
(Vectashiled mounting medium with DAPI, Cat# H-1200, Burlingame, CA, USA) were used. Images 
were acquired using a LSM700 (Zeiss) or LSM780 (Zeiss) confocal microscope and an upright Zeiss 
Axio Observer M35 epifluorescence microscope equipped with structured illumination (Apotome) 
and Axiocam HR camera (Carl Zeiss, Jena, Germany). All images were processed using Fiji or 
Adobe Photoshop CS5 (Adobe System, San Jose, CA). Contrast and brightness were enhanced 
consistently for all representative images used in the publication.  
 
3.3.12. Fabrication of Microfluidic Devices and Cell culture on a Chip  
To recapitulate 3D microvascular networks in vitro, we utilized a microfluidic chip that can 
include cells-trapped hydrogel and cell growth medium with compartmentalization (a central gel 
channel and two lateral media channels). Previous studies have described the fabrication process of 
the chips in detail (243). Briefly, silicon-based organic PDMS microfluidic device fabrication 
includes steps of soft lithography with SU-8 silicon wafer mold (AMED Inc.) and PDMS (1:10, Dow 
Corning), generating reservoirs with 1, 4 mm diameter biopsy punches (KAI medical), and device 
assembly by plasma bonding (Femto Science Inc.) to a coverslip (glass, Duran). The devices were 
sterilized by 15min sonication (Uil Ultrasonic Co., Ltd) in 70% EtOH before the bonding process. 
An 80°C drying oven was used for curing PDMS mixture, dehydration of devices before plasma 
treatment and recovering hydrophobicity after bonding (24hr in advanced cell seeding). In this study, 
120μm depth of microchannel devices was used.  
Human Umbilical Vein Endothelial Cells (HUVECs, Lonza) were grown in endothelial cell growth 
medium (EGM-2, Lonza) supplemented with 5% fetal bovine serum (FBS) at 37°C, 5% CO2. All 
cells were used at passages 6-8 from the supplier. After harvesting of trypsinized cells by 
centrifugation (125 xg, 7 min), cells were resuspended in concentration of 1.4 x 107 cells/mL with 
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4U/mL thrombin solution. We injected 1:1 mixture of cells (1.4 x 107 cells/mL) and fibrinogen 
solution (5 mg/mL) into a gel inlet to fill it up. After incubating the chips at 37 ° C in a humid 
chamber for 15 minutes to wait gelation, we injected cell culture medium into the media channels. 
The cells in the microfluidic chips were incubated for 4 days with daily replacement of medium. 
Self-assembly of HUVECs into a perfusable vascular network (vasculogenesis) was induced by 
adding 50 ng/mL VEGF to EGM from day 0 (D0) to day 4 (D4). 
 
3.3.13. Vascular Permeability Assay in Microfluidic Chips 
After 4 day culture, medium was washed out with a quick PBS rinse before a fluorescent 
molecule solution was infused. Due to the hydrostatic pressure drop between the two media channels, 
the solution in the media channel flows along with the perfusable microvascular networks to the 
opposite media channel. We monitored the diffusion of fluorescent molecules into the fibrin gel 
(ECM) through the vessel wall and the images were captured at 6-10 second intervals for 3 min via 
a fluorescence microscope (Axio Observer Z1, Zeiss). The images were quantified using ImageJ. 
 
3.3.14. Perfusibility test in 3D microvascular network 
At day 4, endothelial growth medium was quickly washed with PBS by filling up two 
reservoirs in only one side channel to rinse out any particles from the 3D vessel lumen efficiently 
using hydrostatic pressure differences. When the interested field of view was found, bright field of 
image was captured before the fluorescent molecule infusion. Then, 5.0-5.9 μm of FITC surface 
labeled beads (0.1% w/v, F1CP-50-2, Spherotech) was infused into one media channel and time-
lapse images were taken at 1.4 second interval for 2 min under fluorescence microscope (Axio, 
Observer Z1, Zeiss). The fluorescent images were overlayed with brightfiled orientation image, and 
processed to video with ImageJ. 
 
 84 
3.3.15. Statistical analysis 
Data are expressed as mean ± SEM and the significant differences was determined where   
p<0.05 resulted from performing statistical analysis with Student’s t-test or multiple t-test and one-
way ANOVA. 
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3.4. RESULTS 
3.4.1. Diabetes increases biodistribution of NIR-labeled full-length adiponectin into target 
tissues  
To accurately investigate adiponectin biodistribution, we developed a model using 
fluorescence molecular tomography (FMT) in which 3-dimensional localization of fluorescently 
tagged adiponectin could be tracked in short time intervals in vivo. Full-length adiponectin 
comprising of high, medium and low molecular weight oligomers was tagged with a near-infrared 
(NIR) peptide (VivoTag-S 750) detectable at 750nm (fAd-VT750). This wavelength, and feeding 
mice with AIN-76A low-chlorophyll chow diet (Harlan, Indianapolis IN), allowed us to avoid 
confounding effects of autofluorescence (24). Western blot and fluorescent imaging confirmed that 
all 3 oligomers of adiponectin were fluorophore conjugated (Supplementary Fig 3.1.A), and we 
demonstrated a linear relationship between adiponectin concentration and fluorescence measurement 
(Supplementary Fig 3.1.B, C). 
To test the hypothesis that hyperglycemia could alter adiponectin biodistribution, we infused 
fAd-VT750 (85µg, via jugular vein) into STZ injected (STZD) or control nu/nu mice, then monitored 
whole body fluorescence in mice by FMT imaging. We found no difference in circulating adiponectin 
levels between control and STZD mice and also observed the same level of fAd-VT750 in serum of 
either STZD or wt mice 2 min after injection via jugular vein (Supplementary Fig 3.2.A, B). 
Consecutive FMT images at 0, 10, 30, 60 and 90 min after fAd-VT750 injection showed increasing 
tissue accumulation of fluorescent adiponectin throughout the body which appeared to be faster or 
higher in STZD mice (Fig 3.1.A-C), particularly showing enhanced liver and/or heart accumulation 
relative to controls. FMT imaging confers the added advantage of providing quantitative analysis of 
whole body fluorescence and clearly measured an increased overall fluorescence intensity in STZD 
mice. As a control, infused unconjugated VT750 displayed a completely different biodistribution 
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pattern, clearing quickly through the kidneys and localized primarily to the bladder within 60 min, 
with very little signal coming from other peripheral tissues (Supplementary Fig 3.3).  
To conduct further analysis of the tissue localization of fluorescent signal, mice also 
underwent x-ray computed tomography (CT) imaging for fluorescence co-registration (Fig 3.1.D). 
Coronal and sagittal sections of FMT/CT co-registration data showed accumulation of fAd-VT750 
in the heart, liver, kidney, and bladder (Fig 3.1.E). To eliminate potential tissue scattering effects, 
major target tissues of adiponectin action were removed 90 min following fAd-VT750 infusion and 
imaged ex-vivo by FMT. Heart, liver, kidney, pancreas, and skeletal muscle (Sk M) of STZD mice 
exhibited a higher fluorescent signal when compared to wt (Fig 3.1.F), although only heart and liver 
reached significance upon quantitation (Fig 3.1.G). In agreement with this, Western blot analysis of 
reduced tissue homogenates, to allow detection of all adiponectin as monomers, clearly showed 
increased levels in all of these target tissues from STZD versus wt at 90min post fAd-VT750 infusion 
(Fig 3.1.H). 
 
3.4.2. Adiponectin accumulation in the heart is upregulated by STZD 
Because the main research focus of our laboratory is cardioprotective effects of adiponectin, 
we then used FMT-CT co-registered images to quantify the fluorescence contained within a 3-
dimensional region of interest mapped to the heart (Fig 3.2.A). FMT quantitation shows that within 
10 minutes fAd-VT750 level in STZD hearts was significantly greater than in wt (Fig 3.2.B). 
Accordingly, area under the curve analysis showed greater accumulation of fAd-VT750 in the hearts 
of STZD mice (Fig 3.2.C). Immunofluorescent analysis of cross-sections from myocardium also 
indicated increased fAd-VT750 in STZD mice 90 min post-infusion compared to wt (Fig 3.2.D,E). 
Interestingly, higher magnification revealed an apparent co-localization of fAd-VT750 with wheat 
germ agglutinin (WGA), suggesting a near-membrane location.  
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Since molecular weight could be an important determinant in the movement of the 
adiponectin isoforms from circulation into the heart, we assessed the amount of fAd-VT750 in 
perfused heart homogenates from control and STZD mice under non-denaturing conditions. There 
was an increased presence of all three oligomeric adiponectin isoforms in STZD heart homogenates 
when compared to wt (Fig 3.2.G). To verify that increased fAd-VT750 localization was not 
influenced by presence of the VivoTag-750 fluorophore, Flag-tagged and non-fluorescent 
recombinant adiponectin was injected into wild-type C57BL/6 mice treated with or without STZ. 
Similar to fAd-VT750, there was increased total heart localization of Flag-adiponectin in STZ treated 
mice compared to controls (Fig 3.2.F). Quantitative PCR analysis showed no difference in 
adiponectin mRNA levels between control and STZD cardiac homogenates (Fig 3.2.H). 
 
3.4.3. High glucose levels regulate claudin-7 expression to increase paracellular movement of 
adiponectin 
We next tested vascular permeability of adiponectin using mesenteric arteries isolated from 
STZD or control mice.  Similar to our in vivo findings, adiponectin flux across the arterial wall of 
STZD mesenteric arteries was greater compared to wt (Fig 3.3.A). We then exposed a monolayer of 
human dermal endothelial cells (HDMECs) cultured on trans-well inserts to high glucose and found 
that flux of adiponectin, added to apical chamber, was higher than in normal glucose conditions. Fig 
3B shows a Western blot, with quantitation below, indicating a significant increase in flux of HMW-, 
MMW-, and LMW-adiponectin from apical to basolateral side in cells grown under hyperglycemic 
conditions (Fig 3.3.B). Immunoblotting of the adiponectin receptors AdipoR1 and AdipoR2 showed 
that their expression in HDMEC monolayers was not affected by high glucose (Supplementary Fig 
3.4.C). Accordingly, we found that endothelial barrier tightness measured by trans-endothelial 
electrical resistance (TEER) was decreased in high glucose treated cells (Fig 3.3.C). This 
corresponded to a decrease in claudin-7 (cldn-7) mRNA and protein expression following high 
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glucose treatment (Fig 3.3.D, E). Immunofluorescence imaging indicated a decrease in cell 
membrane expression of cldn-7 in high glucose treated cells compared to control (Fig 3.3.F), whereas 
there was no difference in expression of another tight junction related protein, ZO-1, between groups 
(Fig 3.3.G). This observation was mirrored when heart homogenates were analyzed. Protein and 
mRNA levels of adiponectin receptors were unchanged by STZD (Supplementary Fig 3.4.A,B). In 
cardiac tissue sections analyzed by qPCR for mRNA and immunohistochemistry, ZO-1 level was not 
significantly lower (Fig 3.3.J, K) while cldn-7 expression was significantly decreased (Fig 3.3.H, I) 
in STZD hearts compared to wt.  
 
3.4.4. Reduced claudin-7 expression decreased TEER and enhanced adiponectin movement 
across endothelial monolayer 
To test the functional importance of cldn-7 in adiponectin flux across an HDMEC monolayer, 
knockdown of cldn-7 was induced by transfection of shRNA (shCLDN7), which resulted in 
approximately 50% decrease in cldn-7 protein compared to cells that received a scrambled shRNA 
sequence not targeting cldn-7 (shNTC) (Fig 3.4.A). TEER was significantly decreased in monolayers 
comprised of shCLDN7 cells compared to shNTC (Fig 3.4.B). Furthermore, there was increased flux 
of LMW-adiponectin from apical to basolateral side of monolayers comprised of shCLDN7 cells 
compared to shNTC controls (Fig 3.4.C). 
 
3.4.5. Functional 3D perfusable microvascular networks allowed to confirm hyperglycemia 
effect on permeability of dextran and adiponectin   
We finally tested the hyperglycemia effect in microfluidic microvascular network of 
HUVECs (human umbilical vein endothelial cells). This in vitro platform of 3D vasculature-on-a-
chip was generated in the ECM mimetic environment with fibrin hydrogel. PDMS 
(polydimethylsiloxane) microfluidic device is useful to induce perfusable microvasculature as well 
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as to monitor the event inside of the highly branched vascular structure. The PDMS mold has a central 
gel channel containing HUVECs and fibrin hydrogel bordered by triangular posts and two media 
fluid channels (Fig 3.5.A,B). 1.4 x 107 cells/mL of HUVECs were seeded with the fibrin hydrogel at 
D0 and incubated for 4 days to form endothelial monolayers of in vivo-like vasculature naturally (Fig 
3.5.C). Additional VEGF was used to increase the dynamic alignment of HUVECs from D0 to D4 
(Fig 3.5.D). At day 4, the formation of open-ended EC monolayer 3D vessels between two PDMS 
posts were completed. GFP transfected HUVECs showed highly branched features of microvascular 
networks in a device (Fig 3.5.E) and vascular endothelial cadherin (VE-Cadherin) positive stained 
structures indicated that vessel-like EC monolayer barrier allows the perfusion of fluids (Fig 3.5.F, 
Supplementary Video 3). To confirm the functionality of this vasculature, we performed perfusibility 
test with 5 μm beads conjugated with FITC and timelapes images were taken under fluorescence 
exposure at every 1.4 sec (Fig 3.5.G, Supplementary Video 4). Next, we wanted to test the effect of 
hyperglycemia on permeability of 3D microvascular networks using full length adiponectin (fAd) 
and changes of paracellular movement across of this barrier with 3, 70kDa dextran. 
Immunofluorescent detection of VE-C showed that the integrity of interconnected vascular structures 
appeared not to loosen in hyperglycemia compared to control (Supplementary Fig 3.5). To assess the 
permeability, 10 μg/mL fAd conjugated with rhodamine was injected into one reservoir of a device 
and fluorescent images were captured overtime. The apparent permeability (Papp, cm/sec) was 
calculated by the fluorescent intensity measurement from a linear ROI spanning the microvessel-
ECM interface. Because the perfused fluorescent molecules were transmoved to ECM from the 
vessels by concentration gradient, the intensity increase was observed in ECM area overtime (Fig 
3.5.H). Permeability of rhodamine labeled fAd (Rho-fAd) increased in hyperglycemia (1.285 x 10-5 
± 0.09363 x 10-5 cm/sec) compared with 19.5mM mannitol with 5.5mM glucose treated control 
(2.290 x 10-5 ± 0.1651 x 10-5 cm/sec) (Fig 3.5.K). 70kDa Dextran which is smaller than LMW 
adiponectin (around 90kDa) also showed significantly higher permeability in high glucose treated 
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condition (Papp of HG was 6.812 x 10-5 ± 1.152 x 10-5 cm/sec and control Papp was 2.180 x 10-5 ± 
0.2277 x 10-5 cm/sec) (Fig 3.5.J). However, for the small size of dextran (3kDa-FITC), hyperglycemia 
did not significantly change the permeability (Fig 3.5.I). These suggested that paracellular movement 
regulates transendothelial accessibility depending on the size of molecules. And it confirmed that 
hyperglycemia in vitro with 25mM glucose altered the movement of full-length adiponectin in 
microfluidic vessels-on-a-chip. 
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Figure 3.1. Fluorescence molecular tomography shows in vivo biodistribution of full-length 
adiponectin is increased in diabetic conditions. (A) 85 µg of near-infrared labeled full-length 
adiponectin (fAd-VT750) was injected via cannulated jugular vein into control or diabetic (STZD) 
nu/nu mice. Representative images from a control and STZD mouse before injection and at 10, 30, 
60, and 90 minutes post-injection are shown. (B, C) Total signal intensity from whole body 3D field 
of view were calculated as nM (n³8, *p<0.05 from multiple t-test). Time course data was converted 
to area under curve (AUC) (*p<0.05 from student t-test). (D) Co-registration of FMT (colour) and 
computed tomography (CT) data (white/grey). (E) Coronal and sagittal view of FMT-CT co-
registration with organs of interest identified. (F) Ex-vivo 2D FMT analysis of fAd-VT750 from 
isolated tissues (heart, liver, kidney, pancreas and skeletal muscle (tibialis anterior)). (G) 
Quantification of these 2D images using TrueQuant software. * indicates p < 0.05, compared to its 
control (n³4). The p values were given by student t-test. (H) Cardiac homogenates from control and 
STZD mice were analyzed by Western Blot under non-denaturing conditions to compare total 
amount of reduced (i.e. monomeric, 30 kDa) adiponectin. 
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Figure 3.2. Adiponectin uptake into the heart is increased by diabetes.  
(A) Representative heart regions of interest (ROIs) generated by alignment of CT and FMT 3D 
images using IRW software. (B) Quantitation of fAd-VT750 within mapped ROIs. Fluorescence 
intensity of localized fAd-VT750 (nM) was calculated over time by FMT-CT co-registration analysis 
(n³8). * indicates p<0.05 with respect to control at each time point and the p values were from the 
multiple t-test. (C) Area under curve analysis of fAd-VT750 within the heart ROI (*p<0.05) (D, E) 
Immunofluorescence analysis of transverse heart cryosections stained with adiponectin (red), Wheat 
Germ Aglutinin (WGA, green), and DAPI (blue). Co-localization of adiponectin and WGA appear 
orange. (F) Cardiac homogenates from C57BL/6 mice 90 minutes following Flag-tagged adiponectin 
infusion, run under non-denaturing conditions by SDS-PAGE to detect different adiponectin 
oligomers: High-Molecular Weight (HMW, >250 kDa), Mid-Molecular Weight (MMW, ~180 kDa), 
and Low-Molecular Weight (LMW, ~90 kDa). Total adiponectin combines densitometry from all 
three oligomers, adjusted to GAPDH as loading control (n=5, *p<0.05). The quantification analyzed 
by multiple t-test. (G) Detection of fAd-VT750 by SDS-PAGE in heart homogenates from nu/nu 
mice 90 min post fAd-VT750 infusion. (H) Real-time quantitative PCR analysis of heart 
homogenates 90mins post-injection adjusted for GAPDH (n=5). 
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Figure 3.3. Hyperglycemia reduces Claudin-7 expression and permits greater flux of 
adiponectin movement across the endothelium. (A) Mesenteric arteries extracted from control or 
STZD rats were perfused with flag-tagged fAd, with samples of extravascular fluid taken at 30, 60, 
and 90 minutes post adiponectin and analyzed by ELISA. AUC analysis shows greater adiponectin 
flux from STZD arteries vs control (n³5, *p<0.05). (B) HDMEC cells were cultured in a transwell 
insert before treatment with high glucose (HG) or control. Adiponectin was added to the apical 
surface then basolateral media was collected 24hr following adiponectin administration. Samples 
were run under non-denaturing conditions. (n=3, * indicates p<0.05 with respect to each adiponectin 
isomer’s control.) (C) TEER (transendothelial electrical resistance) was lower in hyperglycemia 
significantly (*p<0.05, n³11). Claudin-7 in hyperglycemia treated endothelial cell also decreased at 
(D) cldn-7 mRNA expression (*p<0.05, n=4) as well as (E) CLDN-7 protein expression (*p<0.05, 
n=3). (F) Lower CLDN-7 was localized on cell membrane in hyperglycemia. CLDN-7(red) and 
PECAM-1(green, endothelial marker) are co-staining in HDMEC. (G) However, ZO-1 (green) 
aligned underneath of cell membrane was not changed by HG treatment. As same as mouse hearts, 
(H) cldn-7 mRNA level decreased in diabetic heart induced by STZ (n=5, *p<0.05), (J) but no 
significant different was shown in zo-1 mRNA level (n=4). (I) And lower CLDN-7(red) surrounded 
by alpha-SMA (green) was observed in heart tissue sections from STZD, (K) although there was no 
difference of ZO-1. Immunostaining for ZO-1 (green) to identify endothelial cell-specific tight 
junction structure, α-SMA (red) to identify vascular smooth muscle cells, and desmin (blue) to 
identify cardiomyocytes. Shown are representative images of n=3 mice per experimental group. High 
magnification images show junction formation between endothelial cells in small vessels. Scale bars: 
50 μm and 150 μm, respectively. And all the p values were analyzed by student t-test. 
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Figure 3.4. Reduced CLDN-7 expression decreased TEER and increased LMW of adiponectin 
movement across monolayer of HDMECs. (A) One of major component of tight junction proteins, 
CLDN-7, was targeted to knock down by shRNA transfection after 96h. Transfected HDMECs were 
transferred into transmembrane culturing system (0.9cm2) and formed monolayer 72h after 
transfection. The cells having lower CLDN-7 expression (**p<0.01, n=3) showed (B) significantly 
lower TEER (*p<0.05, n³7). TEER was measured at 96hr later from transfection starting. (C) The 
monolayer of CLDN-7 knockdown HDMECs were used for adiponectin permeability assay for 24hr. 
The decreased CLDN-7 led adiponectin movement increase, especially in LMW form with statistical 
significance (*p<0.05, n³5). The values were mean ± SEM and p values were given by statistical 
analysis from student’s t-test. 
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Figure 3.5. Functional 3D microvascular networks of HUVECs in ECM/fibrin hydrogel showed 
permeability alteration depending on molecular sizes as well as hyperglycemia effect.  
(A) Schematic representation of 3D perfusable microvascular network model with HUVECs in a  
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PDMS (polydimethylsiloxane) microfluidic device. The PDMS mold has a central gel channel 
containing HUVEC cells and fibrin hydrogel bordered by triangle posts. The HUVEC/fibrin gel 
channel is flanked on both sides by fluid channels leading to four reservoirs filled with culture 
medium. (B) A device photo is shown with the area dimension (20,000 μm x 38,000 μm) and a dime 
as size reference. (C) Experiment timeline is shown. (D) Daily images (D1-D4) of HUVECs in the 
3D fibrin gel shows cellular alignment dynamics during vasculogenesis (10X magnification was 
used). (E) The continuously GFP expressed HUVECs showed the perfusable vasculature on day 4. 
(F) Confocal reconstructed 3D image of VE-Cadherin (Red) stained with nucleus (DAPI, blue). A 
single plane from the stacked images showed three ortho-positions (x position/pink at 570 μm, y 
position/green at 700 μm and z position/blue at 18 μm) of continuous endothelial hollow. (G) To 
confirm the generated 3D vessels were perfusable, 5 µm beads conjugated with FITC were loaded 
into one reservoir and timelapes images were taken under fluorescence using Axio Observer Z1 
microscope. (Time interval average was 1.4 sec.) (H) Rhodamine labeled full-length adiponectin 
(Rho-fAd, red) was injected with a concentration of 10 μg/mL. Fluorescent images were captured 
every 6-10 sec for 3 min from 2 or 3 different fields of view. Three representative images are shown 
at 0, 40, and 80 sec post infusion. To assess permeability, fluorescent signal intensity (AU) was 
quantified along a linear ROI spanning the microvessel-ECM interface as shown, and depicted as a 
distance from the ROI origin (closed circle). Permeabilized fluorescent signal were observed in the 
ECM (out of vessel) area overtime. Apparent permeability (Papp) was quantified using ImageJ with 
measurement from randomly selected ROIs. Hyperglycemia with 25mM glucose (J) did not change 
the permeability of 3kDa-FITC dextran. However, (I) 70kDa-Texas Red dextran and (K) Rho-fAd 
increased Papp significantly in high glucose (HG) treated condition. (D, E, G, H) The scale bar 
indicates 100 μm. (I-K) Data presented mean values ± SEM and error bars. Statistical evaluation was 
done by t-test with the values from 15-25 ROIs (4-6 different fields of view of 2-3 devices) for each 
condition. * indicates p=0.0005 and ** indicates p<0.0001. 
 100 
 
 
Supplementary Figure 3.1. Full-length adiponectin (fAd) conjugated with VivoTag750 had 3 
different forms by adiponectin oligomerization (LMW, MMW and HMW) and gave a linear 
slope of signal intensity depending on concentration of fAd. (A) To confirm the labeled 
adiponectin, non-labeled fAd and VT750-conjugated fAd were separated side by side in a SDS-
PAGE gel and scanned by Li-Cor image scanner. Then, the both separated fAds were transferred 
from the SDS-PAGE gel into PVDF membrane to be detected by adiponectin antibody via 
immunoblotting. It was confirmed that the labeled fAd had 3 different forms as same as non-labeled 
fAd. (HMW >250 kDa, MMW ~180 kDa and LMW ~90 kDa) (B) To assess the meaning of signal 
intensity with labeled adiponectin from the field of view under FMT system, fluorochrome 
concentration was measured in dose dependent conditions. It showed linear regression with R2=0.991 
of the trendline. (C) FMT imaging was taken using a pin-channel imaging block and VT750-
conjugated fAd was diluted serially in the range of 0 to 160 µg. 
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Supplementary Figure 3.2. Equal amount of VT750-conjugated fAd was infused into mice via 
jugular vein cannula. Serum samples were collected before adiponectin infusion (0min) as well as 
right after within 2 min. (A) The serum samples were separated in SDS-PAGE gel and scanned it 
with LiCor imager. 3 forms of labeled adiponectin were only detected from 2min samples with no 
different level of fluorescence intensity from control vs STZD animals. (B) Before labeled-
adiponectin infusion, basal level of circulatory adiponectin amount was compared from control and 
diabetic, 4 days post induced from 150μg/g STZ injection by i.p., individuals (n>3). Serum level of 
adiponectin was measured by ELISA. At the same time, the total adiponectin level from the serum 
showed no changes in STZD mice comparing to control after labeled adiponectin infusion (at 2min). 
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Supplementary Figure 3.3. FMT 2500 system could monitor biodistribution of VT750 over time 
in a mouse.  To validate feasibility of biodistribution monitoring with NIR probe, 2 nmol of protein 
free VT750 only was infused into mouse via tail vein and imaging with FMT was taken at 0, 10, 30, 
60, and 90 min. The pattern of VT750’s circulation and accumulation was observed. 
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Supplementary Figure 3.4. Hyperglycemia did not change adiponectin receptors. In mouse 
hearts, STZ-induced hyperglycemina did not change AdipoR1 and AdipoR2 (A) mRNA and (B) 
protein expression. (C) As same as HDMEC, expression of adiponectin receptors (AdipoR1 and 
AdipoR2) were not changed in between hyperglycemia and control. (n=4) 
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Supplementary Figure 3.5. Vasculature of HUVECs on a chip. VE-Cadherin(red) was stained 
with DAPI(blue) after 96hr cell culture (at D4) with 50 ng/mL VEGF. During 4 days vasculature 
formation in hyperglycemia, the integrity of VE-C did not change when it compared to control in 2D 
endothelial monolayer of HUVECs as well as 3D perfusable vessels of HUVECs. All scale bars 
indicate 200 μm. 
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Supplementary Video 3.6. 3D reconstruction of FMT/CT co-registration for control mouse. 
Vehicle only infused subject was used. FMT data from Infused VT-750 labeled fAd indicates in color, 
and computed tomography (CT) data showed in white/grey. 
 
Supplementary Video 3.7. 3D reconstruction of FMT/CT co-registration for STZD mouse. 
Rotated movie showed higher intensity of VT-750 labeled fAd (color) than control subject from FMT 
data. White/grey scale indicates CT data.   
 
Supplementary Video 3.8. 3D perfusable vasculature of HUVECs. The confocal reconstruction 
showed 3D microvasculature with VE-Cadherin (Red) and nucleus (DAPI, blue) staining, which has 
a perfusable lumen aligned with interconnected endothelial cells. 
 
Supplementary Video 3.9. Perfusion of 5μm beads conjugated with FITC in microvascular 
network. FITC polystyrene particles flow through the continuous 3D microvasculature. 
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3.5. DISCUSSION 
Adiponectin has been shown to mediate widespread physiological effects with resulting anti-
diabetic, anti-inflammatory and cardioprotective effects (73). Hence, there has been great interest 
within academic institutes and pharmaceutical companies to develop therapeutics targeting 
adiponectin action. To accomplish this, it is critical to fully understand the mechanisms regulating 
adiponectins cellular effects in various tissues. Whilst we have learned much about adiponectin 
receptor mediated signaling mechanisms, few studies have focused on examining mechanisms 
regulating the transit of adiponectin from the circulation to the interstitial space, and thus target cells 
such as cardiomyocytes, hepatocytes, beta-cells and other cells. We previously proposed that 
vascular permeability was likely to be an important, and underappreciated, determinant of 
adiponectin’s physiological actions (316). This is particularly relevant since adiponectin is a complex 
molecule comprised of multiple oligomeric forms, each with a different molecular weight and radial 
size estimated to be 3.96 to 10.1 nm (222). This is exactly the range within which tight junctions of 
around 4nm in dimension can be expected to strongly contribute to dictating adiponectin flux. Indeed, 
we recently demonstrated that glucocorticoid-mediated decreases in transcellular endothelial 
permeability restricted adiponectin transit across endothelial monolayers (58). The observation that 
adiponectin in cerebrospinal fluid is almost completely in the small trimeric form, and the total 
amount is only 0.1% of that in peripheral circulation (145), suggests that the tight blood brain barrier 
restricts movement of adiponectin oligomers. Conversely, many studies focusing on metabolic 
effects of adiponectin have focused on liver, which has a highly fenestrated leaky vasculature, and 
found that the high molecular weight adiponectin is highly bioactive and correlates well with clinical 
readouts of liver function (50, 259). 
In this study, we used a real time non-invasive approach to monitor and quantify the 
biodistribution of exogenously administered fluorescent adiponectin. The use of FMT as a non-
invasive approach to examine biodistribution of a circulating hormone such as adiponectin has strong 
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advantages (276). The ability to monitor individual mice non-invasively for time-course studies 
vastly reduces the number of animals required and avoids issues such as inter-animal metabolic 
variation and variability in fluorophore injection. In addition, time and expense of isolating numerous 
tissues followed by analysis by western blot can be a significant limiting factor to the identification 
of novel target tissues. Having a clear, temporal, whole-body indicator of kinetics can provide a 
wealth of mechanistic insight, potentially leading to new therapeutics. In this study, we 
complemented FMT imaging with CT, which offered us high-resolution anatomical detail to improve 
the spatial and temporal localization of adiponectin. Analysis of co-registered FMT-CT data 
improves upon methodologies which offer only 2D fluorescence acquisition. Through 3-dimensional 
analysis, we were able to precisely quantify fAd-VT750 in the heart through creation of CT-guided 
3D regions of interest (ROIs). This is vital for accuracy as many factors can impair rough localization 
of a fluorophore including: mouse orientation, variability in organ size, potential “bleed over” from 
highly targeted tissues (e.g. liver), and spatial overlap of several tissues such as the lungs, heart and 
thymus, from certain mouse orientations. Analysis of our in vivo findings were substantially 
corroborated by ex vivo scanning of target tissues and classic molecular biology techniques including 
western blot analysis and immunofluorescence imaging. For fluorescence in vivo imaging of whole 
body biodistribution, it is important to avoid autofluorescence which requires near-infrared (NIR) 
labeling of a target (24).  Probes and fluorophores are available in this range, from 680 to 750nm and 
800nm, offering the potential for some creative multiplexing studies such as co-tracking of insulin 
and adiponectin in circulation under various disease models. Imaging at 750-800nm wavelengths 
completely avoids autofluorescence, and imaging at 680nm only requires the use of low-chlorophyll 
chow to minimize confounding gastrointestinal background fluorescence. 
Using this approach, we studied mice with or without streptozotocin-induced diabetes. 
Interestingly, an accumulation of adiponectin occurred in the peripheral tissues, particularly liver, 
and to a greater extent in STZD mice. This was confirmed by quantitative analysis of in vivo FMT 
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images, ex vivo imaging and by analyzing tissue homogenates by Western blot. It was also interesting 
to note that we found no difference in endogenous adiponectin between control and STZD animals. 
As we are interested in the cardioprotective effects of adiponectin(71, 90) when we focused on 
myocardial adiponectin we again found greater levels in STZD mice. The increased total amount of 
fAd-VT750 appeared to be accounted for by MMW, plus HMW and to a lesser extent LMW 
oligomeric forms. It is worth noting that the relative tightness of an endothelial barrier, whether in 
vivo, ex vivo, or in vitro, and the amount of change induced by a given treatment (e.g. high glucose), 
can lead to seemingly contradictory results such as the data presented here (Fig 3.2.E vs Fig 3.4.C). 
This may be explained through an understanding of protein flux dynamics at the cell junction level: 
slight opening of a tight endothelial barrier may lead to increased flux of only low-molecular weight 
proteins, while with a leakier barrier, the flux of low-molecular weight proteins may already be 
maximum. In this case, further opening of a leaky barrier would manifest as increased flux of only 
higher-molecular weight proteins. STZD is a common diabetic animal model yet data must be 
interpreted with caution since numerous endogenous changes beyond hyperglycemia may impact 
vascular permeability (37, 38, 213, 287). It would be of great interest to examine the same 
phenomenon studied here in models such as high fat diet feeding or in genetically obese models such 
as ob/ob mice (121). Nevertheless, to extend our observations further we examined flux of 
adiponectin upon addition to isolated mesenteric vessels from wt or STZD animals. We observed 
again that vascular permeability of adiponectin was higher in STZD vessels. Furthermore, using an 
endothelial cell monolayer system in vitro we found that flux of adiponectin was significantly greater 
in monolayers cultured in high glucose media versus normal glucose. Collectively, the data suggests 
that in the STZD model hyperglecemia is likely to be one of the principal determinants of altered 
vascular permeability of adiponectin. 
In this study we also focused on alterations in tight junction proteins as a potential 
mechanism underlying the effects observed here. We focused on claudin-7 based on rationale from 
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previous studies which showed that shRNA-mediated reduction in endothelial cell claudin-7 levels 
increased flux of adiponectin across endothelial monolayers (58). Indeed, our data indicated that a 
decrease in claudin-7 may be one important alteration leading to incresed vascular permeability in 
STZD mice. Furthermore, we found ZO-1 was not significantly changed in STZD hearts although 
previously, hyperglycemia was shown to increase permeability of the blood brain barrier (99), and 
retinal pigment epithelial cells (99, 278) through downregulation of occludin and ZO-1. Since 
AdipoR-mediated endocytosis has been shown to have important cellular signaling consequences we 
also believed that this may contribute to a transcellular route of transport (65, 316). However, our 
data in supplementary figure 4 showing no significant change in the level of cardiac AdipoR1 or 
AdipoR2 after hyperglycemia in mice or high glucose level in HDMEC, suggests this is likely not a 
major player. 
We used advanced in vitro platform of 3D microvascular networks on a chip to confirm the 
observation from 2D transwell endothelial monolayer responses in high glucose environment. 
Generating endothelial monolayer of 3D vessels with multiple branches using programmed cellular 
dynamics in hydrogel allows to mimic better in vivo vascular morphology (130). Another strength of 
the 3D microvasculature in microfluidic devices is having perfusibility, which allows to test the 
functionality of the vessels on a chip as well as to better mimic physiological environment with 
application of fluidic shear stress (119, 131, 294). Using paracellular tracers, many literatures have 
shown that the basal permeability of comparably large molecules (40, 70kDa dextran) was lower 
than the permeability of smaller one (4, 10kDa dextran) (84, 104, 118). In this study with the platform, 
we found that HUVECs exposed to high glucose or the same osmotic pressured control condition 
showed size-selective behavior where larger molecules, 70kDa dextran and rhodamine labeled full-
length adiponectin (~90, ~180, > 280kDa), have smaller permeability than smaller ones, 3kDa 
dextran. And the access of 70kDa dextran and rhodamine labeled full-length adiponectin was 
significantly impacted by hyperglycemia-mediated alteration of endothelial permeability.  
 110 
In summary, we have shown that biodistribution of adiponectin can be altered in a diabetic 
environment. Data from a combination of temporal non-invasive imaging in mice, isolated vessels 
ex vivo and in vitro endothelial cell monolayers suggest that hyperglycemia increased vascular flux 
of adiponectin. We believe this may be an important determinant of adiponectin’s physiological 
actions and could provide rationale for further investigation and be exploited from a therapeutic 
perspective. 
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4.1. SUMMARY 
Iron overload is a critical risk factor for the impairment of endothelial integrity and function. 
Even though the adverse effect of iron overload on insulin resistance-mediated diabetes has been 
studied, the effects and underlying mechanism of iron overload on the endothelium remains to be 
elucidated. For the mechanistic studies, it is important to understand whether the endothelial transport 
of adiponectin is regulated by the effect of iron overload on alterations in vascular permeability. Thus, 
I hypothesized that iron overload induces intracellular stress to impair transendothelial permeability, 
and consequently, losing junctional protein alters access of HMW adiponectin for transmovement. 
In this study, I found that the transendothelial electric resistance (TEER) of human dermal 
microvascular endothelial cells (HDMEC) and human umbilical vein endothelial cells (HUVEC) 
decreased under iron overload after 24 hr of tight junction formation. Once the monolayer of 
endothelium formed, molecular permeability was defined by the molecular size, where 3kDa dextran 
demonstrated higher permeability than 70kDa dextran and oligomerized adiponectin. In conditions 
of iron overload, the comparable permeability of the same sized molecules, including adiponectin, 
increased across the barrier compared to control. Correspondingly, expression levels of CLDN7 and 
ZO-1 were decreased in iron overload. These experimental aims were also applied to 3D advanced 
microvascular networks. Under iron overload, increased permeability and the size-dependent 
endothelial movement were observed consistently. Combined, this suggested that endothelial 
regulation could play an important role hormone action in the peripheral tissues by regulating the 
first rate-limiting step of facilitating hormone access to tissue targets.  
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4.2. INTRODUCTION 
Metabolic syndrome is prevalent health problem that is associated with high risk for 
cardiovascular disease and Diabetes Mellitus. The main concern of metabolic syndrome is in the 
effects of insulin resistance. Many of previous studies have provided links between insulin resistance 
and iron overload, from both the systemic and intracellular perspectives (26, 57). Such studies have 
demonstrated that iron overload-induced oxidative stress impairs glucose utilization and glucose 
homeostasis, which leads to insulin resistance. Additionally, iron overload results in loss of the 
pancreatic beta cells due to redox imbalance (223, 263, 298). Ultimately, iron overload plays a causal 
role in Diabetes Mellitus through mediating  loss of both insulin action and insulin secretion.  
Adiponectin, as an insulin sensitizer, plays pivotal roles in cardioprotection, anti-
inflammatory responses, as well as anti-diabetic activity (3). Interestingly, increased serum ferritin 
levels were associated with decreased adiponectin expression and its plasma level, likely due to 
adipocyte damage mediated by oxidative stress (66, 141, 298). On the other hand, overexpression of 
adiponectin attenuated cardiac accumulation of iron (154), however, the specific roles for 
adiponectin under conditions of iron excess have not been clearly described. Particularly, in terms of 
adiponectin action, transendothelial movement of the hormone as a rate-limiting step of its activity 
have not been elucidated in conditions of iron overload. In this regard, it is important to investigate 
iron overload effects on the movement of adiponectin across the endothelial layer, and to elucidate 
the intracellular mechanism of paracellular transport regulation in the environment. 
It has been previously reported that one of the activities of adiponectin is to contribute to the 
suppression of NF-kB activation (266). In contrast, iron overload is known to stimulate NF-kB 
activation by TNF-α signaling-induced phosphorylation in endothelial cells (183). Systemically, 
TNF-α has been shown to increase transferrin receptors and divalent metal transporters to promote 
the accumulation of intracellular iron. Furthermore, Ferroportin 1 was demonstrated to be 
downregulated by TNF-α stimuli, which led to the inhibition of iron export (183). In addition, TNF-
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α signaling regulated not only iron metabolism, but also tight junction proteins (8, 48). Thus, iron-
activated TNF-α signaling may induce NF-kB/P65 translocation into nucleus, which is likely to 
regulate tight junctional protein expression. To examine this, I tested the hypothesis that iron 
overload alters endothelial tight junction expression and consequently changes the adiponectin 
permeability across the barrier.  
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4.3. MATERIAL AND METHODS  
4.3.1. Cell culture (conventional) 
Human dermal microvascular endothelial cells (HDMECs) and human umbilical vascular 
endothelial cells (HUVECs) (ATCC, Manassas, VA, USA) were cultured in microvascular 
endothelial growth medium 2 (EGM2-MV, Lonza, Cat# cc-3202, ON, CA) with 5% fetal bovine 
serum (FBS) at 37°C, and 5% CO2. To mimic the vascular monolayer endothelium, 3.0 μm pore size 
transwell inserts (Corning, Tewksbury, MA, USA) were used, with a surface area of 0.9cm2 designed 
for use with 12-well plates.  Iron overload in endothelial cells was induced by treating cells with 
40μM FeSO4 for 72hr. 
 
4.3.2. Transendothelial electric resistance (TEER) 
TEER of HDMECs was measured using an epithelial voltohmmeter (EVOM; World 
Precision Instruments, Sarasota, FL, USA) and STX-2 chopstick electrodes. All values of TEER 
were corrected by subtracting the value of blank membrane without cells, and they were calculated 
by consideration of time and surface area (W x cm2). 
  
4.3.3. Permeability assay 
2.5 x 105 HDMECs were seeded on 0.9cm2 transwell inserts. Cells were treated with 40μM 
FeSO4 for 72hrs. At the beginning of the assay, 10μg/mL of adiponectin was loaded on the apical 
side of the transwell inserts and an equal amount of plain medium was added into the basolateral side. 
After 24hr, medium from each side was collected and concentrated using 10,000Da MWCO 
(molecular weight cutoff) filter (EMD Millipore, Billerica, MA, USA) according to manufacturer’s 
instructions. 
 
 
 116 
4.3.4. Western blotting 
Only the conventionally (2D) cultured HDMECs were used for western blotting. Cells were 
lysed in complete RIPA buffer with 80mM Tris–HCl (pH 6.8), 2% (w/v) SDS, 20% glycerol, 3.3% 
(v/v) β-mercaptoethanol and 0.01% (w/v) bromophenol blue, 30mM Hepes (pH 7.4), 2.5mM EGTA, 
3mM EDTA, 70mM KCl, 20mM β-glycerolphosphate, 20mM NaF, 1mM Na3VO4, 200μM PMSF, 
10μM E64, 1μM leupeptin, 1μM pepstatin A, 0.1% NP40, and 0.1μM okadaic acid. And the samples 
were denatured at 95°C for 10min. 
Non-denatured adiponectin samples were prepared without β-mercaptoethanol or heating. 
After permeabilization assay, transported adiponectin including 3 forms of isomers were collected 
and concentrated by Amicon Ultra-4 Centrifugal Filter Units with Ultracel-10K (EMD Millipore, 
Billerica, MA, USA). 
After SDS-PAGE electrophoresis and transfer, membranes were incubated in primary 
antibody: a rabbit polyclonal primary anti-Adiponectin antibody (dilution 1:1000) which was 
produced in-house (28), rabbit anti-Claudin-7 (dilution 1:500, Cat#34-9100, Thermo Fisher, 
Rockford, Illinois, USA), and rabbit anti-GAPDH(14C10) (dilution 1:1000, Cat#2118, Cell 
Signaling, Danvers, MA, USA) were used. Membranes were washed and HRP-conjugated secondary 
antibody (anti-rabbit IgG-HRP (dilution 1:5000, Cat#7074, Cell signaling, Danvers, MA, USA) was 
added. Bands were quantified and analyzed by Fiji software. 
 
4.3.5. Immunostaining 
2.5x105 cells/mL of HDMECs were seeded on coverslips and grown for 72hrs with or 
without 40μM FeSO4. Following treatment, cells were fixed using  4% PFA for 10min and 
permeabilized with 0.05% triton-x100. After 30min of blocking, primary antibody against anti-ZO-
1 (rabbit, dilution 1:100, Cat#61-7300, ThermoFisher Scientific, Rockford, Illinois, USA) was added 
overnight at 4°C. Secondary antibody was anti-rabbit IgG-TRITC (1:100, Sigma, St. Louis, Missouri, 
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USA).  DAPI (Vectashiled mounting medium with DAPI, Cat# H-1200, Burlingame, CA, USA) was 
used to stain individual nuclei. Images were taken using an LSM700 (Zeiss) confocal microscope. 
All images were processed using Fiji or Adobe Photoshop CS5 (Adobe System, San Jose, CA). 
Contrast and brightness were enhanced consistently for all representative images used in the 
publication.  
 
4.3.6. Cell culture in microfluidic device 
Microfluidic device having 3D microvascular networks in vitro provides culture 
environment with fibrinogen/ECM in the middle channel and medium supplying in the two side 
channels. Previous studies showed the fabrication process of the PDMS device and it was followed 
by this study (37). Human Umbilical Vein Endothelial Cells (HUVECs, Lonza) were used to perform 
3D vessel experiments with endothelial cell growth medium (EGM-2, Lonza) supplemented with 5% 
fetal bovine serum (FBS) at 37°C, 5% CO2. Each device had 1:1 mixture of cells (1.4 x 107 cells/mL) 
including 4U/mL thrombin solution and fibrinogen solution (5mg/mL) in the middle channel. 
Vasculogenesis by self-assembly of HUVEC performed during 4 days of culture with adding 
50ng/mL VEGF.  
 
4.3.7. Permeability assay in microfluidic device 
On day 4 of vasculogenesis with additional 50ng/mL VEGF in endothelial growth medium, 
one side of each reservoir for a media channel was filled with PBS two times to perform the quick 
wash out any debris from channel and vessel lumen. Fluorescence microscope (Axio, Observer Z1, 
Zeiss) was used for monitoring permeability of molecules by time-lapse imaging at every 1.4 seconds 
for 3 min. Before the fluorescence exposure, the interesting fields of view were selected and 
memorized by software and the bright field of images were taken first without infusion of 
fluorochrome conjugated molecules. 35ul of rhodamine labeled adiponectin, 4kDa FITC-dextran and 
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70kDa TexasRed-dextran were infused into only one reservoir of one side channel. The hydrostatic 
pressure difference made by 35ul of reagent one direction flow of tested molecules. The taken images 
were processed and analyzed by image J.  
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4.4. RESULTS 
4.4.1. Iron overload increased permeability of molecules across an endothelial monolayer of 
HDMECs (2D vasculature system in transwell inserts). 
An endothelial monolayer of 2D vasculature cultured HDMECs (Human dermal 
microvascular endothelial cells) were treated with 40μM FeSO4 in 2% FBS endothelial media for 
72hrs to generate an iron overload environment. In iron overloaded cells, TEER graduation of the 
HDMEC monolayer was attenuated starting from 24hrs and was significantly lower until the 72hr 
timepoint, where the control cells reached to TEER plateau (Fig 4.1A). This treatment also affected 
dextran permeability, which indicated endothelial para-cellular movement was altered. Small MW 
dextran (3kDa) showed significantly higher apparent permeability (Papp), 41.320 x 10-7 ± 0.784 x 
10-7 cm/sec (n=4), than the larger MW dextran (70kDa), 3.134 x 10-7 ± 0.062 x 10-7 cm/sec, (n=4) 
(Figure 1B, C). For both 3kDa- and 70kDa-dextran, iron overload led to increased Papp of the 
HDMECs after 72hr treatment. Papp for 3kDa dextran was 3.503 x 10-7 ± 0.0587 x 10-7 cm/sec (n=4) 
and Papp for 70kDa dextran was 44.100 x 10-7 ± 0.542 x 10-7 cm/sec (n=4) (Fig 4.1 B, C). The 
permeability of full-length adiponectin (fAd), which included the different isomeric forms (LMW, 
MMW and HMW adiponectin) showed a similar effect, where the Papp of fAd was increased (1.305 
± 0.0908 folds, n=7) in the iron overload condition (Fig 4.1D). This was confirmed with SDS-PAGE, 
where specifically LMW adiponectin showed a significant increase in permeability (Fig 4.1E). This 
indicated that the HDMEC monolayer in a 2D culture system showed size-selective permeability of 
molecules that can be altered under iron overload conditions. 
 
4.4.2. Iron overload altered tight junction expression in HDMECs. 
In my previous observations from the other projects, CLDN-7 expression is considered to be 
an important tight junction protein that plays a role in regulating adiponectin permeability. CLDN-7 
expression was measured by immunoblotting and showed a significant decrease in abundance in iron 
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overloaded cells compared to controls (Fig 4.2A). The total intensity of ZO-1, which is localized 
underneath the cell membrane was dramatically reduced, and almost absent in iron overload 
conditions (Fig 4.2B). 
 
4.4.3. 3D microvascular networks of HUVECs showed decreased permeability of 70kDa 
dextran as well as rhodamine-labeled adiponectin under iron overload conditions. 
HUVECs were cultured in a microfluidic chip designed with 2 sided media channels and a 
central hydrogel channel containing cells and fibrin gel as an ECM environment (Fig 4.3A). Based 
on optimization experiments (data not shown), cells were treated with 40μM FeSO4 in 5% FBS 
endothelium growth media for 48hr, with treatment efficacy confirmed by perfusibility testing with 
5μM beads (data not shown). Two different sizes of dextran (3kDa- and 70kDa-) were used to assess 
size-selective behavior on permeability, and each dextran was conjugated with a different 
wavelengths of fluorochromes; 3kDa-Alexa488 and 70kDa-texas red (Fig 4.3B). (*analysis of 3kDa 
Papp results for Figure 3C remains to be completed and I am currently collecting images). The Papp 
of 70kDa dextran was significantly increased under iron overload when it was analyzed from random 
ROIs in each field of view (Fig 4.3D). Papp of the control was 1.955 x 10-5 ± 0.367 x 10-5 cm/sec 
(n=16) and Papp of iron overload was 3.573 x 10-5 ± 0.600 x 10-5 cm/sec (n=24) (Fig 4.3D). 
Rhodamine-labeled adiponectin was also infused into the 3D microvascular networks and Papp was 
measured by capturing timelapse images at every 20 sec (Fig 4.3F). The Papp in iron overload (4.651 
x 10-5  ± 0.585 x 10-5 cm/sec, (n=12)) was significantly increased as compared to the Papp of controls, 
(2.101 x 10-5  ± 0.1908 x 10-5  cm/sec (n=12)) (Fig 4.3E). 
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Figure 4.1. Iron overload-induced alteration on TEER and permeability of 2D HDMEC 
endothelial monolayer in transwell inserts 
Iron overload (IO) condition was generated by treatment with 40μM FeSO4 in 2% FBS endothelial 
media for 72hrs after transferring cells into transwell inserts. (A) TEER was measured every 24hrs. 
* indicates P<0.05 (n>12). (B, C) Apparent permeability (Papp) of different sizes of dextrans was 
measured. 3kDa-Alexa488 and 70kDa-Texas red conjugated dextran were loaded into the apical side 
of the inserts, and 6hr later, the medium from the basolateral side was collected and measured by 
microplate reader. *indicates p<0.05 and ** indicates p<0.01. (n=4) (D) Papp of full-length 
adiponectin (fAd) for 24hr. Collected fAd was measured by ELISA. * indicates p<0.05 (n>7). (E) 
The collected medium including fAd from the basolateral side was concentrated and separated by 
electrophoresis in SDS-PAGE gel without denaturation. (* indicates p<0.05) 
0 24 48 72
0
10
20
30
40
50
TE
ER
 (
xc
m
2 )
Control
I/O
* *
*
0.0
0.5
1.0
1.5
Pe
rm
ea
bi
lit
y 
of
 A
di
po
ne
ci
tn
(fo
ld
 o
ve
r c
on
tro
l)
0.0 0.5 1.0 1.5
LMW
MMW
HMW
Transported Adiponectin
(fold over control)
I/O
Control
*
I/O +-I/O +-
I/O +- I/O +-
*
0
10
20
30
40
50
Pa
pp
 o
f  
3k
D
a 
D
ex
tra
n
(c
m
*s
ec
-1
 x
 1
0-
7)
* **
0
1
2
3
4
Pa
pp
 o
f  
70
kD
a 
D
ex
tra
n
(c
m
*s
ec
-1
 x
 1
0-
7)
A
D E
B C
 122 
 
 
Figure 4.2. Changes of tight junction by iron overload in HDMECs 
(A) Immunoblotting for CLDN7 to compare control versus 40μM FeSO4-treated iron overload 
condition. (B) Immunofluorescence of ZO-1. The total intensity from each field of view was analyzed 
after normalization with background from the negative control images. * indicates p<0.05. 
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Figure 4.3. Permeability analysis of dextrans and adiponectin in 3D microvascular networks of 
HUVECs 
(A) Schematic image for a microfluidic device with 2 media channels and a central cell-hydrogel 
channel. (B) Two different sizes of dextran infused into perfusable vasculature on-a-chip. 3kDa-
Alexa dextran (Green) and 70kDa-Texas red (Red) were perfused and time-lapse images were 
captured at every 20 sec. (C, D) Calculated Papp (cm/sec) for each type of dextran. * indicates p<0.05 
(n=16~24). (E) Papp of rhodamine labeled adiponectin (Rho-fAd) was measured. *indicates p<0.05 
(n=12). (F) The representative captured images at each timepoint overlaying with constitutively 
expressed GFP in HUVECs (Green) and Rho-fAd (Red).  
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4.5. DISCUSSION 
This research was designed to examine endothelial function and integrity, an area of 
fundamental endocrine importance, with a 2D vessel mimic culture system and a 3D closed 
circulatory vasculature system using endothelial cells. It is well established that paracellular transport 
is modulated in response to nutritional factors. Despite this, we know very little about the endothelial 
“machinery” that implements these changes. Specifically, in the condition of iron overload, I 
observed that permeability across vessel-like endothelium barriers of HDMECs and HUVECs 
increased and allowed more transendothelial movement of dextran and full-length adiponectin.  
In terms of permeability, there are three main observations confirmed in both types of in 
vitro vasculature systems. Firstly, the paracellular movement of molecules was regulated in a size-
selective manner, and the basal permeability of adiponectin was similar to that of 70kDa dextran. 
The structure of oligomerized adiponectin is asymmetric and not uniform (191), which would suggest 
it would have an uncertain range of permeability. The permeability assay in the 3D vasculature 
system allowed me to define the accessibility of adiponectin based on structural specificity. Secondly, 
iron overload significantly increased paracellular permeability. Even though the extent of the impact 
of excess iron was represented differently due to differences in the sensitivity for detection in each 
system (2D vs 3D), the trends and significance of the iron effect reproducible in both systems. Lastly, 
the major difference in between two in vitro systems was sheer stress introduced by the fluidics 
setting. Having flow in the perfusable vasculature did not affect the observed alteration in 
permeability mediated by excess intracellular iron.  
This alteration of adiponectin flux is strongly associated with changes in tight junction 
proteins. From the previous studies 1 and 2, CLDN7 plays a key role in adiponectin flux control; 
increased CLND7 reduced the flux of adiponectin, while in contrast, loss or decreased expression of 
CLND7 elevated adiponectin movement. The effect of iron overload on downregulation of CLDN7 
expression supports the suggested role for iron overload in regulation of endothelial tight junctions. 
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In addition to CLDN7, the intracellular protein level of ZO-1 was also upon treatment with 40μM 
FeSO4. However, the mechanism of how the expression of the junctional proteins is altered by iron 
is not known.  
In this study, I will continue to elucidate the underlying mechanism by investigating 
speculated targets, which are oxidative stress and regulation of NF-kB activation by iron overload. 
It is well known that iron-mediated oxidative stress comes from the induced ROS production in 
endothelial cells, and it results in impairing endothelial function (193). The produced intracellular 
ROS is detectable by 2′,7′-dichlorofluorescein diacetate (DCF-DA) fluorescent assay, which 
reagent is permeable non-fluorescent molecule and becomes fluorescent by ROS-induced oxidation 
(108), as well as, by CellROX assay that can detect cellular oxidative stress using reagent turnover 
from reduced form of non-fluorescent probe to oxidized deep red fluorescent one by ROS (251). 
Therefore, either ROS detection methods will be applied to test iron effects on ROS production in 
endothelial cells.  
The aberrant free radical is known to give negative impacts on the barrier function of TJs 
and AJs (163), although the regulatory mechanism is not precise yet. I will examine that the iron-
driven free radical activates NF-kB as a redox-sensitive transcription factor, which can deal with 
the oxidative stress via changes of gene expressions in endothelial cells. In addition, I will also test 
whether the effect of iron subsequently increases permeability by junctional proteins alteration. To 
confirm that the major components of the NF-kB complex and its regulator will be studied.  The 
subunits of NF-kB (P50 and P65) and the inhibitor of NF-kB (IkB) are tightly regulated by 
phosphorylation and ubiquitination. Once NF-kB subunits are phosphorylated, it has less affinity to 
IkB, and it is translocated into the nucleus. The dissociated IkB is phosphorylated and ready for 
ubiquitination as well as proteolytic degradation by ATP-dependent 26S proteasome complex. 
(163) To understand the cellular response to iron overload, the level of phosphorylation for P65 and 
IkBalpha will be detected by immunoblotting. And the activity of luciferase, as a reporter gene 
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under the control of NF-kB promoter, will be tested to measure the NF-kB gene regulation from 
iron overload. This further investigation contributes to a better understanding of the mechanism 
that iron-induced oxidative stress alters the permeability of adiponectin. 
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CHAPTER FIVE: DISCUSSION AND CONCLUSION 
 
5.1 RESEARCH SUMMARY 
Dysfunctional endothelium driven by metabolic syndrome has been observed in cases of 
diabetes and cardiovascular disease. Structural and functional damage to the vasculature is caused 
by a combination of hyperinsulinemia, hyperglycemia, and redox imbalance mediated by cellular 
and mechanical stress. One of the significant roles of the endothelium in the vascular structure is to 
regulate molecular transport across the barrier. To study the effect of hormonal transport in the 
context of metabolic syndrome, particularly in study 1, I examined the effect of glucocorticoids on 
transendothelial permeability. The most prevalent medication for inflammation, glucocorticoids are 
known for having a side effect of building up insulin resistance, as well as being a tightening agent 
of the endothelium. The tightening effect was observed in both in vivo and in vitro systems. 
Consequently, adiponectin movement was restricted. (Fig 5.B) Furthermore, I found that exogenous 
glucocorticoids triggered hyperinsulinemia in the absence of fluctuations in blood glucose levels in 
rats, which may indicate the progressive development of systemic insulin resistance (Fig 5.A). It is 
suggested that hyperinsulinemia mediated by glucocorticoid treatment reduced endothelial 
permeability, which restricted adiponectin movement (Fig 5.A,B). In contrast, in studies 2 and 3, 
hyperglycemia and iron overload both increased adiponectin movement associated with loosened 
permeability (Fig 5.B). In the case of hyperglycemia, many studies have indicated that hyperglycemia 
has a causal relationship to oxidative stress. Additionally, accumulated serum ferritin and increased 
cellular iron content leads to a redox imbalance status by excess ROS production, which contributes 
to synergetic pathologies. (Fig 5.A) 
The endothelial monolayer is an important rate-limiting determinant of hormone and 
substrate access to target tissues. Previous studies focusing on insulin suggest that impaired delivery 
of insulin from the plasma to the interstitial space in obesity may contribute to metabolic insulin 
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resistance and diabetes. Since adiponectin is known to mediate beneficial antidiabetic effects, and 
the molecular weight of biologically active forms of adiponectin ranges widely, I proposed that 
paracellular transport is a major determinant of transendothelial adiponectin flux. This was proven 
throughout studies 1, 2 and 3 paracellular transport was altered by different risk factors of metabolic 
syndrome, leading to changes in adiponectin flux. In study 1, glucocorticoid-treated HUVECs and in 
vivo studies in rats consistently showed restricted adiponectin trans-movement. 
In contrast, for studies 2 and 3, exposure to excess glucose or iron increased adiponectin flux 
in the mouse, as well as HUVECs and HDMECs. The alteration in paracellular transport was highly 
associated with changes in TEER in a monolayer culture system. For example, based on the TEER, 
which is interpreted as measurable tightness of the endothelium, paracellular movement of dextran 
was inversely regulated. Similarly, the amount of transported adiponectin across the monolayer 
showed a negative correlation with TEER.  
In addition, paracellular transport is regulated in a size-selective manner. My studies applied 
two different sizes of dextran (3kDa and 70kDa) to monitor permeability in vitro. Expectedly, 70kDa 
dextran had lower permeability than 3kDa dextran. However, in terms of oligomerized adiponectin 
movement in vivo, it appears as though there is another potential mechanism. In particular, the 
research community has often accepted that fact that the HMW oligomeric form of adiponectin 
targets liver and not muscle, whereas the small globular portion has ‘more potency’ in skeletal muscle. 
This was initially attributed to the higher binding affinity of the globular fragment of adiponectin to 
skeletal muscle cell membranes, which were thought to express more of the AdipoR1 receptor 
isoform. However, such data are not consistent, and easier access of the smaller globular adiponectin 
across the relatively tight endothelial monolayer found in skeletal muscle vasculature, in comparison 
with liver, may be significant. Thus, TJ-mediated, or AJ-mediated, alterations in adiponectin access 
to tissues from the vasculature are likely to be of important functional significance. In this aspect, 
study 1 showed the comparison of the tight junction protein profile upon glucocorticoid treatment vs 
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control. Although the profiles seemed different from the species, alterations in claudin 7 and claudin-
10 were consistent in their response to glucocorticoids. Particularly, CLDN 7 seemed to play an 
important role in the maintenance of endothelial monolayer integrity according to the results of 
increased adiponectin flux across a monolayer of HUVECs with claudin 7 shRNA-mediated 
knockdown. Based on the findings in the following study 2, CLDN 7 is likely to play a pivotal role 
to control adiponectin transport. 
Indeed, numerous studies in kidney and retina have indicated that expression of various TJ 
proteins is altered in diabetes. Although the changes in metabolic target tissues of adiponectin and 
their physiological significance still need to be established, principal mechanisms responsible for 
altered TJ composition and structure in diabetes are partially elucidated in my thesis studies. In study 
3, the underlying mechanism to explain TJ alteration in the endothelium by iron overload was 
investigated with the clue of oxidative stress. Increased cellular ROS production has been reported 
to induce NF-kB phosphorylation (170). In retinal ECs, there was a report that TNF-α activation 
altered TJ proteins (14). Taken together, an NF-kB activation-related cellular response to increased 
ROS by iron overload may be responsible for the decreased TJ proteins in the endothelium, and 
consequently, increased access of adiponectin movement across the barrier of the endothelium.  
For studies 1,2, and 3, I established advanced technical approaches to monitor adiponectin 
movement in vivo, ex vivo and in vitro. FMT-CT imaging allowed 3D non-invasive small animal 
scanning over time, obtaining both temporal and the spatial detailed information. I also applied the 
3D perfusable microvascular network, which allowed me to test the functionality of auto-assembled 
vessels in vitro.  
Overall, these studies suggested that transendothelial movement of adiponectin via 
paracellular permeability of the endothelial barrier is a tightly regulated process which can be 
dynamically adjusted in response to various mediators. The potential contribution to metabolic 
dysfunction due to metabolic syndrome and diabetes is apparent, yet the precise significance has 
 131 
likely been somewhat underestimated. I believe that further investigation of TJ-mediated changes in 
hormone or substrate flux in diabetes, and the characterization of their functional significance, will 
shed additional light on the pathophysiology of disease and identify potential therapeutic 
opportunities. 
 
5.2    FUTURE DIRECTION 
Future studies will continue to explore the mechanisms underlying hormone physiological 
action mediated by alterations of endothelial permeability. Studies 1, 2 and 3 claimed that tight 
junctional alterations directly affected the transendothelial movement of adiponectin. In the case of 
HDMECs and HUVECs, CLDN7 was a major component of the tight junctions to control 
adiponectin movement across the endothelial barrier. Extending this observation to an animal model 
would allow for finding the physiological meaning endothelial permeability regulation, and claudin 
7 knock out mice will be the priority model. Unfortunately, conventional or intestinal-specific 
CLDN7 knockout mice mediated by the Cre/Lox system show a severe phenotype of stunted or 
perinatal death in mice (258, 304). However, recently, an inducible intestine-specific conditional 
knockout mouse was developed for targeting CLDN7. These mice showed a normal phenotype 
before tamoxifen induction via intraperitoneal injection (258). Under conditions of metabolic 
syndrome, alterations in endothelial permeability occur in cardiac vessels, one of the most susceptible 
organs to metabolic syndrome. My study 2 showed that exogenous adiponectin content was increased 
in heart tissue of diabetic mice. Thus, although it could be ambitious to generate an inducible cardiac-
specific claudin 7 knockout animal, my preliminary findings demonstrate that this does warrant 
further investigation. For example, to confirm the physiological importance of claudin 7 on 
adiponectin endothelial movement, I can compare the biodistribution of adiponectin in the claudin 7 
knockout model vs. wildtype using the FMT/CT monitoring system. Furthermore, I can also recover 
the claudin 7 gene expression via adenovirus-mediated overexpression (148). This type of study 
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would provide further therapeutic insights into the application of claudin 7 overexpression via 
adenoviral gene therapy in diabetes. 
In addition, the strategy of restoring CLDN7 by overexpression can also be applied to an 
iron overload animal model to examine changes in adiponectin action in target tissue mediated by 
recovery of endothelial permeability. The iron overload model is produced by dietary supplement or 
iron-dextran injection via various routes, for example, intraperitoneal, subcutaneous, intramuscular, 
parenteral, or intravenous injection (112). In study 3, the presumptive cause of loss of permeability 
was reduced CLDN7 expression in endothelial cells, which depended on alterations in gene 
expression of CLDN7 by iron-mediated oxidative stress. If the compensation of tight junctions works 
on improving endothelial integrity, it also can be a target of future therapy for iron chelator-induced 
complications.    
Both the in vivo animal models and in vitro vasculature platform have opened opportunities 
to extend the study of adiponectin action and endothelial regulation. 3D vasculature networks can be 
applied for diverse purposes and optimized with numerous features. Firstly, even though the 
simplified system containing only endothelial cells has the benefit of providing clear, direct effects, 
it is less physiologically relevant than having harmonious effects with several different cell types like 
pericytes, smooth muscle cells, immune cells or cancer cells (40, 305). In the BBB, renal and retinal 
vessels, pericytes are known to play a crucial role in managing endothelial integrity (128, 267, 305). 
To mimic more physiological and functional vasculature in vitro, I can apply the co-culturing system 
used in study 3 in hydrogel ECM with pericytes or smooth muscle cells by taking advantage of the 
self-assembly feature of endothelial cells. Secondly, I can use this human functional 
microvasculature network to develop a screening platform for other circulatory molecules including 
cytokines, other hormones, adipokines ,and immune-related cells under conditions resembling 
metabolic syndrome. For example, as described in studies 2 and 3, transendothelial adiponectin 
movement is increased in diabetes-related conditions. In the state, I could examine correlations 
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between adiponectin and the permeability of other hormones or cells, for example, LCN2, TNF-alpha, 
neutrophils or monocytes, etc. This approach may contribute to finding future therapeutic targets and 
strategies. 
 
5.3 CONCLUSION 
In summary, all of my studies intended to investigate the mechanisms of physiological 
adiponectin action via transendothelial movement, which is regulated by endothelial permeability in 
diabetes. To prove that reduced endothelial permeability restricted adiponectin movement, I used 
glucocorticoid treatment. The study proved that transendothelial adiponectin moved via the 
paracellular pathway, and also suggested that decreased adiponectin movement depended on 
paracellular permeability which was regulated by tight junctional profiles. In contrast, hyperglycemia 
increased adiponectin transendothelial movement due to increased endothelial permeability, as 
measured by TEER. Examination of the biodistribution of adiponectin in diabetic mice showed that 
a higher amount of exogenous adiponectin existed in the peripheral tissues 90min after infusion 
compared to controls. This in vivo observation was validated in ex vivo isolated vessels, 2D in vitro 
endothelial monolayers and in 3D perfusable in vitro microvasculature. Lastly, I wanted to know 
underlying mechanisms responsible for the alteration of permeability in adiponectin movement, 
particularly in iron overload. Elevation in oxidative stress caused by excess iron is likely to change 
tight junction protein expression. Therefore, I concluded that adiponectin transendothelial movement 
was determined by endothelial permeability, which was strongly regulated by tight junctional protein 
expression. The permeability of diabetic vasculature altered adiponectin movement from plasma to 
peripheral tissues, and thus influenced its action.    
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Figure 5.1. Schematic summary of studies for adiponectin permeability in chronic diabetic 
process  
(A) Depending on the chronic process of diabetes from pre-diabetic to overt-diabetic condition, the 
impaired control of homeostasis reflects alteration of insulin, iron and glucose at the circulatory 
level. (B) The hyperinsulinemia, iron overload and hyperglycemia leads to changes the tightness of 
endothelial barrier and it is negatively correlated to permeability of adiponectin.  
 
 
 135 
Uncategorized References 
1. Intensive blood-glucose control with sulphonylureas or insulin compared with 
conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 
33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 352: 837-853, 1998. 
2. Abe Y, Sakairi T, Kajiyama H, Shrivastav S, Beeson C, and Kopp JB. Bioenergetic 
characterization of mouse podocytes. Am J Physiol Cell Physiol 299: C464-476, 2010. 
3. Achari AE and Jain SK. Adiponectin, a Therapeutic Target for Obesity, Diabetes, and 
Endothelial Dysfunction. Int J Mol Sci 18, 2017. 
4. Agarwal A, Sarwar S, Sepah YJ, and Nguyen QD. What have we learnt about the 
management of diabetic macular edema in the antivascular endothelial growth factor and 
corticosteroid era? Curr Opin Ophthalmol 26: 177-183, 2015. 
5. Aird WC. Phenotypic heterogeneity of the endothelium: I. Structure, function, and 
mechanisms. Circ Res 100: 158-173, 2007. 
6. Aird WC. Phenotypic heterogeneity of the endothelium: II. Representative vascular 
beds. Circ Res 100: 174-190, 2007. 
7. Akude E, Zherebitskaya E, Chowdhury SK, Smith DR, Dobrowsky RT, and 
Fernyhough P. Diminished superoxide generation is associated with respiratory chain 
dysfunction and changes in the mitochondrial proteome of sensory neurons from diabetic 
rats. Diabetes 60: 288-297, 2011. 
8. Al-Sadi R, Guo S, Ye D, Rawat M, and Ma TY. TNF-alpha Modulation of Intestinal 
Tight Junction Permeability Is Mediated by NIK/IKK-alpha Axis Activation of the Canonical 
NF-kappaB Pathway. Am J Pathol 186: 1151-1165, 2016. 
9. Alberts B, Johnson A, Lewis J, Raff M, Roberts K, and Walter P. Molecular biology 
of the cell. new york: Garland science; 2002. Classic textbook now in its 5th Edition, 2002. 
10. Ale A, Ermolayev V, Herzog E, Cohrs C, de Angelis MH, and Ntziachristos V. FMT-
XCT: in vivo animal studies with hybrid fluorescence molecular tomography-X-ray 
computed tomography. Nature methods 9: 615-620, 2012. 
11. Alipoor E, Mohammad Hosseinzadeh F, and Hosseinzadeh-Attar MJ. Adipokines in 
critical illness: A review of the evidence and knowledge gaps. Biomed Pharmacother 108: 
1739-1750, 2018. 
12. Antonetti DA, Barber AJ, Khin S, Lieth E, Tarbell JM, and Gardner TW. Vascular 
permeability in experimental diabetes is associated with reduced endothelial occludin 
content: vascular endothelial growth factor decreases occludin in retinal endothelial cells. 
Penn State Retina Research Group. Diabetes 47: 1953-1959, 1998. 
13. Arita Y, Kihara S, Ouchi N, Maeda K, Kuriyama H, Okamoto Y, Kumada M, Hotta K, 
Nishida M, Takahashi M, Nakamura T, Shimomura I, Muraguchi M, Ohmoto Y, Funahashi 
T, and Matsuzawa Y. Adipocyte-derived plasma protein adiponectin acts as a platelet-
derived growth factor-BB-binding protein and regulates growth factor-induced common 
postreceptor signal in vascular smooth muscle cell. Circulation 105: 2893-2898, 2002. 
14. Aveleira CA, Lin CM, Abcouwer SF, Ambrosio AF, and Antonetti DA. TNF-alpha 
signals through PKCzeta/NF-kappaB to alter the tight junction complex and increase retinal 
endothelial cell permeability. Diabetes 59: 2872-2882, 2010. 
 136 
15. Barber AJ, Antonetti DA, and Gardner TW. Altered expression of retinal occludin 
and glial fibrillary acidic protein in experimental diabetes. The Penn State Retina Research 
Group. Invest Ophthalmol Vis Sci 41: 3561-3568, 2000. 
16. Barbot M, Ceccato F, and Scaroni C. Diabetes Mellitus Secondary to Cushing's 
Disease. Front Endocrinol (Lausanne) 9: 284, 2018. 
17. Barrett EJ and Rattigan S. Muscle perfusion: its measurement and role in metabolic 
regulation. Diabetes 61: 2661-2668, 2012. 
18. Barrett EJ, Wang H, Upchurch CT, and Liu Z. Insulin regulates its own delivery to 
skeletal muscle by feed-forward actions on the vasculature. American journal of physiology 
Endocrinology and metabolism 301: E252-263, 2011. 
19. Beaudry JL, D'Souza A M, Teich T, Tsushima R, and Riddell MC. Exogenous 
glucocorticoids and a high-fat diet cause severe hyperglycemia and hyperinsulinemia and 
limit islet glucose responsiveness in young male Sprague-Dawley rats. Endocrinology 154: 
3197-3208, 2013. 
20. Beaudry JL, Dunford EC, Leclair E, Mandel ER, Peckett AJ, Haas TL, and Riddell MC. 
Voluntary exercise improves metabolic profile in high-fat fed glucocorticoid-treated rats. J 
Appl Physiol (1985) 118: 1331-1343, 2015. 
21. Beaudry JL, Dunford EC, Teich T, Zaharieva D, Hunt H, Belanoff JK, and Riddell MC. 
Effects of selective and non-selective glucocorticoid receptor II antagonists on rapid-onset 
diabetes in young rats. PLoS One 9: e91248, 2014. 
22. Ben-Yosef T, Belyantseva IA, Saunders TL, Hughes ED, Kawamoto K, Van Itallie CM, 
Beyer LA, Halsey K, Gardner DJ, Wilcox ER, Rasmussen J, Anderson JM, Dolan DF, Forge A, 
Raphael Y, Camper SA, and Friedman TB. Claudin 14 knockout mice, a model for autosomal 
recessive deafness DFNB29, are deaf due to cochlear hair cell degeneration. Hum Mol 
Genet 12: 2049-2061, 2003. 
23. Bhattacharjee PS, Huq TS, Potter V, Young A, Davenport IR, Graves R, Mandal TK, 
Clement C, McFerrin HE, Muniruzzaman S, Ireland SK, and Hill JM. High-glucose-induced 
endothelial cell injury is inhibited by a Peptide derived from human apolipoprotein E. PLoS 
One 7: e52152, 2012. 
24. Bhaumik S, DePuy J, and Klimash J. Strategies to minimize background 
autofluorescence in live mice during noninvasive fluorescence optical imaging. Lab animal 
36: 40-43, 2007. 
25. Bischel LL, Sung KE, Jimenez-Torres JA, Mader B, Keely PJ, and Beebe DJ. The 
importance of being a lumen. FASEB J 28: 4583-4590, 2014. 
26. Blasco G, Puig J, Daunis IEJ, Molina X, Xifra G, Fernandez-Aranda F, Pedraza S, 
Ricart W, Portero-Otin M, and Fernandez-Real JM. Brain iron overload, insulin resistance, 
and cognitive performance in obese subjects: a preliminary MRI case-control study. 
Diabetes Care 37: 3076-3083, 2014. 
27. Blecharz KG, Drenckhahn D, and Forster CY. Glucocorticoids increase VE-cadherin 
expression and cause cytoskeletal rearrangements in murine brain endothelial cEND cells. 
J Cereb Blood Flow Metab 28: 1139-1149, 2008. 
28. Bo T, Yamamori T, Suzuki M, Sakai Y, Yamamoto K, and Inanami O. Calmodulin-
dependent protein kinase II (CaMKII) mediates radiation-induced mitochondrial fission by 
 137 
regulating the phosphorylation of dynamin-related protein 1 (Drp1) at serine 616. Biochem 
Biophys Res Commun 495: 1601-1607, 2018. 
29. Bocher M, Blevis IM, Tsukerman L, Shrem Y, Kovalski G, and Volokh L. A fast 
cardiac gamma camera with dynamic SPECT capabilities: design, system validation and 
future potential. European journal of nuclear medicine and molecular imaging 37: 1887-
1902, 2010. 
30. Bodenlenz M, Schaupp LA, Druml T, Sommer R, Wutte A, Schaller HC, Sinner F, 
Wach P, and Pieber TR. Measurement of interstitial insulin in human adipose and muscle 
tissue under moderate hyperinsulinemia by means of direct interstitial access. American 
journal of physiology Endocrinology and metabolism 289: E296-300, 2005. 
31. Breiderhoff T, Himmerkus N, Stuiver M, Mutig K, Will C, Meij IC, Bachmann S, 
Bleich M, Willnow TE, and Muller D. Deletion of claudin-10 (Cldn10) in the thick ascending 
limb impairs paracellular sodium permeability and leads to hypermagnesemia and 
nephrocalcinosis. Proc Natl Acad Sci U S A 109: 14241-14246, 2012. 
32. Bromhead C, Miller JH, and McDonald FJ. Regulation of T-cadherin by hormones, 
glucocorticoid and EGF. Gene 374: 58-67, 2006. 
33. Brownlee M. Biochemistry and molecular cell biology of diabetic complications. 
Nature 414: 813, 2001. 
34. Buechler C, Wanninger J, and Neumeier M. Adiponectin receptor binding proteins-
-recent advances in elucidating adiponectin signalling pathways. FEBS letters 584: 4280-
4286, 2010. 
35. Bugger H, Chen D, Riehle C, Soto J, Theobald HA, Hu XX, Ganesan B, Weimer BC, 
and Abel ED. Tissue-specific remodeling of the mitochondrial proteome in type 1 diabetic 
akita mice. Diabetes 58: 1986-1997, 2009. 
36. Bugger H, Chen D, Riehle C, Soto J, Theobald HA, Hu XX, Ganesan B, Weimer BC, 
and Abel ED. Tissue-specific remodeling of the mitochondrial proteome in type 1 diabetic 
akita mice. Diabetes 58: 1986-1997, 2009. 
37. Capucci MS, Hoffmann ME, De Groot A, and Natarajan AT. Streptozotocin-induced 
toxicity in CHO-9 and V79 cells. Environ Mol Mutagen 26: 72-78, 1995. 
38. Chang KS and Stevens WC. Endothelium-dependent increase in vascular sensitivity 
to phenylephrine in long-term streptozotocin diabetic rat aorta. Br J Pharmacol 107: 983-
990, 1992. 
39. Chen L, Magliano DJ, and Zimmet PZ. The worldwide epidemiology of type 2 
diabetes mellitus--present and future perspectives. Nat Rev Endocrinol 8: 228-236, 2011. 
40. Chen MB, Whisler JA, Frose J, Yu C, Shin Y, and Kamm RD. On-chip human 
microvasculature assay for visualization and quantification of tumor cell extravasation 
dynamics. Nat Protoc 12: 865-880, 2017. 
41. Chen X, Scholl TO, and Stein TP. Association of elevated serum ferritin levels and 
the risk of gestational diabetes mellitus in pregnant women: The Camden study. Diabetes 
Care 29: 1077-1082, 2006. 
42. Chen Y, Pitzer AL, Li X, Li PL, Wang L, and Zhang Y. Instigation of endothelial Nlrp3 
inflammasome by adipokine visfatin promotes inter-endothelial junction disruption: role of 
HMGB1. J Cell Mol Med 19: 2715-2727, 2015. 
 138 
43. Chistiakov DA, Orekhov AN, and Bobryshev YV. Effects of shear stress on 
endothelial cells: go with the flow. Acta Physiol (Oxf) 219: 382-408, 2017. 
44. Chiu JD, Kolka CM, Richey JM, Harrison LN, Zuniga E, Kirkman EL, and Bergman RN. 
Experimental hyperlipidemia dramatically reduces access of insulin to canine skeletal 
muscle. Obesity (Silver Spring) 17: 1486-1492, 2009. 
45. Chiu JD, Richey JM, Harrison LN, Zuniga E, Kolka CM, Kirkman E, Ellmerer M, and 
Bergman RN. Direct administration of insulin into skeletal muscle reveals that the transport 
of insulin across the capillary endothelium limits the time course of insulin to activate 
glucose disposal. Diabetes 57: 828-835, 2008. 
46. Chowdhury SK, Smith DR, and Fernyhough P. The role of aberrant mitochondrial 
bioenergetics in diabetic neuropathy. Neurobiol Dis 51: 56-65, 2013. 
47. Clark AR and Belvisi MG. Maps and legends: the quest for dissociated ligands of the 
glucocorticoid receptor. Pharmacol Ther 134: 54-67, 2012. 
48. Clark PR, Kim RK, Pober JS, and Kluger MS. Tumor necrosis factor disrupts claudin-
5 endothelial tight junction barriers in two distinct NF-kappaB-dependent phases. PLoS One 
10: e0120075, 2015. 
49. Cohen RM, Franco RS, Khera PK, Smith EP, Lindsell CJ, Ciraolo PJ, Palascak MB, and 
Joiner CH. Red cell life span heterogeneity in hematologically normal people is sufficient to 
alter HbA1c. Blood 112: 4284-4291, 2008. 
50. Combs TP and Marliss EB. Adiponectin signaling in the liver. Rev Endocr Metab 
Disord 15: 137-147, 2014. 
51. Combs TP, Pajvani UB, Berg AH, Lin Y, Jelicks LA, Laplante M, Nawrocki AR, Rajala 
MW, Parlow AF, Cheeseboro L, Ding YY, Russell RG, Lindemann D, Hartley A, Baker GR, 
Obici S, Deshaies Y, Ludgate M, Rossetti L, and Scherer PE. A transgenic mouse with a 
deletion in the collagenous domain of adiponectin displays elevated circulating adiponectin 
and improved insulin sensitivity. Endocrinology 145: 367-383, 2004. 
52. Coughlan MT, Thorburn DR, Penfold SA, Laskowski A, Harcourt BE, Sourris KC, Tan 
AL, Fukami K, Thallas-Bonke V, Nawroth PP, Brownlee M, Bierhaus A, Cooper ME, and 
Forbes JM. RAGE-induced cytosolic ROS promote mitochondrial superoxide generation in 
diabetes. J Am Soc Nephrol 20: 742-752, 2009. 
53. D'Souza A M, Beaudry JL, Szigiato AA, Trumble SJ, Snook LA, Bonen A, Giacca A, 
and Riddell MC. Consumption of a high-fat diet rapidly exacerbates the development of 
fatty liver disease that occurs with chronically elevated glucocorticoids. Am J Physiol 
Gastrointest Liver Physiol 302: G850-863, 2012. 
54. Dadson K, Liu Y, and Sweeney G. Adiponectin action: a combination of endocrine 
and autocrine/paracrine effects. Front Endocrinol (Lausanne) 2: 62, 2011. 
55. Dadson K, Turdi S, Boo S, Hinz B, and Sweeney G. Temporal and Molecular Analyses 
of Cardiac Extracellular Matrix Remodeling following Pressure Overload in Adiponectin 
Deficient Mice. PLoS One 10: e0121049, 2015. 
56. Dadson K, Turdi S, Hashemi S, Zhao J, Polidovitch N, Beca S, Backx PH, McDermott 
JC, and Sweeney G. Adiponectin is required for cardiac MEF2 activation during pressure 
overload induced hypertrophy. J Mol Cell Cardiol 86: 102-109, 2015. 
 139 
57. Dandona P, Hussain MA, Varghese Z, Politis D, Flynn DM, and Hoffbrand AV. 
Insulin resistance and iron overload. Ann Clin Biochem 20 Pt 2: 77-79, 1983. 
58. Dang TQ, Yoon N, Chasiotis H, Dunford EC, Feng Q, He P, Riddell MC, Kelly SP, and 
Sweeney G. Transendothelial movement of adiponectin is restricted by glucocorticoids. J 
Endocrinol 234: 101-114, 2017. 
59. Deepa SS and Dong LQ. APPL1: role in adiponectin signaling and beyond. American 
journal of physiology Endocrinology and metabolism 296: E22-36, 2009. 
60. Defronzo RA. Banting Lecture. From the triumvirate to the ominous octet: a new 
paradigm for the treatment of type 2 diabetes mellitus. Diabetes 58: 773-795, 2009. 
61. Deli MA. Potential use of tight junction modulators to reversibly open membranous 
barriers and improve drug delivery. Biochim Biophys Acta 1788: 892-910, 2009. 
62. Diabetes C, Complications Trial Research G, Nathan DM, Genuth S, Lachin J, Cleary 
P, Crofford O, Davis M, Rand L, and Siebert C. The effect of intensive treatment of diabetes 
on the development and progression of long-term complications in insulin-dependent 
diabetes mellitus. N Engl J Med 329: 977-986, 1993. 
63. Ding H and Triggle CR. Endothelial dysfunction in diabetes: multiple targets for 
treatment. Pflugers Arch 459: 977-994, 2010. 
64. Ding L, Lu Z, Foreman O, Tatum R, Lu Q, Renegar R, Cao J, and Chen YH. 
Inflammation and disruption of the mucosal architecture in claudin-7-deficient mice. 
Gastroenterology 142: 305-315, 2012. 
65. Ding Q, Wang Z, and Chen Y. Endocytosis of adiponectin receptor 1 through a 
clathrin- and Rab5-dependent pathway. Cell Res 19: 317-327, 2009. 
66. Dongiovanni P, Ruscica M, Rametta R, Recalcati S, Steffani L, Gatti S, Girelli D, 
Cairo G, Magni P, Fargion S, and Valenti L. Dietary iron overload induces visceral adipose 
tissue insulin resistance. Am J Pathol 182: 2254-2263, 2013. 
67. Dongiovanni P, Valenti L, Ludovica Fracanzani A, Gatti S, Cairo G, and Fargion S. 
Iron depletion by deferoxamine up-regulates glucose uptake and insulin signaling in 
hepatoma cells and in rat liver. Am J Pathol 172: 738-747, 2008. 
68. Du XL, Edelstein D, Rossetti L, Fantus IG, Goldberg H, Ziyadeh F, Wu J, and 
Brownlee M. Hyperglycemia-induced mitochondrial superoxide overproduction activates 
the hexosamine pathway and induces plasminogen activator inhibitor-1 expression by 
increasing Sp1 glycosylation. Proc Natl Acad Sci U S A 97: 12222-12226, 2000. 
69. Dvornik E, Simard-Duquesne N, Krami M, Sestanj K, Gabbay KH, Kinoshita JH, 
Varma SD, and Merola LO. Polyol accumulation in galactosemic and diabetic rats: control 
by an aldose reductase inhibitor. Science 182: 1146-1148, 1973. 
70. Dymock IW, Cassar J, Pyke DA, Oakley WG, and Williams R. Observations on the 
pathogenesis, complications and treatment of diabetes in 115 cases of haemochromatosis. 
Am J Med 52: 203-210, 1972. 
71. Engin A. Adiponectin-Resistance in Obesity. Adv Exp Med Biol 960: 415-441, 2017. 
72. Eskin SG, Ives CL, McIntire LV, and Navarro LT. Response of cultured endothelial 
cells to steady flow. Microvasc Res 28: 87-94, 1984. 
73. Esmaili S, Hemmati M, and Karamian M. Physiological role of adiponectin in 
different tissues: a review. Arch Physiol Biochem: 1-7, 2018. 
 140 
74. Fang ZY, Prins JB, and Marwick TH. Diabetic cardiomyopathy: evidence, 
mechanisms, and therapeutic implications. Endocr Rev 25: 543-567, 2004. 
75. Feder JN, Gnirke A, Thomas W, Tsuchihashi Z, Ruddy DA, Basava A, Dormishian F, 
Domingo R, Jr., Ellis MC, Fullan A, Hinton LM, Jones NL, Kimmel BE, Kronmal GS, Lauer P, 
Lee VK, Loeb DB, Mapa FA, McClelland E, Meyer NC, Mintier GA, Moeller N, Moore T, 
Morikang E, Prass CE, Quintana L, Starnes SM, Schatzman RC, Brunke KJ, Drayna DT, Risch 
NJ, Bacon BR, and Wolff RK. A novel MHC class I-like gene is mutated in patients with 
hereditary haemochromatosis. Nat Genet 13: 399-408, 1996. 
76. Felinski EA and Antonetti DA. Glucocorticoid regulation of endothelial cell tight 
junction gene expression: novel treatments for diabetic retinopathy. Curr Eye Res 30: 949-
957, 2005. 
77. Ferrannini E, Buzzigoli G, Bonadonna R, Giorico MA, Oleggini M, Graziadei L, 
Pedrinelli R, Brandi L, and Bevilacqua S. Insulin resistance in essential hypertension. N Engl 
J Med 317: 350-357, 1987. 
78. Flarsheim CE, Grupp IL, and Matlib MA. Mitochondrial dysfunction accompanies 
diastolic dysfunction in diabetic rat heart. Am J Physiol 271: H192-202, 1996. 
79. Folkman J and Haudenschild C. Angiogenesis in vitro. Nature 288: 551-556, 1980. 
80. Ford ES, Zhao G, and Li C. Pre-diabetes and the risk for cardiovascular disease: a 
systematic review of the evidence. J Am Coll Cardiol 55: 1310-1317, 2010. 
81. Freidenberg GR, Suter S, Henry RR, Nolan J, Reichart D, and Olefsky JM. Delayed 
onset of insulin activation of the insulin receptor kinase in vivo in human skeletal muscle. 
Diabetes 43: 118-126, 1994. 
82. Fujita H, Hamazaki Y, Noda Y, Oshima M, and Minato N. Claudin-4 deficiency 
results in urothelial hyperplasia and lethal hydronephrosis. PLoS One 7: e52272, 2012. 
83. Fumeron F, Pean F, Driss F, Balkau B, Tichet J, Marre M, Grandchamp B, and Insulin 
Resistance Syndrome Study G. Ferritin and transferrin are both predictive of the onset of 
hyperglycemia in men and women over 3 years: the data from an epidemiological study on 
the Insulin Resistance Syndrome (DESIR) study. Diabetes Care 29: 2090-2094, 2006. 
84. Funamoto K, Yoshino D, Matsubara K, Zervantonakis IK, Funamoto K, Nakayama 
M, Masamune J, Kimura Y, and Kamm RD. Endothelial monolayer permeability under 
controlled oxygen tension. Integr Biol (Camb) 9: 529-538, 2017. 
85. Furuse M, Hata M, Furuse K, Yoshida Y, Haratake A, Sugitani Y, Noda T, Kubo A, 
and Tsukita S. Claudin-based tight junctions are crucial for the mammalian epidermal 
barrier: a lesson from claudin-1-deficient mice. J Cell Biol 156: 1099-1111, 2002. 
86. Gathercole LL, Morgan SA, Bujalska IJ, Hauton D, Stewart PM, and Tomlinson JW. 
Regulation of lipogenesis by glucocorticoids and insulin in human adipose tissue. PLoS One 
6: e26223, 2011. 
87. Geer EB, Islam J, and Buettner C. Mechanisms of glucocorticoid-induced insulin 
resistance: focus on adipose tissue function and lipid metabolism. Endocrinol Metab Clin 
North Am 43: 75-102, 2014. 
88. Ginsberg HN and MacCallum PR. The obesity, metabolic syndrome, and type 2 
diabetes mellitus pandemic: Part I. Increased cardiovascular disease risk and the 
 141 
importance of atherogenic dyslipidemia in persons with the metabolic syndrome and type 
2 diabetes mellitus. J Cardiometab Syndr 4: 113-119, 2009. 
89. Goddard LM and Iruela-Arispe ML. Cellular and molecular regulation of vascular 
permeability. Thromb Haemost 109: 407-415, 2013. 
90. Goldstein BJ, Scalia RG, and Ma XL. Protective vascular and myocardial effects of 
adiponectin. Nat Clin Pract Cardiovasc Med 6: 27-35, 2009. 
91. Gonzalez-Mariscal L, Hernandez S, and Vega J. Inventions designed to enhance 
drug delivery across epithelial and endothelial cells through the paracellular pathway. 
Recent Pat Drug Deliv Formul 2: 145-176, 2008. 
92. Gory-Faure S, Prandini MH, Pointu H, Roullot V, Pignot-Paintrand I, Vernet M, and 
Huber P. Role of vascular endothelial-cadherin in vascular morphogenesis. Development 
126: 2093-2102, 1999. 
93. Gow A, Southwood CM, Li JS, Pariali M, Riordan GP, Brodie SE, Danias J, Bronstein 
JM, Kachar B, and Lazzarini RA. CNS myelin and sertoli cell tight junction strands are absent 
in Osp/claudin-11 null mice. Cell 99: 649-659, 1999. 
94. Gronbaek H, Vogel I, Osterby R, Lancranjan I, Flyvbjerg A, and Orskov H. Effect of 
octreotide, captopril or insulin on renal changes and UAE in long-term experimental 
diabetes. Kidney Int 53: 173-180, 1998. 
95. Gunzel D and Fromm M. Claudins and other tight junction proteins. Compr Physiol 
2: 1819-1852, 2012. 
96. Gunzel D and Yu AS. Claudins and the modulation of tight junction permeability. 
Physiol Rev 93: 525-569, 2013. 
97. Gutniak M, Orskov C, Holst JJ, Ahren B, and Efendic S. Antidiabetogenic effect of 
glucagon-like peptide-1 (7-36)amide in normal subjects and patients with diabetes mellitus. 
N Engl J Med 326: 1316-1322, 1992. 
98. Hardie DG and Carling D. The AMP-activated protein kinase--fuel gauge of the 
mammalian cell? European journal of biochemistry / FEBS 246: 259-273, 1997. 
99. Hawkins BT, Lundeen TF, Norwood KM, Brooks HL, and Egleton RD. Increased 
blood-brain barrier permeability and altered tight junctions in experimental diabetes in the 
rat: contribution of hyperglycaemia and matrix metalloproteinases. Diabetologia 50: 202-
211, 2007. 
100. Hayashi D, Tamura A, Tanaka H, Yamazaki Y, Watanabe S, Suzuki K, Suzuki K, 
Sentani K, Yasui W, Rakugi H, Isaka Y, and Tsukita S. Deficiency of claudin-18 causes 
paracellular H+ leakage, up-regulation of interleukin-1beta, and atrophic gastritis in mice. 
Gastroenterology 142: 292-304, 2012. 
101. Heilig CW, Concepcion LA, Riser BL, Freytag SO, Zhu M, and Cortes P. 
Overexpression of glucose transporters in rat mesangial cells cultured in a normal glucose 
milieu mimics the diabetic phenotype. J Clin Invest 96: 1802-1814, 1995. 
102. Herkner H, Klein N, Joukhadar C, Lackner E, Langenberger H, Frossard M, 
Bieglmayer C, Wagner O, Roden M, and Muller M. Transcapillary insulin transfer in human 
skeletal muscle. Eur J Clin Invest 33: 141-146, 2003. 
 142 
103. Herland A, van der Meer AD, FitzGerald EA, Park TE, Sleeboom JJ, and Ingber DE. 
Distinct Contributions of Astrocytes and Pericytes to Neuroinflammation Identified in a 3D 
Human Blood-Brain Barrier on a Chip. PLoS One 11: e0150360, 2016. 
104. Ho YT, Adriani G, Beyer S, Nhan PT, Kamm RD, and Kah JCY. A Facile Method to 
Probe the Vascular Permeability of Nanoparticles in Nanomedicine Applications. Sci Rep 7: 
707, 2017. 
105. Hoes JN, Jacobs JW, Boers M, Boumpas D, Buttgereit F, Caeyers N, Choy EH, Cutolo 
M, Da Silva JA, Esselens G, Guillevin L, Hafstrom I, Kirwan JR, Rovensky J, Russell A, Saag 
KG, Svensson B, Westhovens R, Zeidler H, and Bijlsma JW. EULAR evidence-based 
recommendations on the management of systemic glucocorticoid therapy in rheumatic 
diseases. Ann Rheum Dis 66: 1560-1567, 2007. 
106. Hojbjerre L, Rosenzweig M, Dela F, Bruun JM, and Stallknecht B. Acute exercise 
increases adipose tissue interstitial adiponectin concentration in healthy overweight and 
lean subjects. Eur J Endocrinol 157: 613-623, 2007. 
107. Holland WL, Miller RA, Wang ZV, Sun K, Barth BM, Bui HH, Davis KE, Bikman BT, 
Halberg N, Rutkowski JM, Wade MR, Tenorio VM, Kuo MS, Brozinick JT, Zhang BB, 
Birnbaum MJ, Summers SA, and Scherer PE. Receptor-mediated activation of ceramidase 
activity initiates the pleiotropic actions of adiponectin. Nature medicine 17: 55-63, 2011. 
108. Hsu CP, Lin CH, and Kuo CY. Endothelial-cell inflammation and damage by reactive 
oxygen species are prevented by propofol via ABCA1-mediated cholesterol efflux. Int J Med 
Sci 15: 978-985, 2018. 
109. Hug C, Wang J, Ahmad NS, Bogan JS, Tsao TS, and Lodish HF. T-cadherin is a 
receptor for hexameric and high-molecular-weight forms of Acrp30/adiponectin. Proc Natl 
Acad Sci U S A 101: 10308-10313, 2004. 
110. Hutton BF. New SPECT technology: potential and challenges. European journal of 
nuclear medicine and molecular imaging 37: 1883-1886, 2010. 
111. Hyde D, de Kleine R, MacLaurin SA, Miller E, Brooks DH, Krucker T, and 
Ntziachristos V. Hybrid FMT-CT imaging of amyloid-beta plaques in a murine Alzheimer's 
disease model. NeuroImage 44: 1304-1311, 2009. 
112. Italia K, Colah R, and Ghosh K. Experimental animal model to study iron overload 
and iron chelation and review of other such models. Blood Cells Mol Dis 55: 194-199, 2015. 
113. Iwabu M, Okada-Iwabu M, Yamauchi T, and Kadowaki T. Adiponectin/adiponectin 
receptor in disease and aging. NPJ Aging Mech Dis 1: 15013, 2015. 
114. Iwabu M, Yamauchi T, Okada-Iwabu M, Sato K, Nakagawa T, Funata M, Yamaguchi 
M, Namiki S, Nakayama R, Tabata M, Ogata H, Kubota N, Takamoto I, Hayashi YK, 
Yamauchi N, Waki H, Fukayama M, Nishino I, Tokuyama K, Ueki K, Oike Y, Ishii S, Hirose 
K, Shimizu T, Touhara K, and Kadowaki T. Adiponectin and AdipoR1 regulate PGC-1alpha 
and mitochondria by Ca(2+) and AMPK/SIRT1. Nature 464: 1313-1319, 2010. 
115. Janka HU, Plewe G, Riddle MC, Kliebe-Frisch C, Schweitzer MA, and Yki-Jarvinen 
H. Comparison of basal insulin added to oral agents versus twice-daily premixed insulin as 
initial insulin therapy for type 2 diabetes. Diabetes Care 28: 254-259, 2005. 
116. Jehn M, Clark JM, and Guallar E. Serum ferritin and risk of the metabolic syndrome 
in U.S. adults. Diabetes Care 27: 2422-2428, 2004. 
 143 
117. Jehn ML, Guallar E, Clark JM, Couper D, Duncan BB, Ballantyne CM, Hoogeveen RC, 
Harris ZL, and Pankow JS. A prospective study of plasma ferritin level and incident diabetes: 
the Atherosclerosis Risk in Communities (ARIC) Study. Am J Epidemiol 165: 1047-1054, 2007. 
118. Jeon JS, Bersini S, Gilardi M, Dubini G, Charest JL, Moretti M, and Kamm RD. 
Human 3D vascularized organotypic microfluidic assays to study breast cancer cell 
extravasation. Proc Natl Acad Sci U S A 112: 214-219, 2015. 
119. Jeon JS, Bersini S, Whisler JA, Chen MB, Dubini G, Charest JL, Moretti M, and 
Kamm RD. Generation of 3D functional microvascular networks with human mesenchymal 
stem cells in microfluidic systems. Integr Biol (Camb) 6: 555-563, 2014. 
120. Jeppesen J, Hein HO, Suadicani P, and Gyntelberg F. High triglycerides and low HDL 
cholesterol and blood pressure and risk of ischemic heart disease. Hypertension 36: 226-
232, 2000. 
121. Johnson AM, Costanzo A, Gareau MG, Armando AM, Quehenberger O, Jameson 
JM, and Olefsky JM. High fat diet causes depletion of intestinal eosinophils associated with 
intestinal permeability. PLoS One 10: e0122195, 2015. 
122. Kadowaki T and Yamauchi T. Adiponectin receptor signaling: a new layer to the 
current model. Cell Metab 13: 123-124, 2011. 
123. Kadowaki T, Yamauchi T, Kubota N, Hara K, Ueki K, and Tobe K. Adiponectin and 
adiponectin receptors in insulin resistance, diabetes, and the metabolic syndrome. J Clin 
Invest 116: 1784-1792, 2006. 
124. Kaira K, Oriuchi N, Shimizu K, Ishikita T, Higuchi T, Imai H, Yanagitani N, Sunaga N, 
Hisada T, Ishizuka T, Kanai Y, Endou H, Nakajima T, Endo K, and Mori M. Evaluation of 
thoracic tumors with (18)F-FMT and (18)F-FDG PET-CT: a clinicopathological study. 
International journal of cancer Journal international du cancer 124: 1152-1160, 2009. 
125. Karalliedde J and Gnudi L. Diabetes mellitus, a complex and heterogeneous disease, 
and the role of insulin resistance as a determinant of diabetic kidney disease. Nephrol Dial 
Transplant 31: 206-213, 2016. 
126. Keaney J and Campbell M. The dynamic blood-brain barrier. FEBS J 282: 4067-4079, 
2015. 
127. Kelcz F, Joseph PM, and Hilal SK. Noise considerations in dual energy CT scanning. 
Medical physics 6: 418-425, 1979. 
128. Kim J, Chung M, Kim S, Jo DH, Kim JH, and Jeon NL. Engineering of a Biomimetic 
Pericyte-Covered 3D Microvascular Network. PLoS One 10: e0133880, 2015. 
129. Kim KH, Lopez-Casillas F, Bai DH, Luo X, and Pape ME. Role of reversible 
phosphorylation of acetyl-CoA carboxylase in long-chain fatty acid synthesis. FASEB J 3: 
2250-2256, 1989. 
130. Kim S, Kim W, Lim S, and Jeon JS. Vasculature-On-A-Chip for In Vitro Disease Models. 
Bioengineering (Basel) 4, 2017. 
131. Kim S, Lee H, Chung M, and Jeon NL. Engineering of functional, perfusable 3D 
microvascular networks on a chip. Lab Chip 13: 1489-1500, 2013. 
132. Kim SP, Ellmerer M, Van Citters GW, and Bergman RN. Primacy of hepatic insulin 
resistance in the development of the metabolic syndrome induced by an isocaloric 
moderate-fat diet in the dog. Diabetes 52: 2453-2460, 2003. 
 144 
133. Kissebah AH, Sonnenberg GE, Myklebust J, Goldstein M, Broman K, James RG, 
Marks JA, Krakower GR, Jacob HJ, Weber J, Martin L, Blangero J, and Comuzzie AG. 
Quantitative trait loci on chromosomes 3 and 17 influence phenotypes of the metabolic 
syndrome. Proc Natl Acad Sci U S A 97: 14478-14483, 2000. 
134. Kolka CM and Bergman RN. The barrier within: endothelial transport of hormones. 
Physiology (Bethesda) 27: 237-247, 2012. 
135. Kolka CM and Bergman RN. The endothelium in diabetes: its role in insulin access 
and diabetic complications. Rev Endocr Metab Disord 14: 13-19, 2013. 
136. Kolka CM, Harrison LN, Lottati M, Chiu JD, Kirkman EL, and Bergman RN. Diet-
induced obesity prevents interstitial dispersion of insulin in skeletal muscle. Diabetes 59: 
619-626, 2010. 
137. Kolm-Litty V, Sauer U, Nerlich A, Lehmann R, and Schleicher ED. High glucose-
induced transforming growth factor beta1 production is mediated by the hexosamine 
pathway in porcine glomerular mesangial cells. J Clin Invest 101: 160-169, 1998. 
138. Kowdley KV. Iron Overload in Patients With Chronic Liver Disease. Gastroenterol 
Hepatol (N Y) 12: 695-698, 2016. 
139. Krause MP, Liu Y, Vu V, Chan L, Xu A, Riddell MC, Sweeney G, and Hawke TJ. 
Adiponectin is expressed by skeletal muscle fibers and influences muscle phenotype and 
function. Am J Physiol Cell Physiol 295: C203-212, 2008. 
140. Krug SM, Gunzel D, Conrad MP, Lee IF, Amasheh S, Fromm M, and Yu AS. Charge-
selective claudin channels. Ann N Y Acad Sci 1257: 20-28, 2012. 
141. Ku BJ, Kim SY, Lee TY, and Park KS. Serum ferritin is inversely correlated with serum 
adiponectin level: population-based cross-sectional study. Dis Markers 27: 303-310, 2009. 
142. Kubota N, Yano W, Kubota T, Yamauchi T, Itoh S, Kumagai H, Kozono H, Takamoto 
I, Okamoto S, Shiuchi T, Suzuki R, Satoh H, Tsuchida A, Moroi M, Sugi K, Noda T, Ebinuma 
H, Ueta Y, Kondo T, Araki E, Ezaki O, Nagai R, Tobe K, Terauchi Y, Ueki K, Minokoshi Y, and 
Kadowaki T. Adiponectin stimulates AMP-activated protein kinase in the hypothalamus 
and increases food intake. Cell Metab 6: 55-68, 2007. 
143. Kubota T, Kubota N, Kumagai H, Yamaguchi S, Kozono H, Takahashi T, Inoue M, 
Itoh S, Takamoto I, Sasako T, Kumagai K, Kawai T, Hashimoto S, Kobayashi T, Sato M, 
Tokuyama K, Nishimura S, Tsunoda M, Ide T, Murakami K, Yamazaki T, Ezaki O, Kawamura 
K, Masuda H, Moroi M, Sugi K, Oike Y, Shimokawa H, Yanagihara N, Tsutsui M, Terauchi 
Y, Tobe K, Nagai R, Kamata K, Inoue K, Kodama T, Ueki K, and Kadowaki T. Impaired insulin 
signaling in endothelial cells reduces insulin-induced glucose uptake by skeletal muscle. Cell 
Metab 13: 294-307, 2011. 
144. Kumar P, Shen Q, Pivetti CD, Lee ES, Wu MH, and Yuan SY. Molecular mechanisms 
of endothelial hyperpermeability: implications in inflammation. Expert Rev Mol Med 11: 
e19, 2009. 
145. Kusminski CM, McTernan PG, Schraw T, Kos K, O'Hare JP, Ahima R, Kumar S, and 
Scherer PE. Adiponectin complexes in human cerebrospinal fluid: distinct complex 
distribution from serum. Diabetologia 50: 634-642, 2007. 
 145 
146. Langille BL and Adamson SL. Relationship between blood flow direction and 
endothelial cell orientation at arterial branch sites in rabbits and mice. Circ Res 48: 481-488, 
1981. 
147. Lapointe E, Pichette J, and Berube-Lauziere Y. A multi-view time-domain non-
contact diffuse optical tomography scanner with dual wavelength detection for intrinsic 
and fluorescence small animal imaging. The Review of scientific instruments 83: 063703, 
2012. 
148. Lee CS, Bishop ES, Zhang R, Yu X, Farina EM, Yan S, Zhao C, Zheng Z, Shu Y, Wu X, 
Lei J, Li Y, Zhang W, Yang C, Wu K, Wu Y, Ho S, Athiviraham A, Lee MJ, Wolf JM, Reid RR, 
and He TC. Adenovirus-Mediated Gene Delivery: Potential Applications for Gene and Cell-
Based Therapies in the New Era of Personalized Medicine. Genes Dis 4: 43-63, 2017. 
149. Lee JH, Kim HK, Chandhanayingyong C, Lee FY, and Hielscher AH. Non-contact 
small animal fluorescence imaging system for simultaneous multi-directional angular-
dependent data acquisition. Biomedical optics express 5: 2301-2316, 2014. 
150. Lehmann JM, Moore LB, Smith-Oliver TA, Wilkison WO, Willson TM, and Kliewer 
SA. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-
activated receptor gamma (PPAR gamma). J Biol Chem 270: 12953-12956, 1995. 
151. Lenzen S. Oxidative stress: the vulnerable beta-cell. Biochem Soc Trans 36: 343-347, 
2008. 
152. Li B, Maafi F, Berti R, Pouliot P, Rheaume E, Tardif JC, and Lesage F. Hybrid FMT-
MRI applied to in vivo atherosclerosis imaging. Biomedical optics express 5: 1664-1676, 
2014. 
153. Li R, Zheng K, Hu P, Chen Z, Zhou S, Chen J, Yuan C, Chen S, Zheng W, Ma E, Zhang 
F, Xue J, Chen X, and Huang M. A novel tumor targeting drug carrier for optical imaging 
and therapy. Theranostics 4: 642-659, 2014. 
154. Lin H, Lian WS, Chen HH, Lai PF, and Cheng CF. Adiponectin ameliorates iron-
overload cardiomyopathy through the PPARalpha-PGC-1-dependent signaling pathway. 
Mol Pharmacol 84: 275-285, 2013. 
155. Lin KT and Wang LH. New dimension of glucocorticoids in cancer treatment. 
Steroids 111: 84-88, 2016. 
156. Lin SA, Patel M, Suresch D, Connolly B, Bao B, Groves K, Rajopadhye M, Peterson 
JD, Klimas M, Sur C, and Bednar B. Quantitative Longitudinal Imaging of Vascular 
Inflammation and Treatment by Ezetimibe in apoE Mice by FMT Using New Optical Imaging 
Biomarkers of Cathepsin Activity and alpha(v)beta(3) Integrin. International journal of 
molecular imaging 2012: 189254, 2012. 
157. Liu B, Li Z, and Xie P. Angioplasty and stenting for severe vertebral artery orifice 
stenosis: effects on cerebellar function remodeling verified by blood oxygen level-
dependent functional magnetic resonance imaging. Neural regeneration research 9: 2095-
2101, 2014. 
158. Liu C, Wu J, and Zou MH. Activation of AMP-activated protein kinase alleviates high-
glucose-induced dysfunction of brain microvascular endothelial cell tight-junction 
dynamics. Free Radic Biol Med 53: 1213-1221, 2012. 
 146 
159. Liu Y, Palanivel R, Rai E, Park M, Gabor TV, Scheid MP, Xu A, and Sweeney G. 
Adiponectin stimulates autophagy and reduces oxidative stress to enhance insulin 
sensitivity during high-fat diet feeding in mice. Diabetes 64: 36-48, 2015. 
160. Liu Y, Retnakaran R, Hanley A, Tungtrongchitr R, Shaw C, and Sweeney G. Total 
and high molecular weight but not trimeric or hexameric forms of adiponectin correlate 
with markers of the metabolic syndrome and liver injury in Thai subjects. J Clin Endocrinol 
Metab 92: 4313-4318, 2007. 
161. Liu Y and Sweeney G. Adiponectin action in skeletal muscle. Best practice & 
research Clinical endocrinology & metabolism 28: 33-41, 2014. 
162. Lucas CP, Estigarribia JA, Darga LL, and Reaven GM. Insulin and blood pressure in 
obesity. Hypertension 7: 702-706, 1985. 
163. Lum H and Roebuck KA. Oxidant stress and endothelial cell dysfunction. Am J 
Physiol Cell Physiol 280: C719-741, 2001. 
164. Ly JP, Onay T, Sison K, Sivaskandarajah G, Sabbisetti V, Li L, Bonventre JV, 
Flenniken A, Paragas N, Barasch JM, Adamson SL, Osborne L, Rossant J, Schnermann J, 
and Quaggin SE. The Sweet Pee model for Sglt2 mutation. J Am Soc Nephrol 22: 113-123, 
2011. 
165. Maggs DG, Jacob R, Rife F, Lange R, Leone P, During MJ, Tamborlane WV, and 
Sherwin RS. Interstitial fluid concentrations of glycerol, glucose, and amino acids in human 
quadricep muscle and adipose tissue. Evidence for significant lipolysis in skeletal muscle. J 
Clin Invest 96: 370-377, 1995. 
166. Malaguarnera R and Belfiore A. The insulin receptor: a new target for cancer 
therapy. Front Endocrinol (Lausanne) 2: 93, 2011. 
167. Malatiali S, Francis I, and Barac-Nieto M. Phlorizin prevents glomerular 
hyperfiltration but not hypertrophy in diabetic rats. Exp Diabetes Res 2008: 305403, 2008. 
168. Mao X, Kikani CK, Riojas RA, Langlais P, Wang L, Ramos FJ, Fang Q, Christ-Roberts 
CY, Hong JY, Kim RY, Liu F, and Dong LQ. APPL1 binds to adiponectin receptors and 
mediates adiponectin signalling and function. Nature cell biology 8: 516-523, 2006. 
169. Matsuda K, Fujishima Y, Maeda N, Mori T, Hirata A, Sekimoto R, Tsushima Y, 
Masuda S, Yamaoka M, Inoue K, Nishizawa H, Kita S, Ranscht B, Funahashi T, and 
Shimomura I. Positive feedback regulation between adiponectin and T-cadherin impacts 
adiponectin levels in tissue and plasma of male mice. Endocrinology 156: 934-946, 2015. 
170. Matsunaga T, Hokari S, Koyama I, Harada T, and Komoda T. NF-kappa B activation 
in endothelial cells treated with oxidized high-density lipoprotein. Biochem Biophys Res 
Commun 303: 313-319, 2003. 
171. Michalik L, Auwerx J, Berger JP, Chatterjee VK, Glass CK, Gonzalez FJ, Grimaldi PA, 
Kadowaki T, Lazar MA, O'Rahilly S, Palmer CN, Plutzky J, Reddy JK, Spiegelman BM, Staels 
B, and Wahli W. International Union of Pharmacology. LXI. Peroxisome proliferator-
activated receptors. Pharmacological reviews 58: 726-741, 2006. 
172. Miller NE, Michel CC, Nanjee MN, Olszewski WL, Miller IP, Hazell M, Olivecrona G, 
Sutton P, Humphreys SM, and Frayn KN. Secretion of adipokines by human adipose tissue 
in vivo: partitioning between capillary and lymphatic transport. American journal of 
physiology Endocrinology and metabolism 301: E659-667, 2011. 
 147 
173. Miller RA, Chu Q, Le Lay J, Scherer PE, Ahima RS, Kaestner KH, Foretz M, Viollet B, 
and Birnbaum MJ. Adiponectin suppresses gluconeogenic gene expression in mouse 
hepatocytes independent of LKB1-AMPK signaling. J Clin Invest 121: 2518-2528, 2011. 
174. Miyamoto T, Morita K, Takemoto D, Takeuchi K, Kitano Y, Miyakawa T, Nakayama 
K, Okamura Y, Sasaki H, Miyachi Y, Furuse M, and Tsukita S. Tight junctions in Schwann 
cells of peripheral myelinated axons: a lesson from claudin-19-deficient mice. J Cell Biol 169: 
527-538, 2005. 
175. Miyawaki-Shimizu K, Predescu D, Shimizu J, Broman M, Predescu S, and Malik AB. 
siRNA-induced caveolin-1 knockdown in mice increases lung vascular permeability via the 
junctional pathway. Am J Physiol Lung Cell Mol Physiol 290: L405-413, 2006. 
176. Modan M, Halkin H, Almog S, Lusky A, Eshkol A, Shefi M, Shitrit A, and Fuchs Z. 
Hyperinsulinemia. A link between hypertension obesity and glucose intolerance. J Clin 
Invest 75: 809-817, 1985. 
177. Mohajerani P, Hipp A, Willner M, Marschner M, Trajkovic-Arsic M, Ma X, Burton 
NC, Klemm U, Radrich K, Ermolayev V, Tzoumas S, Siveke JT, Bech M, Pfeiffer F, and 
Ntziachristos V. FMT-PCCT: hybrid fluorescence molecular tomography-x-ray phase-
contrast CT imaging of mouse models. IEEE transactions on medical imaging 33: 1434-1446, 
2014. 
178. Montet X, Figueiredo JL, Alencar H, Ntziachristos V, Mahmood U, and Weissleder 
R. Tomographic fluorescence imaging of tumor vascular volume in mice. Radiology 242: 
751-758, 2007. 
179. Murdolo G, Hammarstedt A, Schmelz M, Jansson PA, and Smith U. Acute 
hyperinsulinemia differentially regulates interstitial and circulating adiponectin oligomeric 
pattern in lean and insulin-resistant, obese individuals. J Clin Endocrinol Metab 94: 4508-
4516, 2009. 
180. Muto S, Hata M, Taniguchi J, Tsuruoka S, Moriwaki K, Saitou M, Furuse K, Sasaki 
H, Fujimura A, Imai M, Kusano E, Tsukita S, and Furuse M. Claudin-2-deficient mice are 
defective in the leaky and cation-selective paracellular permeability properties of renal 
proximal tubules. Proc Natl Acad Sci U S A 107: 8011-8016, 2010. 
181. Nahrendorf M, Keliher E, Marinelli B, Waterman P, Feruglio PF, Fexon L, Pivovarov 
M, Swirski FK, Pittet MJ, Vinegoni C, and Weissleder R. Hybrid PET-optical imaging using 
targeted probes. Proc Natl Acad Sci U S A 107: 7910-7915, 2010. 
182. Nakano Y, Kim SH, Kim HM, Sanneman JD, Zhang Y, Smith RJ, Marcus DC, 
Wangemann P, Nessler RA, and Banfi B. A claudin-9-based ion permeability barrier is 
essential for hearing. PLoS Genet 5: e1000610, 2009. 
183. Nanami M, Ookawara T, Otaki Y, Ito K, Moriguchi R, Miyagawa K, Hasuike Y, Izumi 
M, Eguchi H, Suzuki K, and Nakanishi T. Tumor necrosis factor-alpha-induced iron 
sequestration and oxidative stress in human endothelial cells. Arterioscler Thromb Vasc Biol 
25: 2495-2501, 2005. 
184. Nanayakkara G, Kariharan T, Wang L, Zhong J, and Amin R. The cardio-protective 
signaling and mechanisms of adiponectin. Am J Cardiovasc Dis 2: 253-266, 2012. 
185. Neumeier M, Weigert J, Buettner R, Wanninger J, Schaffler A, Muller AM, Killian 
S, Sauerbruch S, Schlachetzki F, Steinbrecher A, Aslanidis C, Scholmerich J, and Buechler 
 148 
C. Detection of adiponectin in cerebrospinal fluid in humans. American journal of 
physiology Endocrinology and metabolism 293: E965-969, 2007. 
186. Nishikawa T, Edelstein D, Du XL, Yamagishi S, Matsumura T, Kaneda Y, Yorek MA, 
Beebe D, Oates PJ, Hammes HP, Giardino I, and Brownlee M. Normalizing mitochondrial 
superoxide production blocks three pathways of hyperglycaemic damage. Nature 404: 787-
790, 2000. 
187. Nitta T, Hata M, Gotoh S, Seo Y, Sasaki H, Hashimoto N, Furuse M, and Tsukita S. 
Size-selective loosening of the blood-brain barrier in claudin-5-deficient mice. J Cell Biol 161: 
653-660, 2003. 
188. Ntziachristos V, Bremer C, Graves EE, Ripoll J, and Weissleder R. In vivo 
tomographic imaging of near-infrared fluorescent probes. Molecular imaging 1: 82-88, 
2002. 
189. Ntziachristos V, Tung CH, Bremer C, and Weissleder R. Fluorescence molecular 
tomography resolves protease activity in vivo. Nature medicine 8: 757-760, 2002. 
190. Ntziachristos V and Weissleder R. Charge-coupled-device based scanner for 
tomography of fluorescent near-infrared probes in turbid media. Medical physics 29: 803-
809, 2002. 
191. Okamoto Y, Kihara S, Funahashi T, Matsuzawa Y, and Libby P. Adiponectin: a key 
adipocytokine in metabolic syndrome. Clin Sci (Lond) 110: 267-278, 2006. 
192. Omran OM. Effects of thymoquinone on STZ-induced diabetic nephropathy: an 
immunohistochemical study. Ultrastruct Pathol 38: 26-33, 2014. 
193. Ooi BK, Goh BH, and Yap WH. Oxidative Stress in Cardiovascular Diseases: 
Involvement of Nrf2 Antioxidant Redox Signaling in Macrophage Foam Cells Formation. Int 
J Mol Sci 18, 2017. 
194. Orsenigo F, Giampietro C, Ferrari A, Corada M, Galaup A, Sigismund S, Ristagno G, 
Maddaluno L, Koh GY, Franco D, Kurtcuoglu V, Poulikakos D, Baluk P, McDonald D, Grazia 
Lampugnani M, and Dejana E. Phosphorylation of VE-cadherin is modulated by 
haemodynamic forces and contributes to the regulation of vascular permeability in vivo. 
Nat Commun 3: 1208, 2012. 
195. Osorio H, Bautista R, Rios A, Franco M, Arellano A, Vargas-Robles H, Romo E, and 
Escalante B. Effect of phlorizin on SGLT2 expression in the kidney of diabetic rats. J Nephrol 
23: 541-546, 2010. 
196. Pajvani UB, Du X, Combs TP, Berg AH, Rajala MW, Schulthess T, Engel J, Brownlee 
M, and Scherer PE. Structure-function studies of the adipocyte-secreted hormone 
Acrp30/adiponectin. Implications fpr metabolic regulation and bioactivity. J Biol Chem 278: 
9073-9085, 2003. 
197. Pajvani UB, Hawkins M, Combs TP, Rajala MW, Doebber T, Berger JP, Wagner JA, 
Wu M, Knopps A, Xiang AH, Utzschneider KM, Kahn SE, Olefsky JM, Buchanan TA, and 
Scherer PE. Complex distribution, not absolute amount of adiponectin, correlates with 
thiazolidinedione-mediated improvement in insulin sensitivity. J Biol Chem 279: 12152-
12162, 2004. 
 149 
198. Palanivel R, Ganguly R, Turdi S, Xu A, and Sweeney G. Adiponectin stimulates Rho-
mediated actin cytoskeleton remodeling and glucose uptake via APPL1 in primary 
cardiomyocytes. Metabolism 63: 1363-1373, 2014. 
199. Papaspyros NS. The history of diabetes mellitus: G. Thieme, 1964. 
200. Park M and Sweeney G. Direct effects of adipokines on the heart: focus on 
adiponectin. Heart Fail Rev 18: 631-644, 2013. 
201. Park M, Youn B, Zheng XL, Wu D, Xu A, and Sweeney G. Globular adiponectin, 
acting via AdipoR1/APPL1, protects H9c2 cells from hypoxia/reoxygenation-induced 
apoptosis. PLoS One 6: e19143, 2011. 
202. Peters KE, Beilby J, Cadby G, Warrington NM, Bruce DG, Davis WA, Davis TM, 
Wiltshire S, Knuiman M, McQuillan BM, Palmer LJ, Thompson PL, and Hung J. A 
comprehensive investigation of variants in genes encoding adiponectin (ADIPOQ) and its 
receptors (ADIPOR1/R2), and their association with serum adiponectin, type 2 diabetes, 
insulin resistance and the metabolic syndrome. BMC Med Genet 14: 15, 2013. 
203. Pickup J, Mattock M, and Kerry S. Glycaemic control with continuous subcutaneous 
insulin infusion compared with intensive insulin injections in patients with type 1 diabetes: 
meta-analysis of randomised controlled trials. BMJ 324: 705, 2002. 
204. Pietrangelo A. Hereditary hemochromatosis: pathogenesis, diagnosis, and 
treatment. Gastroenterology 139: 393-408, 408 e391-392, 2010. 
205. Pingle SC, Mishra S, Marcuzzi A, Bhat SG, Sekino Y, Rybak LP, and Ramkumar V. 
Osmotic diuretics induce adenosine A1 receptor expression and protect renal proximal 
tubular epithelial cells against cisplatin-mediated apoptosis. J Biol Chem 279: 43157-43167, 
2004. 
206. Pollare T, Lithell H, and Berne C. Insulin resistance is a characteristic feature of 
primary hypertension independent of obesity. Metabolism 39: 167-174, 1990. 
207. Pratley RE, Nauck M, Bailey T, Montanya E, Cuddihy R, Filetti S, Thomsen AB, 
Sondergaard RE, Davies M, and Group L-D-S. Liraglutide versus sitagliptin for patients with 
type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, 
randomised, parallel-group, open-label trial. Lancet 375: 1447-1456, 2010. 
208. Pries AR and Kuebler WM. Normal endothelium. Handb Exp Pharmacol: 1-40, 2006. 
209. Protzek AO, Rezende LF, Costa-Junior JM, Ferreira SM, Cappelli AP, de Paula FM, 
de Souza JC, Kurauti MA, Carneiro EM, Rafacho A, and Boschero AC. Hyperinsulinemia 
caused by dexamethasone treatment is associated with reduced insulin clearance and 
lower hepatic activity of insulin-degrading enzyme. J Steroid Biochem Mol Biol 155: 1-8, 
2016. 
210. Raasch M, Rennert K, Jahn T, Peters S, Henkel T, Huber O, Schulz I, Becker H, 
Lorkowski S, Funke H, and Mosig A. Microfluidically supported biochip design for culture 
of endothelial cell layers with improved perfusion conditions. Biofabrication 7: 015013, 
2015. 
211. Raignault A, Bolduc V, Lesage F, and Thorin E. Pulse pressure-dependent 
cerebrovascular eNOS regulation in mice. J Cereb Blood Flow Metab 37: 413-424, 2017. 
212. Rao A, Pandya V, and Whaley-Connell A. Obesity and insulin resistance in resistant 
hypertension: implications for the kidney. Adv Chronic Kidney Dis 22: 211-217, 2015. 
 150 
213. Raza H and John A. Streptozotocin-induced cytotoxicity, oxidative stress and 
mitochondrial dysfunction in human hepatoma HepG2 cells. Int J Mol Sci 13: 5751-5767, 
2012. 
214. Razani B, Engelman JA, Wang XB, Schubert W, Zhang XL, Marks CB, Macaluso F, 
Russell RG, Li M, Pestell RG, Di Vizio D, Hou H, Jr., Kneitz B, Lagaud G, Christ GJ, Edelmann 
W, and Lisanti MP. Caveolin-1 null mice are viable but show evidence of hyperproliferative 
and vascular abnormalities. J Biol Chem 276: 38121-38138, 2001. 
215. Reaven GM. Insulin resistance/compensatory hyperinsulinemia, essential 
hypertension, and cardiovascular disease. J Clin Endocrinol Metab 88: 2399-2403, 2003. 
216. Reaven GM. Relationship between insulin resistance and hypertension. Diabetes 
Care 14 Suppl 4: 33-38, 1991. 
217. Reverchon M, Rame C, Bertoldo M, and Dupont J. Adipokines and the female 
reproductive tract. International journal of endocrinology 2014: 232454, 2014. 
218. Rincon-Choles H, Vasylyeva TL, Pergola PE, Bhandari B, Bhandari K, Zhang JH, 
Wang W, Gorin Y, Barnes JL, and Abboud HE. ZO-1 expression and phosphorylation in 
diabetic nephropathy. Diabetes 55: 894-900, 2006. 
219. Rochfort KD and Cummins PM. The blood-brain barrier endothelium: a target for 
pro-inflammatory cytokines. Biochem Soc Trans 43: 702-706, 2015. 
220. Rosca MG, Monnier VM, Szweda LI, and Weiss MF. Alterations in renal 
mitochondrial respiration in response to the reactive oxoaldehyde methylglyoxal. Am J 
Physiol Renal Physiol 283: F52-59, 2002. 
221. Roy Chowdhury SK, Smith DR, Saleh A, Schapansky J, Marquez A, Gomes S, Akude 
E, Morrow D, Calcutt NA, and Fernyhough P. Impaired adenosine monophosphate-
activated protein kinase signalling in dorsal root ganglia neurons is linked to mitochondrial 
dysfunction and peripheral neuropathy in diabetes. Brain 135: 1751-1766, 2012. 
222. Rutkowski JM, Halberg N, Wang QA, Holland WL, Xia JY, and Scherer PE. 
Differential transendothelial transport of adiponectin complexes. Cardiovasc Diabetol 13: 
47, 2014. 
223. Ryan JD, Armitage AE, Cobbold JF, Banerjee R, Borsani O, Dongiovanni P, 
Neubauer S, Morovat R, Wang LM, Pasricha SR, Fargion S, Collier J, Barnes E, Drakesmith 
H, Valenti L, and Pavlides M. Hepatic iron is the major determinant of serum ferritin in 
NAFLD patients. Liver Int 38: 164-173, 2018. 
224. Sacks DB. Measurement of hemoglobin A(1c): a new twist on the path to harmony. 
Diabetes Care 35: 2674-2680, 2012. 
225. Sacks DB, Arnold M, Bakris GL, Bruns DE, Horvath AR, Kirkman MS, Lernmark A, 
Metzger BE, and Nathan DM. Guidelines and recommendations for laboratory analysis in 
the diagnosis and management of diabetes mellitus. Clin Chem 57: e1-e47, 2011. 
226. Saitou M, Furuse M, Sasaki H, Schulzke JD, Fromm M, Takano H, Noda T, and 
Tsukita S. Complex phenotype of mice lacking occludin, a component of tight junction 
strands. Mol Biol Cell 11: 4131-4142, 2000. 
227. Sayeski PP and Kudlow JE. Glucose metabolism to glucosamine is necessary for 
glucose stimulation of transforming growth factor-alpha gene transcription. J Biol Chem 
271: 15237-15243, 1996. 
 151 
228. Scaroni C, Zilio M, Foti M, and Boscaro M. Glucose Metabolism Abnormalities in 
Cushing Syndrome: From Molecular Basis to Clinical Management. Endocr Rev 38: 189-219, 
2017. 
229. Scheid MP and Sweeney G. The role of adiponectin signaling in metabolic syndrome 
and cancer. Rev Endocr Metab Disord 15: 157-167, 2014. 
230. Schubert W, Frank PG, Woodman SE, Hyogo H, Cohen DE, Chow CW, and Lisanti 
MP. Microvascular hyperpermeability in caveolin-1 (-/-) knock-out mice. Treatment with a 
specific nitric-oxide synthase inhibitor, L-NAME, restores normal microvascular 
permeability in Cav-1 null mice. J Biol Chem 277: 40091-40098, 2002. 
231. Seco J, Clasie B, and Partridge M. Review on the characteristics of radiation 
detectors for dosimetry and imaging. Physics in medicine and biology 59: R303-347, 2014. 
232. Selvin E, Steffes MW, Zhu H, Matsushita K, Wagenknecht L, Pankow J, Coresh J, 
and Brancati FL. Glycated hemoglobin, diabetes, and cardiovascular risk in nondiabetic 
adults. N Engl J Med 362: 800-811, 2010. 
233. Sente T, Van Berendoncks AM, Hoymans VY, and Vrints CJ. Adiponectin resistance 
in skeletal muscle: pathophysiological implications in chronic heart failure. J Cachexia 
Sarcopenia Muscle 7: 261-274, 2016. 
234. Shan CY, Yang JH, Kong Y, Wang XY, Zheng MY, Xu YG, Wang Y, Ren HZ, Chang BC, 
and Chen LM. Alteration of the intestinal barrier and GLP2 secretion in Berberine-treated 
type 2 diabetic rats. J Endocrinol 218: 255-262, 2013. 
235. Shapiro L and Scherer PE. The crystal structure of a complement-1q family protein 
suggests an evolutionary link to tumor necrosis factor. Current biology : CB 8: 335-338, 1998. 
236. Sharma K, Ramachandrarao S, Qiu G, Usui HK, Zhu Y, Dunn SR, Ouedraogo R, 
Hough K, McCue P, Chan L, Falkner B, and Goldstein BJ. Adiponectin regulates albuminuria 
and podocyte function in mice. J Clin Invest 118: 1645-1656, 2008. 
237. Shen DC, Shieh SM, Fuh MM, Wu DA, Chen YD, and Reaven GM. Resistance to 
insulin-stimulated-glucose uptake in patients with hypertension. J Clin Endocrinol Metab 
66: 580-583, 1988. 
238. Shenouda SM, Widlansky ME, Chen K, Xu G, Holbrook M, Tabit CE, Hamburg NM, 
Frame AA, Caiano TL, Kluge MA, Duess MA, Levit A, Kim B, Hartman ML, Joseph L, Shirihai 
OS, and Vita JA. Altered mitochondrial dynamics contributes to endothelial dysfunction in 
diabetes mellitus. Circulation 124: 444-453, 2011. 
239. Sheu WH, Chen YT, Lee WJ, Wang CW, and Lin LY. A relationship between serum 
ferritin and the insulin resistance syndrome is present in non-diabetic women but not in 
non-diabetic men. Clin Endocrinol (Oxf) 58: 380-385, 2003. 
240. Sheu WH, Jeng CY, Shieh SM, Fuh MM, Shen DD, Chen YD, and Reaven GM. Insulin 
resistance and abnormal electrocardiograms in patients with high blood pressure. Am J 
Hypertens 5: 444-448, 1992. 
241. Shikatani EA, Trifonova A, Mandel ER, Liu ST, Roudier E, Krylova A, Szigiato A, 
Beaudry J, Riddell MC, and Haas TL. Inhibition of proliferation, migration and proteolysis 
contribute to corticosterone-mediated inhibition of angiogenesis. PLoS One 7: e46625, 
2012. 
 152 
242. Shin JY, Sohn J, and Park KH. Chlorogenic acid decreases retinal vascular 
hyperpermeability in diabetic rat model. J Korean Med Sci 28: 608-613, 2013. 
243. Shin Y, Han S, Jeon JS, Yamamoto K, Zervantonakis IK, Sudo R, Kamm RD, and 
Chung S. Microfluidic assay for simultaneous culture of multiple cell types on surfaces or 
within hydrogels. Nat Protoc 7: 1247-1259, 2012. 
244. Shpilberg Y, Beaudry JL, D'Souza A, Campbell JE, Peckett A, and Riddell MC. A 
rodent model of rapid-onset diabetes induced by glucocorticoids and high-fat feeding. Dis 
Model Mech 5: 671-680, 2012. 
245. Sjostrand M, Holmang A, and Lonnroth P. Measurement of interstitial insulin in 
human muscle. Am J Physiol 276: E151-154, 1999. 
246. Smirnova E, Griparic L, Shurland DL, and van der Bliek AM. Dynamin-related 
protein Drp1 is required for mitochondrial division in mammalian cells. Mol Biol Cell 12: 
2245-2256, 2001. 
247. Somwar R, Kim DY, Sweeney G, Huang C, Niu W, Lador C, Ramlal T, and Klip A. 
GLUT4 translocation precedes the stimulation of glucose uptake by insulin in muscle cells: 
potential activation of GLUT4 via p38 mitogen-activated protein kinase. Biochem J 359: 639-
649, 2001. 
248. Stelter L, Pinkernelle JG, Michel R, Schwartlander R, Raschzok N, Morgul MH, Koch 
M, Denecke T, Ruf J, Baumler H, Jordan A, Hamm B, Sauer IM, and Teichgraber U. 
Modification of aminosilanized superparamagnetic nanoparticles: feasibility of multimodal 
detection using 3T MRI, small animal PET, and fluorescence imaging. Molecular imaging 
and biology : MIB : the official publication of the Academy of Molecular Imaging 12: 25-34, 
2010. 
249. Stuker F, Ripoll J, and Rudin M. Fluorescence molecular tomography: principles and 
potential for pharmaceutical research. Pharmaceutics 3: 229-274, 2011. 
250. Suh S and Park MK. Glucocorticoid-Induced Diabetes Mellitus: An Important but 
Overlooked Problem. Endocrinol Metab (Seoul) 32: 180-189, 2017. 
251. Sung HK, Song E, Jahng JWS, Pantopoulos K, and Sweeney G. Iron induces insulin 
resistance in cardiomyocytes via regulation of oxidative stress. Sci Rep 9: 4668, 2019. 
252. Suzuki S, Wilson-Kubalek EM, Wert D, Tsao TS, and Lee DH. The oligomeric 
structure of high molecular weight adiponectin. FEBS letters 581: 809-814, 2007. 
253. Swislocki AL, Hoffman BB, and Reaven GM. Insulin resistance, glucose intolerance 
and hyperinsulinemia in patients with hypertension. Am J Hypertens 2: 419-423, 1989. 
254. Symons JD and Abel ED. Lipotoxicity contributes to endothelial dysfunction: a focus 
on the contribution from ceramide. Rev Endocr Metab Disord 14: 59-68, 2013. 
255. Takahashi M, Arita Y, Yamagata K, Matsukawa Y, Okutomi K, Horie M, Shimomura 
I, Hotta K, Kuriyama H, Kihara S, Nakamura T, Yamashita S, Funahashi T, and Matsuzawa 
Y. Genomic structure and mutations in adipose-specific gene, adiponectin. International 
journal of obesity and related metabolic disorders : journal of the International Association 
for the Study of Obesity 24: 861-868, 2000. 
256. Takimoto C, Kumagai H, Osaka M, Sakata K, Onami T, Kamayachi T, Iigaya K, 
Hayashi K, Saruta T, and Itoh H. Candesartan and insulin reduce renal sympathetic nerve 
activity in hypertensive type 1 diabetic rats. Hypertens Res 31: 1941-1951, 2008. 
 153 
257. Tamura A, Kitano Y, Hata M, Katsuno T, Moriwaki K, Sasaki H, Hayashi H, Suzuki Y, 
Noda T, Furuse M, Tsukita S, and Tsukita S. Megaintestine in claudin-15-deficient mice. 
Gastroenterology 134: 523-534, 2008. 
258. Tanaka H, Takechi M, Kiyonari H, Shioi G, Tamura A, and Tsukita S. Intestinal 
deletion of Claudin-7 enhances paracellular organic solute flux and initiates colonic 
inflammation in mice. Gut 64: 1529-1538, 2015. 
259. Tao C, Sifuentes A, and Holland WL. Regulation of glucose and lipid homeostasis by 
adiponectin: effects on hepatocytes, pancreatic beta cells and adipocytes. Best practice & 
research Clinical endocrinology & metabolism 28: 43-58, 2014. 
260. Tatum R, Zhang Y, Salleng K, Lu Z, Lin JJ, Lu Q, Jeansonne BG, Ding L, and Chen YH. 
Renal salt wasting and chronic dehydration in claudin-7-deficient mice. Am J Physiol Renal 
Physiol 298: F24-34, 2010. 
261. Tewari S, Santos JM, and Kowluru RA. Damaged mitochondrial DNA replication 
system and the development of diabetic retinopathy. Antioxid Redox Signal 17: 492-504, 
2012. 
262. Tian R. Another role for the celebrity: Akt and insulin resistance. Circ Res 96: 139-
140, 2005. 
263. Tiedge M, Lortz S, Drinkgern J, and Lenzen S. Relation between antioxidant enzyme 
gene expression and antioxidative defense status of insulin-producing cells. Diabetes 46: 
1733-1742, 1997. 
264. Tiwari S, Halagappa VK, Riazi S, Hu X, and Ecelbarger CA. Reduced expression of 
insulin receptors in the kidneys of insulin-resistant rats. J Am Soc Nephrol 18: 2661-2671, 
2007. 
265. Tomas E, Tsao TS, Saha AK, Murrey HE, Zhang Cc C, Itani SI, Lodish HF, and 
Ruderman NB. Enhanced muscle fat oxidation and glucose transport by ACRP30 globular 
domain: acetyl-CoA carboxylase inhibition and AMP-activated protein kinase activation. 
Proc Natl Acad Sci U S A 99: 16309-16313, 2002. 
266. Tomizawa A, Hattori Y, Kasai K, and Nakano Y. Adiponectin induces NF-kappaB 
activation that leads to suppression of cytokine-induced NF-kappaB activation in vascular 
endothelial cells: globular adiponectin vs. high molecular weight adiponectin. Diab Vasc Dis 
Res 5: 123-127, 2008. 
267. Trost A, Lange S, Schroedl F, Bruckner D, Motloch KA, Bogner B, Kaser-Eichberger 
A, Strohmaier C, Runge C, Aigner L, Rivera FJ, and Reitsamer HA. Brain and Retinal 
Pericytes: Origin, Function and Role. Front Cell Neurosci 10: 20, 2016. 
268. Tsao TS, Murrey HE, Hug C, Lee DH, and Lodish HF. Oligomerization state-
dependent activation of NF-kappa B signaling pathway by adipocyte complement-related 
protein of 30 kDa (Acrp30). J Biol Chem 277: 29359-29362, 2002. 
269. Tsao TS, Tomas E, Murrey HE, Hug C, Lee DH, Ruderman NB, Heuser JE, and Lodish 
HF. Role of disulfide bonds in Acrp30/adiponectin structure and signaling specificity. 
Different oligomers activate different signal transduction pathways. J Biol Chem 278: 
50810-50817, 2003. 
270. Tuomilehto J and Bahijri S. Epidemiology: Lifetime risk of diabetes mellitus--how 
high? Nat Rev Endocrinol 12: 127-128, 2016. 
 154 
271. Turer AT and Scherer PE. Adiponectin: mechanistic insights and clinical implications. 
Diabetologia 55: 2319-2326, 2012. 
272. Turrens JF and Boveris A. Generation of superoxide anion by the NADH 
dehydrogenase of bovine heart mitochondria. Biochem J 191: 421-427, 1980. 
273. Vallon V, Platt KA, Cunard R, Schroth J, Whaley J, Thomson SC, Koepsell H, and 
Rieg T. SGLT2 mediates glucose reabsorption in the early proximal tubule. J Am Soc Nephrol 
22: 104-112, 2011. 
274. van der Goes MC, Jacobs JW, Boers M, Andrews T, Blom-Bakkers MA, Buttgereit 
F, Caeyers N, Cutolo M, Da Silva JA, Guillevin L, Kirwan JR, Rovensky J, Severijns G, 
Webber S, Westhovens R, and Bijlsma JW. Monitoring adverse events of low-dose 
glucocorticoid therapy: EULAR recommendations for clinical trials and daily practice. Ann 
Rheum Dis 69: 1913-1919, 2010. 
275. van Staa TP, Leufkens HG, Abenhaim L, Begaud B, Zhang B, and Cooper C. Use of 
oral corticosteroids in the United Kingdom. QJM 93: 105-111, 2000. 
276. Vasquez KO, Casavant C, and Peterson JD. Quantitative whole body biodistribution 
of fluorescent-labeled agents by non-invasive tomographic imaging. PLoS One 6: e20594, 
2011. 
277. Verma SK and Molitoris BA. Renal endothelial injury and microvascular dysfunction 
in acute kidney injury. Semin Nephrol 35: 96-107, 2015. 
278. Villarroel M, Garcia-Ramirez M, Corraliza L, Hernandez C, and Simo R. Effects of 
high glucose concentration on the barrier function and the expression of tight junction 
proteins in human retinal pigment epithelial cells. Exp Eye Res 89: 913-920, 2009. 
279. Wada M, Tamura A, Takahashi N, and Tsukita S. Loss of claudins 2 and 15 from 
mice causes defects in paracellular Na+ flow and nutrient transport in gut and leads to 
death from malnutrition. Gastroenterology 144: 369-380, 2013. 
280. Waki H, Yamauchi T, Kamon J, Ito Y, Uchida S, Kita S, Hara K, Hada Y, Vasseur F, 
Froguel P, Kimura S, Nagai R, and Kadowaki T. Impaired multimerization of human 
adiponectin mutants associated with diabetes. Molecular structure and multimer 
formation of adiponectin. J Biol Chem 278: 40352-40363, 2003. 
281. Wang C, Xin X, Xiang R, Ramos FJ, Liu M, Lee HJ, Chen H, Mao X, Kikani CK, Liu F, 
and Dong LQ. Yin-Yang regulation of adiponectin signaling by APPL isoforms in muscle cells. 
J Biol Chem 284: 31608-31615, 2009. 
282. Wang W, Yang X, Lopez de Silanes I, Carling D, and Gorospe M. Increased AMP:ATP 
ratio and AMP-activated protein kinase activity during cellular senescence linked to 
reduced HuR function. J Biol Chem 278: 27016-27023, 2003. 
283. Wang Y and Alexander JS. Analysis of endothelial barrier function in vitro. Methods 
Mol Biol 763: 253-264, 2011. 
284. Wang Y, Heilig K, Saunders T, Minto A, Deb DK, Chang A, Brosius F, Monteiro C, 
and Heilig CW. Transgenic overexpression of GLUT1 in mouse glomeruli produces renal 
disease resembling diabetic glomerulosclerosis. Am J Physiol Renal Physiol 299: F99-F111, 
2010. 
 155 
285. Wang Y, Lam KS, Xu JY, Lu G, Xu LY, Cooper GJ, and Xu A. Adiponectin inhibits cell 
proliferation by interacting with several growth factors in an oligomerization-dependent 
manner. J Biol Chem 280: 18341-18347, 2005. 
286. Wang Y, Lu G, Wong WP, Vliegenthart JF, Gerwig GJ, Lam KS, Cooper GJ, and Xu A. 
Proteomic and functional characterization of endogenous adiponectin purified from fetal 
bovine serum. Proteomics 4: 3933-3942, 2004. 
287. Wang Y, Ma XL, and Lau WB. Cardiovascular Adiponectin Resistance: The Critical 
Role of Adiponectin Receptor Modification. Trends Endocrinol Metab 28: 519-530, 2017. 
288. Wang Y, Xu A, Knight C, Xu LY, and Cooper GJ. Hydroxylation and glycosylation of 
the four conserved lysine residues in the collagenous domain of adiponectin. Potential role 
in the modulation of its insulin-sensitizing activity. J Biol Chem 277: 19521-19529, 2002. 
289. Wang ZV and Scherer PE. Adiponectin, the past two decades. J Mol Cell Biol 8: 93-
100, 2016. 
290. Watts GF and Playford DA. Dyslipoproteinaemia and hyperoxidative stress in the 
pathogenesis of endothelial dysfunction in non-insulin dependent diabetes mellitus: an 
hypothesis. Atherosclerosis 141: 17-30, 1998. 
291. Wehrl HF, Sauter AW, Divine MR, and Pichler BJ. Combined PET/MR: A Technology 
Becomes Mature. Journal of nuclear medicine : official publication, Society of Nuclear 
Medicine 56: 165-168, 2015. 
292. Welborn TA, Breckenridge A, Rubinstein AH, Dollery CT, and Fraser TR. Serum-
insulin in essential hypertension and in peripheral vascular disease. Lancet 1: 1336-1337, 
1966. 
293. Welsh GI, Hale LJ, Eremina V, Jeansson M, Maezawa Y, Lennon R, Pons DA, Owen 
RJ, Satchell SC, Miles MJ, Caunt CJ, McArdle CA, Pavenstadt H, Tavare JM, Herzenberg AM, 
Kahn CR, Mathieson PW, Quaggin SE, Saleem MA, and Coward RJM. Insulin signaling to 
the glomerular podocyte is critical for normal kidney function. Cell Metab 12: 329-340, 2010. 
294. Whisler JA, Chen MB, and Kamm RD. Control of perfusable microvascular network 
morphology using a multiculture microfluidic system. Tissue Eng Part C Methods 20: 543-
552, 2014. 
295. Will C, Breiderhoff T, Thumfart J, Stuiver M, Kopplin K, Sommer K, Gunzel D, 
Querfeld U, Meij IC, Shan Q, Bleich M, Willnow TE, and Muller D. Targeted deletion of 
murine Cldn16 identifies extra- and intrarenal compensatory mechanisms of Ca2+ and 
Mg2+ wasting. Am J Physiol Renal Physiol 298: F1152-1161, 2010. 
296. Witt KA and Sandoval KE. Steroids and the blood-brain barrier: therapeutic 
implications. Adv Pharmacol 71: 361-390, 2014. 
297. Witte DL, Crosby WH, Edwards CQ, Fairbanks VF, and Mitros FA. Practice guideline 
development task force of the College of American Pathologists. Hereditary 
hemochromatosis. Clin Chim Acta 245: 139-200, 1996. 
298. Wlazlo N, van Greevenbroek MM, Ferreira I, Jansen EH, Feskens EJ, van der Kallen 
CJ, Schalkwijk CG, Bravenboer B, and Stehouwer CD. Iron metabolism is associated with 
adipocyte insulin resistance and plasma adiponectin: the Cohort on Diabetes and 
Atherosclerosis Maastricht (CODAM) study. Diabetes Care 36: 309-315, 2013. 
 156 
299. Won SM, Lee JH, Park UJ, Gwag J, Gwag BJ, and Lee YB. Iron mediates endothelial 
cell damage and blood-brain barrier opening in the hippocampus after transient forebrain 
ischemia in rats. Exp Mol Med 43: 121-128, 2011. 
300. Wood CM, Gilmour KM, Perry SF, Part P, and Walsh PJ. Pulsatile urea excretion in 
gulf toadfish (Opsanus beta): evidence for activation of a specific facilitated diffusion 
transport system. J Exp Biol 201: 805-817, 1998. 
301. Wu W-H, Punde TH, Shih P-C, Fu C-Y, Wang T-P, Hsu L, Chang H-Y, and Liu C-H. A 
capillary-endothelium-mimetic microfluidic chip for the study of immune responses. 
Sensors and Actuators B: Chemical 209: 470-477, 2015. 
302. Wu X, Zha D, Xiang G, Zhang B, Xiao SY, and Jia R. Combined MMF and insulin 
therapy prevents renal injury in experimental diabetic rats. Cytokine 36: 229-236, 2006. 
303. Xu A, Yin S, Wong L, Chan KW, and Lam KS. Adiponectin ameliorates dyslipidemia 
induced by the human immunodeficiency virus protease inhibitor ritonavir in mice. 
Endocrinology 145: 487-494, 2004. 
304. Xu C, Wang K, Ding YH, Li WJ, and Ding L. Claudin-7 gene knockout causes 
destruction of intestinal structure and animal death in mice. World J Gastroenterol 25: 584-
599, 2019. 
305. Yamamoto K, Tanimura K, Watanabe M, Sano H, Uwamori H, Mabuchi Y, 
Matsuzaki Y, Chung S, Kamm RD, Tanishita K, and Sudo R. Construction of Continuous 
Capillary Networks Stabilized by Pericyte-like Perivascular Cells. Tissue Eng Part A 25: 499-
510, 2019. 
306. Yamauchi T, Iwabu M, Okada-Iwabu M, and Kadowaki T. Adiponectin receptors: a 
review of their structure, function and how they work. Best practice & research Clinical 
endocrinology & metabolism 28: 15-23, 2014. 
307. Yamauchi T, Kamon J, Ito Y, Tsuchida A, Yokomizo T, Kita S, Sugiyama T, Miyagishi 
M, Hara K, Tsunoda M, Murakami K, Ohteki T, Uchida S, Takekawa S, Waki H, Tsuno NH, 
Shibata Y, Terauchi Y, Froguel P, Tobe K, Koyasu S, Taira K, Kitamura T, Shimizu T, Nagai 
R, and Kadowaki T. Cloning of adiponectin receptors that mediate antidiabetic metabolic 
effects. Nature 423: 762-769, 2003. 
308. Yamauchi T, Kamon J, Minokoshi Y, Ito Y, Waki H, Uchida S, Yamashita S, Noda M, 
Kita S, Ueki K, Eto K, Akanuma Y, Froguel P, Foufelle F, Ferre P, Carling D, Kimura S, Nagai 
R, Kahn BB, and Kadowaki T. Adiponectin stimulates glucose utilization and fatty-acid 
oxidation by activating AMP-activated protein kinase. Nature medicine 8: 1288-1295, 2002. 
309. Yamauchi T, Kamon J, Waki H, Imai Y, Shimozawa N, Hioki K, Uchida S, Ito Y, 
Takakuwa K, Matsui J, Takata M, Eto K, Terauchi Y, Komeda K, Tsunoda M, Murakami K, 
Ohnishi Y, Naitoh T, Yamamura K, Ueyama Y, Froguel P, Kimura S, Nagai R, and Kadowaki 
T. Globular adiponectin protected ob/ob mice from diabetes and ApoE-deficient mice from 
atherosclerosis. J Biol Chem 278: 2461-2468, 2003. 
310. Yamauchi T, Nio Y, Maki T, Kobayashi M, Takazawa T, Iwabu M, Okada-Iwabu M, 
Kawamoto S, Kubota N, Kubota T, Ito Y, Kamon J, Tsuchida A, Kumagai K, Kozono H, Hada 
Y, Ogata H, Tokuyama K, Tsunoda M, Ide T, Murakami K, Awazawa M, Takamoto I, Froguel 
P, Hara K, Tobe K, Nagai R, Ueki K, and Kadowaki T. Targeted disruption of AdipoR1 and 
 157 
AdipoR2 causes abrogation of adiponectin binding and metabolic actions. Nature medicine 
13: 332-339, 2007. 
311. Yang L, Peng XH, Wang YA, Wang X, Cao Z, Ni C, Karna P, Zhang X, Wood WC, Gao 
X, Nie S, and Mao H. Receptor-targeted nanoparticles for in vivo imaging of breast cancer. 
Clinical cancer research : an official journal of the American Association for Cancer Research 
15: 4722-4732, 2009. 
312. Yang YJ, Hope ID, Ader M, and Bergman RN. Importance of transcapillary insulin 
transport to dynamics of insulin action after intravenous glucose. Am J Physiol 266: E17-25, 
1994. 
313. Ye R and Scherer PE. Adiponectin, driver or passenger on the road to insulin 
sensitivity? Mol Metab 2: 133-141, 2013. 
314. Yeon JH, Na D, Choi K, Ryu SW, Choi C, and Park JK. Reliable permeability assay 
system in a microfluidic device mimicking cerebral vasculatures. Biomed Microdevices 14: 
1141-1148, 2012. 
315. Yoo HJ, Lee JS, and Lee JM. Integrated Whole Body MR/PET: Where Are We? Korean 
journal of radiology : official journal of the Korean Radiological Society 16: 32-49, 2015. 
316. Yoon N, Dang TQ, Chasiotis H, Kelly SP, and Sweeney G. Altered transendothelial 
transport of hormones as a contributor to diabetes. Diabetes Metab J 38: 92-99, 2014. 
317. Yu T, Robotham JL, and Yoon Y. Increased production of reactive oxygen species in 
hyperglycemic conditions requires dynamic change of mitochondrial morphology. Proc Natl 
Acad Sci U S A 103: 2653-2658, 2006. 
318. Yuan D and He P. Vascular remodeling alters adhesion protein and cytoskeleton 
reactions to inflammatory stimuli resulting in enhanced permeability increases in rat 
venules. J Appl Physiol (1985) 113: 1110-1120, 2012. 
319. Yuan D, Xu S, and He P. Enhanced permeability responses to inflammation in 
streptozotocin-induced diabetic rat venules: Rho-mediated alterations of actin 
cytoskeleton and VE-cadherin. Am J Physiol Heart Circ Physiol 307: H44-53, 2014. 
320. Zdychova J and Komers R. Emerging role of Akt kinase/protein kinase B signaling in 
pathophysiology of diabetes and its complications. Physiol Res 54: 1-16, 2005. 
321. Zdychova J, Vesela J, Kazdova L, and Komers R. Renal activity of Akt kinase in 
experimental Type 1 diabetes. Physiol Res 57: 709-715, 2008. 
322. Zhang H, Schin M, Saha J, Burke K, Holzman LB, Filipiak W, Saunders T, Xiang M, 
Heilig CW, and Brosius FC, 3rd. Podocyte-specific overexpression of GLUT1 surprisingly 
reduces mesangial matrix expansion in diabetic nephropathy in mice. Am J Physiol Renal 
Physiol 299: F91-98, 2010. 
323. Zhang Q, Bindokas V, Shen J, Fan H, Hoffman RM, and Xing HR. Time-course 
imaging of therapeutic functional tumor vascular normalization by antiangiogenic agents. 
Molecular cancer therapeutics 10: 1173-1184, 2011. 
324. Zhang X, Badea CT, Hood G, Wetzel AW, Stiles JR, and Johnson GA. Free-space 
fluorescence tomography with adaptive sampling based on anatomical information from 
microCT. Proceedings - Society of Photo-Optical Instrumentation Engineers 7757, 2010. 
 158 
325. Zhang X, Wang N, Schachat AP, Bao S, and Gillies MC. Glucocorticoids: structure, 
signaling and molecular mechanisms in the treatment of diabetic retinopathy and diabetic 
macular edema. Curr Mol Med 14: 376-384, 2014. 
326. Zhang Y, Zhang B, Liu F, Luo J, and Bai J. In vivo tomographic imaging with 
fluorescence and MRI using tumor-targeted dual-labeled nanoparticles. International 
journal of nanomedicine 9: 33-41, 2014. 
327. Zhang Z, Apse K, Pang J, and Stanton RC. High glucose inhibits glucose-6-phosphate 
dehydrogenase via cAMP in aortic endothelial cells. J Biol Chem 275: 40042-40047, 2000. 
328. Zhao RZ, Jiang S, Zhang L, and Yu ZB. Mitochondrial electron transport chain, ROS 
generation and uncoupling (Review). Int J Mol Med 44: 3-15, 2019. 
329. Zheng F, Zhang S, Lu W, Wu F, Yin X, Yu D, Pan Q, and Li H. Regulation of insulin 
resistance and adiponectin signaling in adipose tissue by liver X receptor activation 
highlights a cross-talk with PPARgamma. PLoS One 9: e101269, 2014. 
330. Zhong Q and Kowluru RA. Diabetic retinopathy and damage to mitochondrial 
structure and transport machinery. Invest Ophthalmol Vis Sci 52: 8739-8746, 2011. 
331. Zhou L, Deepa SS, Etzler JC, Ryu J, Mao X, Fang Q, Liu DD, Torres JM, Jia W, 
Lechleiter JD, Liu F, and Dong LQ. Adiponectin activates AMP-activated protein kinase in 
muscle cells via APPL1/LKB1-dependent and phospholipase C/Ca2+/Ca2+/calmodulin-
dependent protein kinase kinase-dependent pathways. J Biol Chem 284: 22426-22435, 
2009. 
332. Zhou X and He P. Temporal and spatial correlation of platelet-activating factor-
induced increases in endothelial [Ca(2)(+)]i, nitric oxide, and gap formation in intact venules. 
Am J Physiol Heart Circ Physiol 301: H1788-1797, 2011. 
 
 
 
 
 
 
 
 
 
 
 
 
 159 
APPENDICES 
 
Appendix A: A list of publication 
 
1. Yoon N, Dadson K, Dang T, Chu T, Noskovicova N, Hinz B, Raignault A, Thorin E, Kim S, Jeon 
JS, Jonkman J, McKee T, Grant J, Peterson JD, Kelly SP, Sweeney G. 
Tracking adiponectin biodistribution via fluorescence molecular tomography indicates increased 
vascular permeability after streptozotocin-induced diabetes. 
Am J Physiol Endocrinol Metab. 2019 Jul 16. doi: 10.1152/ajpendo.00564.2018. (Appendix B) 
 
2. Dang TQ#, Yoon N#, Chasiotis H, Dunford EC, Feng Q, He P, Riddell MC, Kelly SP, Sweeney G. 
Transendothelial movement of adiponectin is restricted by glucocorticoids. 
J Endocrinol. 2017 Aug;234(2):101-114. doi: 10.1530/JOE-16-0363. (Appendix C) #co-first authors 
 
3. Yoon N, Dang TQ, Chasiotis H, Kelly SP, Sweeney G. 
Altered transendothelial transport of hormones as a contributor to diabetes. 
Diabetes Metab J. 2014 Apr;38(2):92-9. doi: 10.4093/dmj.2014.38.2.92. Review (Appendix D) 
 
 
 
 
 
 
 
 
 160 
Appendix B 
 
Tracking adiponectin biodistribution via fluorescence molecular tomography indicates 
increased vascular permeability after streptozotocin-induced diabetes. 
 
Yoon N, Dadson K, Dang T, Chu T, Noskovicova N, Hinz B, Raignault A, Thorin E, Kim S, Jeon 
JS, Jonkman J, McKee T, Grant J, Peterson JD, Kelly SP, Sweeney G. 
Am J Physiol Endocrinol Metab. 2019 Jul 16. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
RESEARCH ARTICLE Translational Physiology
Tracking adiponectin biodistribution via fluorescence molecular tomography
indicates increased vascular permeability after streptozotocin-induced diabetes
Nanyoung Yoon,1 Keith Dadson,1 Thanh Dang,1 Teresa Chu,1 Nina Noskovicova,2 Boris Hinz,2
Adeline Raignault,3 X Eric Thorin,3 Seunggyu Kim,4,5 Jessie S. Jeon,4,5 James Jonkman,6
Trevor D. McKee,7 Justin Grant,7 Jeffrey D. Peterson,8 Scott P. Kelly,1 and Gary Sweeney1
1Department of Biology, York University, Toronto, Canada; 2Faculty of Dentistry, University of Toronto, Toronto, Canada;
3Montreal Heart Institute, University of Montreal, Quebec, Canada; 4Department of Mechanical Engineering, Korea
Advanced Institute of Science and Technology, Daejeon, Republic of Korea; 5KAIST Institute for Health Science and
Technology, Korea & Advanced Institute of Science and Technology, Daejeon, Republic of Korea; 6Advanced Optical
Microscopy Facility, University Health Network, Toronto, Canada; 7Spatio-temporal Targeting and Amplification of
Radiation Response, University Health Network, Toronto, Canada; and 8Applied Biology, Life Sciences & Technology,
PerkinElmer, Hopkinton, Massachusetts
Submitted 24 December 2018; accepted in final form 27 June 2019
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Raignault A, Thorin E, Kim S, Jeon JS, Jonkman J, McKee TD,
Grant J, Peterson JD, Kelly SP, Sweeney G. Tracking adiponectin
biodistribution via fluorescence molecular tomography indicates in-
creased vascular permeability after streptozotocin-induced diabetes.
Am J Physiol Endocrinol Metab 317: E760–E772, 2019. First pub-
lished July 16, 2019; doi:10.1152/ajpendo.00564.2018.—Adiponec-
tin, a highly abundant polypeptide hormone in plasma, plays an
important role in the regulation of energy metabolism in a wide
variety of tissues, as well as providing important beneficial effects in
diabetes, inflammation, and cardiovascular disease. To act on target
tissues, adiponectin must move from the circulation to the interstitial
space, suggesting that vascular permeability plays an important role in
regulating adiponectin action. To test this hypothesis, fluorescently
labeled adiponectin was used to monitor its biodistribution in mice
with streptozotocin-induced diabetes (STZD). Adiponectin was, in-
deed, found to have increased sequestration in the highly fenestrated
liver and other tissues within 90 min in STZD mice. In addition,
increased myocardial adiponectin was detected and confirmed using
computed tomography (CT) coregistration. This provided support of
adiponectin delivery to affected cardiac tissue as a cardioprotective
mechanism. Higher adiponectin content in the STZD heart tissues was
further examined by ex vivo fluorescence molecular tomography
(FMT) imaging, immunohistochemistry, and Western blot analysis. In
vitro mechanistic studies using an endothelial monolayer on inserts
and three-dimensional microvascular networks on microfluidic chips
further confirmed that adiponectin flux was increased by high glucose.
However, in the in vitro model and mouse heart tissue, high glucose
levels did not change adiponectin receptor levels. An examination of
the tight junction (TJ) complex revealed a decrease in the TJ protein
claudin (CLDN)-7 in high glucose-treated endothelial cells, and the
functional significance of this change was underscored by increased
endothelium permeability upon siRNA-mediated knockdown of
CLDN-7. Our data support the idea that glucose-induced effects on
permeability of the vascular endothelium contribute to the actions of
adiponectin by regulating its transendothelial movement from blood
to the interstitial space. These observations are physiologically sig-
nificant and critical when considering ways to harness the therapeutic
potential of adiponectin for diabetes.
adiponectin; diabetes; endothelial; fluorescence molecular tomogra-
phy; heart; vascular permeability
INTRODUCTION
Extensive research on adiponectin has validated this hor-
mone as a biomarker for cardiometabolic diseases and as a
therapeutic target with enormous potential (43). To harness the
numerous beneficial effects of adiponectin, it is essential to
fully understand the mechanisms governing adiponectin action
(29, 31, 39). To date, the vast majority of studies have focused
on correlating changes in circulating adiponectin levels and
disease markers (1). As a result, reduced adiponectin levels are
well established to inversely correlate with diabetes and car-
diovascular diseases (43). Adiponectin acts via binding to
membrane receptors AdipoR1, AdipoR2, and T-cadherin (19,
45), and reductions in their expression or posttranslational
modification in disease states has been proposed to lead to
adiponectin resistance (11, 36, 42). However, another critical
factor that likely determines adiponectin action is vascular
permeability (25, 26, 46). More specifically, to directly elicit a
response in a target tissue, adiponectin must transit from the
circulation to interstitial space across the endothelial barrier (46).
The monolayer of endothelial cells lining the circulatory
system acts as a barrier that regulates the movement of blood-
borne factors to the interstitial space. In turn, the barrier
properties of the endothelium are regulated by the transcellular
pathway (i.e., solute transport across endothelial cells), as well
as the paracellular pathway (i.e., solute movement between
adjacent endothelial cells) (46). In general, larger macromole-
cules move via facilitated transcellular trafficking, while the
paracellular route typically restricts solutes in the range of 3
nm radius (16). Tight junctions (TJ) provide a selective barrier
to solute movement between cells, and altered expression of
components, including zona occludens-1 (ZO-1), occludin,
tricellulin, and claudins alter TJ structure to make a leakier or
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tighter barrier for paracellular movement of solutes (15). Nu-
merous previous studies, particularly focusing on insulin, have
shown that vascular permeability can play an important role in
contributing to the development of diabetes and heart failure
(25, 46). It is important to note that endothelial permeability
varies widely throughout the body in a tissue (and intra-tissue)-
specific manner (46). It has also been shown that endothelial
barriers control adiponectin transport in a cell- and tissue-specific
manner (35), and we have reported that transendothelial move-
ment of adiponectin was reduced by glucocorticoids (9).
We believe that the role of endothelial permeability as an
important determinant of adiponectin action has been some-
what underappreciated. In this study, we further considered a
link between vascular permeability, adiponectin flux, and hy-
perglycemia/diabetes by producing recombinant adiponectin,
which we then conjugated with a near-infrared probe to track
its biodistribution in live wild-type control and diabetic mice
using fluorescence molecular tomography (FMT). We also
examined the effects of high glucose levels on adiponectin flux
across isolated arteries and cultured monolayers of endothelial
cells. Finally, because the cardioprotective actions of adiponec-
tin are currently the focus in our laboratory (6–8, 30, 32), we
considered the role of the vascular barrier and diabetes on
adiponectin access and action in the heart. These studies
provide a novel and integrated view on the movement of
adiponectin across the endothelial barrier under conditions that
relate to diabetes and offers new insight on the impact that
vascular permeability has on the actions of adiponectin on key
organs.
MATERIALS AND METHODS
Experimental animal model. Male nu/nu homozygous mice and
C57BL6 aged 8–13 wk were used for assessing adiponectin biodis-
tribution. All mice were maintained with access to water and low-
fluorescent chow [Teklad Global 18% protein rodent diet (Irradiated),
Harlan Laboratories, Indianapolis, IN] throughout each experimental
period. Age- and weight-matched pairs were grouped for each injec-
tion (averaging 23–25 g). After 12 h of starvation, diabetes was
induced by single intraperitoneal injection of 150 mg/kg (body
weight) streptozotocin (STZ; Sigma-Aldrich, St. Louis, MO). Exper-
iments were performed 4 days after STZ injection, and diabetes was
diagnosed when mice exhibited a blood glucose level 14 mmol/l at
this time, while all control mice received only a saline injection.
Circulating adiponectin was detected in serum before and after infu-
sion of VivoTag-750-conjugated adiponectin using a mouse adiponec-
tin ELISA kit with a sensitivity of 3.12–200 ng/ml (Immunodiagnos-
tics, Hong Kong, China), which detects all adiponectin oligomeric
forms.
Fluorescence molecular tomography to detect VivoTag-750-adiponectin.
Recombinant adiponectin prepared in our laboratory was labeled with
VivoTag-S 750 (NEV10123, Perkin Elmer, Boston, MA). Impor-
tantly, this recombinant protein formed oligomeric forms in a ratio,
which closely mirrors those found in circulation (see Supplemental
Figs. S1 and S2; all Supplemental material is available at https://
doi.org/10.5281/zenodo.3332774). Labeling efficiency was assessed
by running labeled full-length adiponectin on a SDS-PAGE gel and
then scanned on a LI-COR Odyssey infrared imaging system to
visualize the three adiponectin isoforms. Labeled proteins were trans-
ferred from the gels onto nitrocellulose membranes before probing
with adiponectin-specific antibodies to assess fluorescence-to-total
protein ratio. Labeled adiponectin was infused into lightly anesthe-
tized mice (1–2% isoflurane) via a surgically placed permanent
jugular vein cannula. For cannulation insertion, the mice were first
anesthetized with 5% isoflurane then maintained at 2% isoflurane. The
surgical site was cleaned with iodine solution and alcohol before a
longitudinal incision of ~15 mm was made in the skin at the neck of
the animal, just above the right front leg. Connective tissue surround-
ing the jugular vein was carefully separated before two sutures of 6-0
Ethilon surgeon’s silk (Johnson & Johnson, Brussels, Belgium) were
placed ~5–10 mm apart on the vein. A fine lateral incision was made
between the sutures using microscissors, which allowed insertion of a
saline-filled polyethylene (PE-10) tube into the vein between the
sutures. When placement was confirmed, the caudal suture was
released, and the cannula was slowly fed caudally ~5 mm into the vein
toward (but not entering) the heart. To confirm correct placement, 50
L saline was delivered through the cannula using a 31-gauge insulin
needle. The cannula was then securely tied to the jugular vein with
silk suture and 85 g of adiponectin conjugated with VivoTag-S was
administered followed by a 50-L saline flush. The cannula was
sealed using a heated hemostat, the skin incision was closed using silk
suture, and a serum sample was collected from the tail vein within 2
min of adiponectin infusion. Mice were maintained at 2% isoflurane,
while being positioned in a glass mouse imaging cassette, then
scanned 10, 30, 60, and 90 min postadiponectin infusion with a
fluorescence molecular tomography (FMT) 2500 LX quantitative
tomography system (VisEn Medical, Perkin Elmer, Downers Grove,
IL) using the 750-nm near-infrared channel (750/800 nm excitation/
emission). Once FMT scanning was completed, mice in the imaging
cassette were immediately taken for a computed tomography (CT)
scan (Locus eXplore MicroCT, GE Healthcare, London, ON, Canada
and XRAD 225Cx, Precision X-Ray, North Banford, CT) under
constant anesthesia to ensure identical mouse positioning and accurate
alignment between CT and FMT. FMT software (TrueQuant, Perkin
Elmer) reconstructs a quantitative three-dimensional (3D) data set, in
which fluorescence/voxel is expressed in nanomoles per liter. FMT
and CT data sets (dicom format) were imported into Inveon Research
Workplace (Siemens Healthcare, Erlangen, Germany) or AMIDE
(http://amide.sourceforge.net) for FMT-CT coregistration to permit
accurate localization of the fluorescent signal.
FMT analysis of tissues ex vivo. To avoid potential scatter from
adjacent tissue, heart, liver, kidney, pancreas, and skeletal muscle,
those tissues were excised from mice after cervical dislocation imme-
diately following FMT and CT scanning (~100–120 min postadi-
ponectin infusion). Two-dimensional (2D) epifluorescence FMT im-
ages were taken of these tissues on an opaque resin imaging block in
the FMT imaging cassette. Quantitative analysis of the fluorescent
signal was performed using the FMT software (TrueQuant, Perkin
Elmer).
Ex vivo vascular permeability of adiponectin assay. Five-week-old
Wistar rats were used. After 2 wk of standard diet in the animal
facility, rats were fasted 5 h before induction of diabetes by a single
intraperitoneal injection of streptozotocin (STZ; Sigma-Aldrich) at a
dose of 100 mg/kg body wt (200 L/rat). Diabetes was diagnosed
when hyperglycemia was higher than 10 mmol/L (180 mg/dL). Rats
developed diabetes within 7 days of STZ injection. A control group of
rats was injected with an equivalent volume of the vehicle solution
(citrate buffer 0.5 mM, pH 4.5). Rats that failed to respond to STZ
injection were not used for the study. Control or diabetic rats were
anesthetized with isoflurane, and a midline laparotomy was performed
to expose and remove the mesenteric bed. Isolated mesenteric arteries
were mounted on a glass cannula immersed in a 2-mL organ bath
filled with a physiological salt solution (PSS; in mmol/L: 130 NaCl,
4.7 KCl, 1.18 KH2PO4, 1.17 MgSO4, 14.9 NaHCO3, 1.6 CaCl2, 0.023
EDTA, 10 glucose; pH 7.4) aerated with 12% O2; 5% CO2; 83% N2
at 37°C following a method previously described (33). Arterial seg-
ments were pressurized at 80 mmHg in no-flow conditions and
equilibrated for 30 min before starting experiments. Ten micrograms
per milliliter adiponectin (200 L) was added to the arterial perfusate,
which circulated at a flow rate of 2 L/min for 90 min at a constant
pressure of 80 mmHg. At 0, 30, 60, and 90 min, 100-L samples of
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the extra-vascular bath containing transported adiponectin were col-
lected, and an equivalent volume of physiological solution was added
to the bath. Adiponectin levels were quantitatively determined by
ELISA kit (Immunodiagnostics).
Cell culture. Human dermal microvascular endothelial cells
(HDMEC; American Type Culture Collection, Manassas, VA) were
grown in vascular cell basal medium (American Type Culture Col-
lection) supplemented with 10% FBS at 37°C, 5% CO2. All cells were
used at passages 3 and 4 from the supplier. 500K HDMECs were
seeded onto Transwell inserts (Corning, Tewksbury, MA) sized for
12-well plates having 3.0-m pore sizes. Hyperglycemia was induced
with 25 mM glucose in vascular cell basal medium supplemented with
2% FBS for 6 days. To adjust for osmotic pressure differences, control
cells were treated with 5.5 mM glucose and 19.5 mM mannitol.
Measurement of transendothelial electric resistance. Measure-
ments of transendothelial electric resistance (TEER) were conducted
using STX-2 chopstick electrodes attached to an epithelial voltohm-
meter (EVOM; World Precision Instruments, Sarasota, FL). All TEER
measurements were corrected for background by subtracting TEER
recorded across a blank membrane primed with appropriate cell
culture medium. Resistance measurements were taken at day 0 and
day 6 of treatment with 25 mM glucose and control (5.5 mM
glucose  19.5 mM mannitol).
Permeability assay using endothelial monolayers. HDMECs were
seeded onto Transwell inserts and treated with 25 mM glucose and 5.5
mM glucose with 19.5 mM mannitol for 5 days before the start of
experiments. At the start of the experiment, 10 g/mL of adiponectin
with the 25 mM glucose or 5.5 mM glucose with 19.5 mM mannitol,
including 2% FBS vascular cell basal medium (American Type
Culture Collection PCS-100-030; Cedarlane, Burlington, ON, Can-
ada), was applied to the apical chamber only. After 24 h, apical and
basolateral media were assessed for adiponectin concentration by gel
electrophoresis after concentrating with 10,000 Da MWCO (molecu-
lar weight cutoff) filter (EMD Millipore, Billerica, MA) or by fluo-
rescence intensity reader, respectively, and concentrations were cal-
culated by comparison to standard curves prepared in culture medium.
Quantitative RT-PCR. Using aliquots of total extracted RNA, we
synthesized cDNA, and we performed quantitative RT-PCR (qRT-
PCR) reactions using the SYBR Green PCR Master Mix (Life Tech-
nologies, Carlsbad, CA). Gene-specific primer sets were designed:
human CLDN7, forward: 5=-GGAGACGACAAAGTGAAGAA-
GG-3= and reverse: 5=-GGACAGGAACAGGAGAGCAG-3=; human
GAPDH, forward: 5=-AACATCATCCCTGCCTCTACTG-3= and re-
verse: 5=-CCTGCTTCACCACCTTCTTG-3=; murine AdipoR1, for-
ward: 5=-ACGTTGGAGAGTCATCCCGTAT-3=and reverse: 5=-CT-
CTGTGTGGATGCGGAAGAT-3=; murine AdipoR2, forward: 5=-
TCCCAGGAAGATGAAGGGTTTAT-3= and reverse: 5=-TTCCA-
TTCGTTCCATAGCATGA-3=; murine adiponectin, forward: 5=-
TGTTCCTCTTAATCCTGCCCA-3= and reverse: 5=-CCAACCTG-
CACAAGTTCCCTT-3=; murine CLDN7, forward: 5=-GGACCTGC-
CATCTTTATCGGC-3= and reverse: 5=-AGCTTTGCTTTCACTGC-
CTGG-3=; murine ZO-1, forward: 5=-GTCCCTGTGAGTCCTT-
CAGCTG-3= and reverse: 5=-ACTCAACACACCACCATTGCTG-
3=; murine 18s RNA, forward: 5=-AGTGAAACTGCGAATGGC-
TCA-3= and reverse: 5=-CGAGCGACCAAAGGAACCA-3=.
Claudin-7 knockdown by shRNA in HDMEC. Claudin-7 gene
expression was knocked-down in HDMECs using a pGPU6/Neo-
claudin-7 plasmid, as shown previously (9) using the following
shRNA target sequence: 5=-GGCCATCAG ATTGTCACAGAC-3=
(GenePharma, Shanghai, China). Lipofectamine 3000 reagent (Life
Technologies, Carlsbad, CA) was used for all transfections following
the manufacturer’s instructions. A nontargeted control (NTC) shRNA
plasmid was designed with a nonspecific scrambled sequence. The
transfected cells were stabilized for 24 h with 10% FBS medium and
subjected to antibiotic selection (500 g/mL G418; Sigma-Aldrich)
for 2 days. During antibiotic selection, transfected cells were seeded
on Transwell inserts or six-well plates for further experiments.
Western blot analysis. Proteins from mouse tissues were homoge-
nized by TissueLyser II (QIAGEN, Hilden, Germany) in RIPA buffer
with 80 mM Tris·HCl (pH 6.8), 2% (wt/vol) SDS, 20% glycerol, 3.3%
(vol/vol) -mercaptoethanol, 0.01% (wt/vol) bromophenol blue, 30
mM HEPES (pH 7.4), 2.5 mM EGTA, 3 mM EDTA, 70 mM KCl, 20
mM -glycerolphosphate, 20 mM NaF, 1 mM Na3VO4, 200 M
PMSF, 10 M E64, 1 M leupeptin, 1 M pepstatin A, 0.1% NP40,
and 0.1 M okadaic acid. To detect the three forms of adiponectin,
samples were prepared without -mercaptoethanol or heating. For
detection of other protein targets, samples were lysed in complete
RIPA buffer and denatured at 95°C for 10 min. Transported adiponec-
tin was collected from basolateral HDMEC medium and concentrated
using Amicon Ultra-4 centrifugal filter units with Ultracel-10K (EMD
Millipore, Billerica, MA). To detect the three adiponectin oligomers,
concentrated adiponectin samples were prepared without denaturation
or reduction. Prepared samples were run on SDS-PAGE gels and then
transferred onto PVDF membranes (Bio-Rad Laboratories, Hercules
CA), before incubation with primary antibody and detection by
chemiluminescence. Polyclonal primary antibody of rabbit anti-adi-
ponectin (dilution 1:1,000) is produced in-house (28). Rabbit anti-
AdipoR1/2 antibodies were from Phoenix Biotech (Toronto, ON,
Canada) (32). Mouse anti-FLAG M2 (dilution 1:1,,000, F1804;
Sigma, Oakville, ON, Canada), rabbit anti-claudin-7 (dilution 1:500,
cat. no. 34-9100; Thermo Fisher Scientific, Waltham, MA), rabbit
anti-/-tubulin (dilution 1:1,000, cat. no. 2148; Cell Signaling,
Danvers, MA), and rabbit anti-GAPDH(14C10) (dilution 1:1,000, cat.
no. 2118; Cell Signaling) were purchased. The appropriate HRP-conju-
gated secondary antibody [anti-rabbit IgG-HRP (dilution 1:5,000, cat. no.
7074), anti-mouse IgG-HRP (dilution 1:5,000; cat. no. 7076)] was
used from Cell Signaling. Bands were quantified by densitometry
using Fiji software and normalized to relevant loading controls as
indicated.
Immunofluorescence. Mouse hearts were isolated following isoflu-
rane anesthesia, and the ventricles were excised and then cross-
sectioned at the midline with a surgical blade before being embedded
into a mold with optimal cutting temperature compound (OCT)
(Sakura Finetek, Torrance, CA) and frozen on dry ice. Five-m-thick
cryosections were made using a cryostat and mounted onto positively
charged glass slides (Superfrost; Thermo Fisher Scientific). Mounted
slides were fixed in 4% PFA solution for 10 min to stain adiponectin
or fixed in 100% ice-cold acetone, air-dried at room temperature, and
rehydrated in distilled water followed by washing with PBS buffer.
Permeabilization was followed by 0.5% Triton X-100. Before per-
meabilization, cell border staining was performed by incubating with
5 g/mL Alexa Fluor 488-conjugated wheat germ agglutinin (WGA;
Thermo Fisher Scientific) for 10 min in adiponectin staining. Sections
were then incubated with adiponectin primary antibody (1:100),
Texas-red secondary antibody (1:250), and DAPI for nuclear visual-
ization. For vasculature staining, primary antibodies directed against
claudin-7 (dilution 1:50, cat. no. 34-9100; Thermo Fisher Scientific),
VE-cadherin (dilution 1:100; cat. no. PA5-17401; Thermo Fisher Scien-
tific), PECAM-1 (dilution 1:50; cat. no. SC-376764; Santa Cruz Biotech,
Mississauga, CA), ZO-1 (dilution 1:100, cat. no. 61-7300; Thermo Fisher
Scientific), -SMA (1:100; -SM1, a kind gift from Dr. Giulio Gabbiani,
University of Geneva, Switzerland), and desmin (1:30, cat. no. M076029;
Dako, Burlington, ON, Canada) were used. Isotype-specific secondary
antibodies anti-rabbit IgG-TRITC (1:100; Sigma), Alexa Fluor 568-
conjugated IgG (1:100; Abcam, Cambridge, MA), Alexa Fluor 647-
conjugated IgG2a (1:100; Molecular Probes, LifeTechnologies), and
anti-mouse IgG1-FITC (1:200; SouthernBiotech, Birmingham, AL),
and DAPI (Vectashield mounting medium with DAPI, cat. no.
H-1200; Vector Laboratories, Burlingame, CA) were used. Images
were acquired using a LSM700 (Zeiss, Jena, Germany) or LSM780
(Zeiss) confocal microscope and an upright Zeiss Axio Observer M35
epifluorescence microscope equipped with structured illumination
(Apotome) and Axiocam HR camera (Carl Zeiss). All images were
processed using Fiji or Adobe Photoshop CS5 (Adobe System, San
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Jose, CA). Contrast and brightness were enhanced consistently for all
representative images used in this article.
Fabrication of microfluidic devices and cell culture on a chip. To
recapitulate 3D microvascular networks in vitro, we used a microflu-
idic chip that included cells embedded in hydrogel. Previous studies
have described the fabrication process of the chips in detail (37).
Briefly, silicon-based organic PDMS microfluidic device fabrication
includes steps of soft lithography with SU-8 silicon wafer mold
(A-Med, Conroe, TX) and PDMS (1:10; Dow Corning, Midland, MI),
generating reservoirs with 1–4-mm diameter biopsy punches (KAI
Medical, Rockville, MD), and device assembly by plasma bonding
(Femto Science, Somerset, NJ) to a coverslip (glass; Duran). The
devices were sterilized by 15 min of sonication (Uil Ultrasonic,
Wa-dong, South Korea) in 70% EtOH before the bonding process. An
80°C drying oven was used for curing PDMS mixture, dehydration of
devices before plasma treatment, and recovering hydrophobicity after
bonding (24 h in advanced cell seeding). In this study, a 120-m
depth of microchannel devices was used.
Human umbilical vein endothelial cells (HUVECs; Lonza) were
grown in endothelial cell growth medium (EGM-2, Lonza) supple-
mented with 5% FBS at 37°C, 5% CO2. All cells were used at
passages 6–8 from the supplier. After harvesting of trypsinized cells
by centrifugation (125 g, 7 min), cells were resuspended in a concen-
tration of 1.4  107 cells/mL within a 4 U/mL thrombin solution. We
injected a 1:1 mixture of cells (1.4  107 cells/mL) and fibrinogen
solution (5 mg/mL) into a gel inlet to fill it up. After incubating the
chips at 37°C in a humid chamber for 15 min to produce gelation, we
injected cell culture medium into the media channels. The cells in the
microfluidic chips were incubated for 4 days with daily replacement
of medium. Self-assembly of HUVECs into a perfusable vascular
network (vasculogenesis) was induced by adding 50 ng/mL VEGF to
EGM from day 0 (D0) to day 4 (D4).
Vascular permeability assay in microfluidic chips. After a 4-day
culture, the medium was washed out with a quick PBS rinse before a
fluorescent molecule solution was infused. Because of the hydrostatic
pressure drop between the two media channels, the solution in the
media channel flows along with the perfusable microvascular net-
works to the opposite media channel. We monitored the diffusion of
fluorescent molecules into the fibrin gel (extracellular matrix, ECM)
through the vessel wall, and the images were captured at 6–10-s
intervals for 3 min via a fluorescence microscope (Axio Observer Z1,
Zeiss). The images were quantified using ImageJ.
Perfusibility test in three-dimensional microvascular network. At
day 4, endothelial growth medium was quickly washed with PBS by
filling up two reservoirs in only one side channel to rinse out any
particles from the 3D vessel lumen efficiently using hydrostatic
pressure differences. When a desired field of view was found, bright-
field images were captured. Then, 5.0–5.9 m of FITC surface-
labeled beads (0.1% wt/vol, F1CP-50-2; Spherotech) was infused into
one media channel and time-lapse images were taken at 1.4-s intervals
for 2 min using the fluorescence microscope (Axio, Observer Z1;
Zeiss). The fluorescent images were overlaid with bright-field orien-
tation image, and processed to video with ImageJ.
Statistical analysis. Data are expressed as means	 SE, and the
significant differences were determined where P
 0.05 resulted from
performing statistical analysis with Student’s t-test or multiple t-test
and one-way ANOVA.
RESULTS
Diabetes increases biodistribution of NIR-labeled full-length
adiponectin into target tissues. To accurately investigate adi-
ponectin biodistribution, we developed a model using FMT in
which three-dimensional localization of fluorescently tagged
adiponectin could be tracked in short time intervals in vivo.
Full-length adiponectin comprising high-, medium-, and low-
molecular weight oligomers was tagged with a near-infrared
(NIR) peptide (VivoTag-S 750) detectable at 750 nm [full-
length adiponectin (fAd)-VT750]. Using this wavelength and
feeding mice with AIN-76A low-chlorophyll chow diet (Har-
lan, Indianapolis IN) allowed us to avoid confounding effects
of autofluorescence (2). Western blot and fluorescent imaging
confirmed that all three oligomers of adiponectin were fluoro-
phore conjugated (Supplemental Fig. S1A, https://doi.org/
10.5281/zenodo.3332774), and we demonstrated a linear rela-
tionship between adiponectin concentration and fluorescence
measurement (Supplemental S1, A–C).
To test the hypothesis that hyperglycemia could alter adi-
ponectin biodistribution, we infused fAd-VT750 (85 g, via
jugular vein) into STZ-injected (STZD) or control nu/nu mice,
and then we monitored whole body fluorescence in mice by
FMT imaging. We found no difference in circulating adiponec-
tin levels between control and STZD mice and also observed
the same level of fAd-VT750 in serum of either STZD or wt
mice 2 min after injection via jugular vein (Supplemental Fig.
S2A). Consecutive FMT images at 0, 10, 30, 60, and 90 min
after fAd-VT750 injection showed increasing tissue accumu-
lation of fluorescent adiponectin throughout the body, which
appeared to be faster or higher in STZD mice (Fig. 1, A–C),
particularly showing enhanced liver and/or heart accumulation
relative to controls. FMT imaging confers the added advantage
of providing quantitative analysis of whole body fluorescence
and clearly measured an increased overall fluorescence inten-
sity in STZD mice. As a control, infused unconjugated VT750
displayed a completely different biodistribution pattern, clear-
ing quickly through the kidneys and localized primarily to the
bladder within 60 min, with very little signal coming from
other peripheral tissues (Supplemental Fig S3).
To conduct further analysis of the tissue localization of
fluorescent signal, mice also underwent X-ray computed to-
mography (CT) imaging for fluorescence coregistration (Fig.
1D). Coronal and sagittal sections of FMT/CT coregistration
data showed accumulation of fAd-VT750 in the heart, liver,
kidney, and bladder (Fig. 1E). To eliminate potential tissue-
scattering effects, major target tissues of adiponectin action
were removed 90 min following fAd-VT750 infusion and
imaged ex vivo by FMT. Heart, liver, kidney, pancreas, and
skeletal muscle (Sk M) of STZD mice exhibited a higher
fluorescent signal when compared with control (Fig. 1F),
although only heart and liver reached significance upon
quantitation (Fig. 1G). In agreement with this, Western blot
analysis of reduced tissue homogenates, to allow detection
of all adiponectin as monomers, clearly showed increased
levels in all of these target tissues from STZD versus
wild-type control mice at 90 min post fAd-VT750 infusion
(Fig. 1H).
Adiponectin accumulation in the heart is upregulated by
STZD. Because the main research focus of our laboratory is the
cardioprotective effect of adiponectin, we then used FMT-CT
coregistered images to quantify the fluorescence contained
within a three-dimensional region of interest mapped to the
heart (Fig. 2A). FMT quantitation shows that within 10 min,
fAd-VT750 level in STZD hearts was significantly greater than
that in wild-type control mice (Fig. 2B). Accordingly, area
under the curve analysis showed greater accumulation of fAd-
VT750 in the hearts of STZD mice (Fig. 2C). Immunofluores-
cent analysis of cross sections from myocardium also indicated
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Fig. 1. Fluorescence molecular tomography shows in vivo biodistribution of full-length adiponectin is increased in diabetic conditions. A: 85 g of near-infrared
labeled full-length adiponectin (fAd-VT750) was injected via cannulated jugular vein into control or diabetic (streptozotocin-induced diabetes, STZD) nu/nu
mice. Representative images from a control and STZD mouse before injection and at 10, 30, 60, and 90 min postinjection are shown. B and C: total signal intensity
from whole body three-dimensional (3D) field of view was calculated as nM (n  8; *P 
 0.05 from multiple t-test). Time course data were converted to area
under curve (AUC) (*P 
 0.05 from Student’s t-test). D: coregistration of fluorescence molecular tomography (FMT) (color) and computed tomography (CT)
data (white/gray). E: coronal and sagittal view of FMT-CT coregistration with organs of interest identified. F: ex vivo two-dimensional (2D) FMT analysis of
fAd-VT750 from isolated tissues [heart, liver, kidney, pancreas, and skeletal muscle (tibialis anterior)]. G: quantification of these 2D images using TrueQuant
software. *P
 0.05, compared with its control (n 4). Statistical analysis was performed using Student’s t-test. H: cardiac homogenates from control and STZD
mice were analyzed by Western blot analysis under nondenaturing conditions to compare total amount of reduced (i.e., monomeric, 30 kDa) adiponectin.
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increased fAd-VT750 in STZD mice 90 min postinfusion
compared with wild-type control mice (Fig. 2, D and E).
Interestingly, higher magnification revealed an apparent colo-
calization of fAd-VT750 with WGA, suggesting a near-mem-
brane location.
Because molecular weight could be an important determi-
nant in the movement of the adiponectin isoforms from circu-
lation into the heart, we assessed the amount of fAd-VT750 in
perfused heart homogenates from control and STZD mice
under nondenaturing conditions. There was an increased pres-
ence of all three oligomeric adiponectin isoforms in STZD
heart homogenates when compared with those of wild-type
control mice (Fig. 2G). To verify that increased fAd-VT750
localization was not influenced by the presence of the VivoTag-
750 fluorophore, Flag-tagged and nonfluorescent recombinant
adiponectin was injected into wild-type C57BL/6 mice
treated with or without STZ. Similar to fAd-VT750, there
was increased total heart localization of Flag-adiponectin in
STZ-treated mice compared with controls (Fig. 2F). Quan-
titative PCR analysis showed no difference in adiponectin
mRNA levels between control and STZD cardiac homoge-
nates (Fig. 2H).
High glucose levels regulate claudin-7 expression to in-
crease paracellular movement of adiponectin. We next tested
vascular permeability of adiponectin using mesenteric arteries
isolated from STZD or control mice. Similar to our in vivo
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findings, adiponectin flux across the arterial wall of STZD
mesenteric arteries was greater compared with those of wild-
type control mice (Fig. 3A). We then exposed a monolayer of
human dermal endothelial cells (HDMECs) cultured on Trans-
well inserts to high glucose and found that the flux of adi-
ponectin, added to the apical chamber, was higher than in
normal glucose conditions. Figure 3B shows a Western blot,
with quantitation below, indicating a significant increase in
flux of high-molecular weight (HMW)-, middle-molecular
weight (MMW)-, and low-molecular weight (LMW)-adiponec-
tin from apical to basolateral side in cells grown under hyper-
glycemic conditions (Fig. 3B). Immunoblotting of the adi-
ponectin receptors AdipoR1 and AdipoR2 showed that their
expression in HDMEC monolayers was not affected by high
glucose (Supplemental Fig. S4C). Accordingly, we found that
endothelial barrier tightness measured by transendothelial elec-
trical resistance (TEER) was decreased in high glucose-treated
cells (Fig. 3C). This corresponded to a decrease in claudin-7
(cldn-7) mRNA and protein expression following high glucose
treatment (Fig. 3, D and E). Immunofluorescence imaging
indicated a decrease in cell membrane expression of cldn-7 in
high glucose-treated cells compared with control (Fig. 3F),
whereas there was no difference in expression of another tight
junction-related protein, ZO-1, between groups (Fig. 3G). This
observation was mirrored when heart homogenates were ana-
lyzed. Protein and mRNA levels of adiponectin receptors were
unchanged by STZD (Supplemental Fig. S4, A and B). In
cardiac tissue sections analyzed by qPCR for mRNA and
immunohistochemistry, ZO-1 level was not significantly lower
(Fig. 3, J and K), while cldn-7 expression was significantly
decreased (Fig. 3, H and I) in STZD hearts compared with that
in wild-type control mice.
Reduced claudin-7 expression decreased TEER and enhanced
adiponectin movement across the endothelial monolayer. To test
the functional importance of cldn-7 in adiponectin flux across
an HDMEC monolayer, knockdown of cldn-7 was induced by
transfection of shRNA (shCLDN7), which resulted in ~50%
decrease in cldn-7 protein compared with cells that received a
scrambled shRNA sequence not targeting cldn-7 (shNTC) (Fig.
4A). TEER was significantly decreased in monolayers com-
prising shCLDN7 cells compared with shNTC (Fig. 4B). Fur-
thermore, there was increased flux of LMW-adiponectin from
apical to basolateral side of monolayers comprising shCLDN7
cells compared with shNTC controls (Fig. 4C).
Functional 3D perfusable microvascular networks allowed
to confirm hyperglycemia effect on permeability of dextran and
adiponectin. Finally, we tested the hyperglycemia effect in
microfluidic microvascular network of HUVECs. This in vitro
platform of 3D vasculature-on-a-chip was generated in the
ECM mimetic environment with fibrin hydrogel. PDMS (poly-
dimethylsiloxane) microfluidic device is useful to induce per-
fusable microvasculature, as well as to monitor the event inside
of the highly branched vascular structure. The PDMS mold has
a central gel channel containing HUVECs and fibrin hydrogel
bordered by triangular posts and two media fluid channels (Fig.
5, A and B). 1.4  107 cells/mL of HUVECs were seeded with
the fibrin hydrogel at D0 and incubated for 4 days to form
endothelial monolayers of in vivo-like vasculature naturally
(Fig. 5C). Additional VEGF was used to increase the dynamic
alignment of HUVECs from D0 to D4 (Fig. 5D). At day 4, the
formation of open-ended EC monolayer 3D vessels between
two PDMS posts were completed. GFP transfected HUVECs
showed highly branched features of microvascular networks in
a device (Fig. 5E) and vascular endothelial cadherin (VE-
cadherin)-positive-stained structures indicated that vessel-like
EC monolayer barrier allows the perfusion of fluids (Fig. 5F;
Supplemental Video S3). To confirm the functionality of this
vasculature, we performed perfusibility test with 5-m beads
conjugated with FITC, and time-lapse images were taken under
fluorescence exposure at every 1.4 s (Fig. 5G, Supplemental
Video S4). Next, we wanted to test the effect of hyperglycemia
on permeability of 3D microvascular networks using fAd and
changes of paracellular movement across this barrier with 70
kDa dextran at several time intervals. Immunofluorescent de-
tection of VE-C showed that the integrity of interconnected
vascular structures appeared not to loosen in hyperglycemia
compared with control (Supplemental Fig. S5). To assess the
permeability, 10 g/mL fAd conjugated with rhodamine was
injected into one reservoir of a device, and fluorescent images
were captured over time. The apparent permeability (Papp,
cm/s) was calculated by the fluorescent intensity measurement
from a linear region of interest (ROI) spanning the microves-
sel-ECM interface. Because the perfused fluorescent molecules
were transferred to the ECM from the vessels via the concen-
tration gradient, the intensity increase was observed in ECM
area over time (Fig. 5H). Permeability of rhodamine-labeled
fAd (Rho-fAd) increased in hyperglycemia (1.285  105 	
0.09363  105 cm/s) compared with 19.5 mM mannitol with
5.5 mM glucose-treated control (2.290  105 	 0.1651 
Fig. 3. Hyperglycemia reduces claudin-7 expression and permits greater flux of adiponectin movement across the endothelium. A: mesenteric arteries extracted
from control or streptozotocin-induced diabetes (STZD) rats were perfused with flag-tagged fAd, with samples of extravascular fluid taken at 30, 60, and 90 min
postadiponectin and analyzed by ELISA. Area under the curve (AUC) analysis shows greater adiponectin flux from STZD arteries vs. control (n 5; *P
 0.05).
B: human dermal microvascular endothelial cells (HDMEC) were cultured in a Transwell insert before treatment with high glucose (HG) or control. Adiponectin
was added to the apical surface, and then basolateral media were collected 24 h following adiponectin administration. Samples were run under nondenaturing
conditions; n  3; *P 
 0.05, with respect to each adiponectin isomer’s control. C: TEER (transendothelial electrical resistance) was lower in hyperglycemia
significantly (*P 
 0.05; n  11). Claudin-7 in hyperglycemia-treated endothelial cells also decreased at cldn-7 mRNA expression (*P 
 0.05; n  4) (D), as
well as claudin-7 (CLDN-7) protein expression (*P 
 0.05; n  3) (E). F: lower CLDN-7 was localized on the cell membrane in hyperglycemia. CLDN-7 (red)
and PECAM-1 (green; endothelial marker) costain in HDMEC. G: however, zona occludens (ZO-1; green), aligning under the cell membrane, was not changed
by high glucose (HG) treatment. H: cldn-7 mRNA level decreased in the hearts of mice with STZ-induced diabetes (n 5; *P
 0.05). J: no significant difference
was shown in zo-1 mRNA level (n  4). Statistical analysis was performed using the Student’s t-test. I: lower CLDN-7(red) surrounded by -SMA (green) was
observed in heart tissue sections from STZD (K), although there was no difference of ZO-1. Immunostaining for ZO-1 (green) to identify endothelial cell-specific
tight junction structure, -SMA (red) to identify vascular smooth muscle cells, and desmin (blue) to identify cardiomyocytes. Shown are representative images
of n  3 mice per experimental group. High-magnification images show junction formation between endothelial cells in small vessels. Scale bars: 50 m and
150 m, respectively.
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105 cm/s) (Fig. 5K). 70 kDa dextran, which is smaller than
LMW adiponectin (around 90 kDa), also showed significantly
higher permeability in high glucose-treated condition (Papp of
HG was 6.812  105 	 1.152  105 cm/s and control Papp
was 2.180 105 	 0.2277 105 cm/s) (Fig. 5J). However,
for the small size of dextran (3 kDa-FITC), hyperglycemia did
not significantly change the permeability (Fig. 5I). These
suggested that paracellular movement regulates transendothe-
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lial accessibility depending on the size of molecules. It also
confirmed that hyperglycemia in vitro with 25 mM glucose
altered the movement of full-length adiponectin in microfluidic
vessels-on-a-chip.
DISCUSSION
Adiponectin has been shown to mediate widespread physi-
ological effects with resulting antidiabetic, anti-inflammatory,
and cardioprotective effects (12). Hence, there has been great
interest within academic institutes and pharmaceutical compa-
nies to develop therapeutics targeting adiponectin action. To
accomplish this, it is critical to fully understand the mecha-
nisms regulating adiponectin’s cellular effects in various tis-
sues. Although we have learned much about adiponectin re-
ceptor-mediated signaling mechanisms, few studies have fo-
cused on examining mechanisms regulating the transit of
adiponectin from the circulation to the interstitial space and,
thus, target cells, such as cardiomyocytes, hepatocytes, -cells,
and other cells. We previously proposed that vascular perme-
ability was likely to be an important, and underappreciated,
determinant of adiponectin’s physiological actions (46). This is
particularly relevant since adiponectin is a complex molecule
comprising multiple oligomeric forms, each with a different
molecular weight and radial size estimated to be 3.96 to 10.1
nm (35). This is exactly the range within which tight junctions
of around 4 nm in dimension can be expected to strongly
contribute to dictating adiponectin flux. Indeed, we recently
demonstrated that glucocorticoid-mediated decreases in trans-
cellular endothelial permeability-restricted adiponectin transit
across endothelial monolayers (9). The observation that adi-
Fig. 5. Functional three-dimensional (3D) microvascular networks demonstrated size-dependent permeability and the effect of hyperglycemia on adiponectin
transport. A: schematic representation of 3D perfusable microvascular network model with human umbilical vein endothelial cells (HUVECs) in a
polydimethylsiloxane (PDMS) microfluidic device. The PDMS mold has a central gel channel containing HUVEC cells and fibrin hydrogel bordered by triangle
posts. The HUVEC/fibrin gel channel is flanked on both sides by fluid channels, leading to four reservoirs filled with culture medium. B: a device photo is shown
with an area dimension of 20,000 m  38,000 m; a dime is shown alongside of it as a size reference. C: experimental timeline is shown. D: daily images
(D1–D4) of HUVECs in the 3D fibrin gel shows cellular alignment dynamics during vasculogenesis (10 magnification was used). E: continuously green
fluorescent protein (GFP)-expressed HUVECs showed the perfusable vasculature on day 4. F: confocal reconstructed 3D image of VE-cadherin (red) stained with
nucleus (DAPI, blue). A single plane from the stacked images showed three ortho-positions (x position/pink at 570 m, y position/green at 700 m, and z
position/blue at 18 m) of continuous endothelial hollow. G: to confirm the generated 3D vessels were perfusable, 5-m beads conjugated with FITC were loaded
into one reservoir, and time-lapse images were taken under fluorescence using Axio Observer Z1 microscope. Time interval average was 1.4 s. H:
rhodamine-labeled, full-length adiponectin (Rho-fAd, red) was injected with a concentration of 10 g/ml. Fluorescent images were captured every 6–10 s for
3 min from two or three different fields of view. Three representative images are shown at 0, 40, and 80 s postinfusion. To assess permeability, fluorescent signal
intensity (arbitrary units, AU) was quantified along a linear region of interest (ROI) spanning the microvessel-ECM interface as shown and depicted as a distance
from the ROI origin (). Permeabilized fluorescent signals were observed in the extracellular matrix (ECM) (out of vessel) area over time. Apparent permeability
(Papp) was quantified using ImageJ with measurement from randomly selected ROIs. Hyperglycemia with 25 mM glucose (J) did not change the permeability
of 3 kDa-FITC dextran. However, 70-kDa Texas red dextran (I) and Rho-fAd (K) increased Papp significantly in high glucose (HG)-treated condition. D, E, G,
H: scale bar indicates 100 m. I–K: data presented are means 	 SE. Statistical evaluation was done by Student’s t-test with the values from 15 to 25 ROIs (four
to six different fields of view from two or three devices) for each condition. *P  0.0005. **P 
 0.0001.
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Fig. 4. Reduced claudin-7 (CLDN-7) expres-
sion decreased transendothelial electric resis-
tance (TEER) and increased low-molecular-
weight (LMW) adiponectin movement across
the monolayer of human dermal microvascu-
lar endothelial cells (HDMECs). A: one of the
major components of tight junction proteins,
CLDN-7, was targeted to knock down by
shRNA transfection after 96 h. Transfected
HDMECs were transferred into the trans-
membrane culturing system (0.9 cm2) and
formed a monolayer 72 h after transfection.
B: the cells with lower CLDN-7 expression
(**P 
 0.01; n  3) showed significantly
lower TEER (*P 
 0.05; n  7). TEER was
measured at 96 h after transfection had
started. C: monolayer of CLDN-7 knock-
down HDMECs was used for adiponectin
permeability assay for 24 h. The decreased
CLDN-7 led the adiponectin movement in-
crease, especially in LMW form with statis-
tical significance (*P 
 0.05; n  5). The
values were expressed as means	 SE, and
statistical analysis was performed using Stu-
dent’s t-test.
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ponectin in cerebrospinal fluid is almost completely in the
small trimeric form, and the total amount is only 0.1% of that
in peripheral circulation (27), suggests that the tight blood-
brain barrier restricts movement of adiponectin oligomers.
Conversely, many studies focusing on metabolic effects of
adiponectin have focused on liver, which has a highly fenes-
trated leaky vasculature, and found that the HMW adiponectin
is highly bioactive and correlates well with clinical readouts of
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liver function (5, 38). Hence, this study was designed to use
FMT to investigate distribution of fluorescently labeled adi-
ponectin after systemic introduction in diabetic versus wild-
type control mice. Given the critical need for adiponectin to
access target tissues and the well-established regulatory role of
vascular permeability in both physiology and therapeutics, we
believe this work has widespread relevance.
We used a real-time noninvasive approach to monitor and
quantify the biodistribution of exogenously administered fluo-
rescent adiponectin. The use of FMT as a noninvasive ap-
proach to examine biodistribution of a circulating hormone,
such as adiponectin, has strong advantages (40). The ability to
monitor individual mice noninvasively for time-course studies
vastly reduces the number of animals required and avoids
issues, such as interanimal metabolic variation and variability
in fluorophore injection. In addition, time and expense of
isolating numerous tissues followed by analysis by Western
blot can be a significant limiting factor to the identification of
novel target tissues. Having a clear, temporal, whole body
indicator of kinetics can provide a wealth of mechanistic
insight, potentially leading to new therapeutics. In this study,
we complemented FMT imaging with CT, which offered us
high-resolution anatomical detail to improve the spatial and
temporal localization of adiponectin. Analysis of coregistered
FMT-CT data improves upon methodologies, which offer only
2D fluorescence acquisition. Through 3D analysis, we were
able to precisely quantify fAd-VT750 in the heart through
creation of CT-guided 3D ROIs. This is vital for accuracy, as
many factors can impair rough localization of a fluorophore,
including mouse orientation, variability in organ size, potential
“bleed over” from highly targeted tissues (e.g., liver), and
spatial overlap of several tissues, such as the lungs, heart, and
thymus, from certain mouse orientations. Analysis of our in
vivo findings were substantially corroborated by ex vivo scan-
ning of target tissues and classic molecular biology techniques,
including Western blot analysis and immunofluorescence im-
aging. For fluorescence in vivo imaging of whole body biodis-
tribution, it is important to avoid autofluorescence, which
requires near-infrared (NIR) labeling of a target (2). Probes and
fluorophores are available in this range, from 680 to 750 nm
and 800 nm, offering the potential for some creative multiplex-
ing studies such as cotracking of insulin and adiponectin in
circulation under various disease models. Imaging at 750–800
nm wavelengths completely avoids autofluorescence, and im-
aging at 680 nm only requires the use of low-chlorophyll chow
to minimize confounding gastrointestinal background fluores-
cence.
Using this approach, we studied mice with or without
streptozotocin-induced diabetes. Interestingly, an accumula-
tion of adiponectin occurred in the peripheral tissues, particu-
larly the liver, and to a greater extent in STZD mice. This was
confirmed by quantitative analysis of in vivo FMT images, ex
vivo imaging, and by analyzing tissue homogenates by West-
ern blot. It was also interesting to note that we found no
difference in endogenous adiponectin between control and
STZD animals. As we are interested in the cardioprotective
effects of adiponectin (11, 14), when we focused on myocar-
dial adiponectin, we again found greater levels in STZD mice.
The increased total amount of fAd-VT750 appeared to be
accounted for by MMW, plus HMW and to a lesser extent
LMW oligomeric forms. It is worth noting that the relative
tightness of an endothelial barrier, whether in vivo, ex vivo, or
in vitro, and the amount of change induced by a given treat-
ment (e.g., high glucose), can lead to seemingly contradictory
results, such as the data presented here (Fig. 2E vs. Fig. 4C).
This may be explained through an understanding of protein
flux dynamics at the cell junction level: slight opening of a
tight endothelial barrier may lead to increased flux of only
low-molecular weight proteins, while with a leakier barrier, the
flux of low-molecular weight proteins may already be maxi-
mum. In this case, further opening of a leaky barrier would
manifest as increased flux of only higher-molecular weight
proteins. STZD is a common diabetic animal model, yet data
must be interpreted with caution, since numerous endogenous
changes beyond hyperglycemia may impact vascular permea-
bility (3, 4, 34, 42). It would be of great interest to examine the
same phenomenon studied here in models such as a high-fat
diet feeding or in genetically obese models such as ob/ob mice
(22). Nevertheless, to extend our observations further, we
examined flux of adiponectin upon its addition to isolated
mesenteric vessels from wild-type control or STZD animals.
We observed again that vascular permeability of adiponectin
was higher in STZD vessels. Furthermore, using an endothelial
cell monolayer system in vitro, we found that flux of adiponec-
tin was significantly greater in monolayers cultured in high
glucose media versus normal glucose. Collectively, the data
suggest that in the STZD model, hyperglycemia is likely to be
one of the principal determinants of altered vascular permea-
bility of adiponectin.
In this study, we also focused on alterations in tight junction
proteins as a potential mechanism underlying the effects ob-
served here. We focused on claudin-7 based on the rationale
from previous studies, which showed that shRNA-mediated
reduction in endothelial cell claudin-7 levels increased flux of
adiponectin across endothelial monolayers (9). Indeed, our data
indicated that a decrease in claudin-7 may be one important
alteration leading to increased vascular permeability in STZD
mice. Furthermore, we found ZO-1 was not significantly
changed in STZD hearts, although previously, hyperglycemia
was shown to increase permeability of the blood-brain barrier
(17), and retinal pigment epithelial cells (17, 41) through
downregulation of occludin and ZO-1. Because AdipoR-medi-
ated endocytosis has been shown to have important cellular
signaling consequences, we also believed that this may con-
tribute to a transcellular route of transport (10, 46). However,
the data in Supplemental Fig. S4, showing no significant
change in the level of cardiac AdipoR1 or AdipoR2 after
hyperglycemia in mice or high glucose level in HDMEC,
suggest that this is likely not a major player.
We used advanced in vitro platform of 3D microvascular
networks on a chip to confirm the observation from 2D Trans-
well endothelial monolayer responses in a high-glucose envi-
ronment. Generating endothelial monolayer of 3D vessels with
multiple branches using programmed cellular dynamics in
hydrogel allows one to better mimic in vivo vascular morphol-
ogy (23). Another strength of the showing 3D microvascula-
ture in microfluidic devices is perfusibility, which allows one
to test the functionality of the vessels on a chip, as well as to
better mimic the physiological environment with application of
fluidic shear stress (21, 24, 44). Using paracellular tracers,
many researchers have shown that the basal permeability of
comparably large molecules (40–70 kDa dextran) was lower
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than the permeability of smaller molecules (4–10 kDa dextran)
(13, 18, 20). In this study, using the platform, we confirmed
size-selective transport behavior and showed for the first time
that movement of rhodamine-labeled full-length adiponectin
was significantly impacted by hyperglycemia-mediated altera-
tion of endothelial permeability.
In summary, we have shown that biodistribution of adi-
ponectin can be altered in a diabetic environment. Data from a
combination of temporal noninvasive imaging in mice, isolated
vessels ex vivo and in vitro endothelial cell monolayers suggest
that hyperglycemia increased vascular flux of adiponectin.
We believe this may be an important determinant of adi-
ponectin’s physiological actions and could provide rationale
for further investigation and be exploited from a therapeutic
perspective.
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Abstract
Altered permeability of the endothelial barrier in a variety of tissues has implications both in 
disease pathogenesis and treatment. Glucocorticoids are potent mediators of endothelial 
permeability and this forms the basis for their heavily-prescribed use as medications to treat ocular 
disease. However, the effect of glucocorticoids on endothelial barriers elsewhere in the body is less 
well-studied. Here we investigated glucocorticoid-mediated changes in endothelial flux of 
Adiponectin (Ad), a hormone with a critical role in diabetes. First, we used monolayers of 
endothelial cells in vitro and found that the glucocorticoid dexamethasone increased 
transendothelial electrical resistance and reduced permeability of polyethylene glycol (PEG, 
molecular weight 4000kDa). Dexamethasone reduced flux of Ad from the apical to basolateral 
side, measured both by ELISA and Western blotting. We then examined a diabetic rat model 
induced by treatment with exogenous corticosterone, which was characterized by glucose 
intolerance and hyperinsulinemia. There was no change in circulating Ad but less Ad protein in 
skeletal muscle homogenates, despite slightly higher mRNA levels, in diabetic versus control 
muscles. Dexamethasone-induced changes in Ad flux across endothelial monolayers were 
associated with alterations in the abundance of select claudin (CLDN) tight junction (TJ) proteins. 
shRNA-mediated knockdown of one such gene, claudin-7, in HUVEC resulted in decreased TEER 
and increased adiponectin flux, confirming the functional significance of Dex-induced changes in 
its expression. In conclusion, our study identifies glucocorticoid-mediated reductions in flux of Ad 
across endothelial monolayers in vivo and in vitro. This suggests that impaired Ad action in target 
tissues, as a consequence of reduced transendothelial flux, may contribute to the glucocorticoid-
induced diabetic phenotype.
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Introduction
As the primary barrier to the movement of circulating endocrine factors from the 
bloodstream to the interstitial space, the endothelium plays a critical role in hormone action 
(Kolka and Bergman 2012; Yoon, et al. 2014). Endothelial permeability can significantly 
impact hormone action by preventing or delaying access of the hormone to target tissues 
(Kolka and Bergman 2012; Won, et al. 2011). Transendothelial solute movement can occur 
via the transcellular pathway where solutes are transported across the endothelium cell 
membrane or via the paracellular pathway where solutes passively move through the 
intercellular space between adjacent endothelial cells (Yoon et al. 2014) .Previous work has 
shown that hormone and nutrient concentrations in blood differ from surrounding cells on 
the tissue side of the blood vessel endothelium (Barrett, et al. 2011; Herkner, et al. 2003; 
Yang, et al. 1994).Of note, this has been best documented in the case of insulin where 
concentrations of the hormone are significantly lower in the target tissue than in the 
circulation (Kolka and Bergman 2012).
Glucocorticoids are among the most commonly prescribed anti-inflammatory and 
immunosuppressive medications worldwide (Clark and Belvisi 2012). They are also 
commonly used in oncology treatment (Lin and Wang 2016) and for the treatment of 
macular edema and, more recently, retinopathy (Agarwal, et al. 2015; Zhang, et al. 2014). 
However, glucocorticoids have been shown to have potent effects on restricting endothelial 
transport (Felinski and Antonetti 2005; Witt and Sandoval 2014) and they contribute to the 
development of diabetes at least in part by increasing hepatic glucose production and 
reducing GLUT4 translocation in muscle (Beaudry, et al. 2015) . Yet despite these 
observations, the potential importance of glucocorticoid-induced alterations in the 
transendothelial flux of circulating glucoregulatory hormones such as Ad is unclear.
Ad is one of the most abundant plasma proteins and exists in three different isoforms: low 
molecular weight (LMW; trimer), medium molecular weight (MMW; hexamer) and high 
molecular weight (HMW; oligomer) (Dadson, et al. 2011). Ad has important and beneficial 
anti-diabetic, anti-inflammatory and cardioprotective actions (Arita, et al. 2002; Dadson et 
al. 2011). Ad levels, in particular HMW, are decreased in obese individuals and this 
correlates with development of associated complications, including diabetes and 
cardiovascular disease (Kadowaki, et al. 2006; Peters, et al. 2013). Transendothelial 
movement of Ad across the blood-brain barrier (BBB) into cerebrospinal fluid (CSF) was 
studied and only LMW and MMW were found in the CSF, suggesting that passage of HMW 
complexes were restricted (Kubota, et al. 2007; Kusminski, et al. 2007; Neumeier, et al. 
2007). This may be functionally significant since HMW Ad is often considered to be the 
most biologically active and physiologically relevant form (Dadson et al. 2011; 
Nanayakkara, et al. 2012). A recent study calculated the Stokes radii for the Ad oligomers 
Dang et al. Page 2
J Endocrinol. Author manuscript; available in PMC 2018 November 12.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
and found that endothelial barriers controlled Ad transport in a cell- and tissue-specific 
manner (Rutkowski, et al. 2014). Thus, emerging evidence suggests that Ad action may be at 
least in part mediated by endothelial transport, although whether this is influenced by 
glucocorticoid-induced changes in transendothelial permeability remains unknown.
Given the large size of Ad multimers it seem likely that transendothelial Ad movement is an 
important variable in determining it presence within, and action on, target tissues. Therefore 
we hypothesized that glucocorticoid-induced alterations in transendothelial permeability will 
modulate the transendothelial movement of Ad. In this regard, the objective of this study 
was to examine how glucocorticoid treatment of a cultured endothelium influences Ad flux 
in association with changes in permeability and apical junction protein abundance as well as 
investigate Ad content within the skeletal muscle in a diabetic rat model induced by 
exogenous glucocorticoid treatment. The overall goal of this work was to significantly 
advance our understanding of the glucocorticoid-induced diabetic phenotype by determining 
whether Ad movement out of the circulatory system might play a role in its pathogenesis.
Materials and methods
HUVEC cell culture and treatments
Normal primary human umbilical vein endothelial cells (HUVECs; Pooled, PCS-100–013) 
were obtained from ATCC (Manassas, VA, USA) and grown at 37°C and 5% CO2 on 
uncoated T75 flasks in vascular cell basal medium (ATCC, PCS-100–030) containing 10% 
fetal bovine serum (FBS), VEGF endothelial cell growth kit (ATCC, PCS-100–041) and 
treated with DEX using 2% FBS (both medium were prepared without hydrocortisone 
hemisuccinate), 100 units/mL penicillin and 100 μg/mL streptomycin. Cells were kept 
frozen in medium containing 10% DMSO (Bio-Rad Laboratories Canada Ltd., Mississauga, 
ON, Canada). For experiments, passage 3 was used. Cells were counted using a 
haemocytometer and seeded onto permeable polyethylene terephthalate (PET) filters at the 
base of BD Falcon cell culture inserts (BD Biosciences, Mississauga, ON, Canada) at a 
density of 0.5 × 106 cells/insert.
Dexamethasone (DEX) was obtained from Sigma-Aldrich (Oakville, ON, Canada), and full-
length Ad was produced in-house using a mammalian expression system (i.e. HEK 293 
cells) according to methods described by (Wang, et al. 2002; Xu, et al. 2004). HUVECs 
were treated for 5 days with DEX (1 μM) starting 24 h after seeding cells into inserts, 
HUVECs were treated with DEX added to both apical and basolateral sides of inserts at 
concentrations indicated above
shRNA-mediated knockdown of claudin-7 in HUVEC
We used pGPU6/Neo-claudin-7 shRNA vector with target sequence (5’- 
GGCCATCAGATTGTCACAGAC-3’) (GenePharma Co., Ltd., Shanghai, China). These 
were transfected into HUVEC using Lipofectamine™ 3000 Reagent (Invitrogen, Carlsbad, 
CA, USA) exactly according to manufacturer’s protocol. Non-specific scrambed target 
sequence shRNA vector was used as control. Following selection with 50 ug/ml Neomycin 
(Sigma-Aldrich, Oakville, ON, CA) for 24 hours, cells were seeded onto inserts for analysis 
Dang et al. Page 3
J Endocrinol. Author manuscript; available in PMC 2018 November 12.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
of TEER, examining adiponectin flux or preparation of cell lysates to confirm claudin-7 
knock-down.
Transendothelial electrical resistance (TEER),and [3H]PEG4000 and Adflux
TEER was measured daily using chopstick electrodes (STX-2) connected to an EVOM 
voltohmmeter (World Precision Instruments, Sarasota, FL, USA). As a measure of 
paracellular permeability, apical to basolateral flux rates of [3H] polyethylene glycol at 1 
μCi; 1 h flux(molecular mass 4000 Da; PEG-4000; PerkinElmer, Woodbridge, ON, 
Canada)or Ad (10 μg/mL; 24 h flux) to apical culture medium were determined across 
HUVEC endothelia. [3H]PEG-4000 in basolateral culture medium was detected using a 
liquid scintillation counter, Ad was detected using a mouse Ad ELISA kit (Antibody 
Immunoassay Services, Hong Kong) or Western blot. Permeability measurements were 
expressed according to calculations previously outlined by (Wood, et al. 1998).
L6 and H9C2 cell culture and treatment with HUVEC-conditioned medium
Rat myoblasts and cardiomyocytes at passage 22–30 were grown in α_AMEM(Life 
Technologies Inc., Manassas, MA, USA) and DMEM containing 10% FBS and 1% 
antibiotic-antimycotic (Wisent Inc., St- Bruno QC, Canada). Culture media from the 
basolateral compartment of HUVEC inserts were collected and applied.L6/ H9C2 cells were 
starved with medium containing 0.5% FBS and 1% antibiotic-antimycotic for 3 h prior to 
treatment with HUVEC-conditioned medium.
Quantitative real-time PCR analysis
Total RNA was isolated from control and DEX-treated HUVECs and from soleus skeletal 
muscle using TRIzol Reagent . Extracted RNA was then treated with DNase I and first-
strand cDNA was synthesized using SuperScript III reverse transcriptase and oligo(dT)12–18 
primers (Life Technologies Inc.,Manassas MA, USA). Quantitative real-time PCR (qRT-
PCR) analyses were conducted using gene specific primers. SYBR Green I Supermix (Bio-
Rad Laboratories Canada Ltd.Mississauga, ON, Canada) and a Chromo4 Detection System 
(CFB-3240; Bio-Rad Laboratories Canada Ltd.) Samples were run in duplicate. For all qRT-
PCR analyses, TJ protein mRNA expression was normalized to GAPDH transcript 
abundance. For the expression profile, TJ protein transcripts were expressed relative to 
occludin mRNA. For TJ protein transcripts that were not detected in HUVECs, normal 
human adult kidney cDNA was obtained (BioChain Institute, Inc., Newark, CA, USA) and 
used as a positive control in qRT-PCR reactions. Agarose gel electrophoresis verified single 
qRT-PCR products at predicted amplicon sizes from positive control reactions.
Animal model of diabetes induced by exogenous corticosterone treatment
We used a well-established hyperinsulinemic/hyperglycemic rodent model of chronic 
glucocorticoid treatment (Beaudry, et al. 2013; Beaudry et al. 2015; D’Souza A, et al. 2012; 
Shikatani, et al. 2012; Shpilberg, et al. 2012). Upon experiment cessation, the tibialis 
anterior (TA) and soleus skeletal muscles were excised and immediately frozen in liquid N2 
and kept at −80oC until future analysis.
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Oral glucose tolerance test
Animals were fasted overnight (16 hours), 11 days after pellet implantation, and were 
administered an oral glucose tolerance test (OGTT, 1.5 g/kg body mass) on day 12 using 
glucometer (Bayer One Touch), additional fasted plasma was collected for later analysis of 
insulin concentrations via an ELISA 96-well kit (Crystal Chem, USA). Plasma for 
measurement of Ad concentration was obtained 7 days after pellet implantation at 0800 h 
and assessed using a mouse Ad ELISA kit (AIS, Hong Kong).
Measurement of hydraulic conductivity (Lp) in individually perfused rat mesenteric 
microvessel
Female Sprague-Dawley rats of 220 to 250 g (2 to 3 mo old, Sage Laboratory Animal, PA) 
were used for the experiments. All procedures and animal use were approved by the Animal 
Care and Use Committee at Pennsylvania State University. Inactin hydrate (Sigma) was used 
for anesthesia and given subcutaneously at 170 mg/kg body weight. Microvessel 
permeability was assessed by measuring Lp in individually perfused microvessels, which 
measures the volume of water flux across the microvessel wall. Details have been described 
previously (Yuan and He 2012; Yuan, et al. 2014).
Staining for metachromatic myosin ATPase
To identify skeletal muscle fiber type, a metachromatic myosin ATPase stain was performed 
using a modified protocol (Ogilvie and Feeback 1990). Sections were pre-incubated in an 
acidic buffer (pH=4.25) to differentially inhibit myosin ATPase within the different fiber 
types. In this protocol, type I fibers appear dark blue, type IIa appear light blue and type IIb 
and IIx are not apparent from each other and are classfied as IIb/x. These fibers appear 
almost white and are the largest. Images were acquired with a Nikon Eclipse 90i microscope 
and Q-imaging MicroPublisher with Q-Capture software at 10x magnification.
Immunohistochemistry of Ad and dystrophin in skeletal muscle
Tibialis anterior (TA) from Control and CORT treated rats were cryostat sectioned (10 µm 
thick) for analysis of muscle Ad content. Sections were stained as previously described 
(Krause, et al. 2008). Quantification was performed using Zen 2.0 software. The total Ad 
and dystrophin signal was determined bythe sum of red/green signal intensity obtained 
arbitrary values in the field of view. Diagram view intensity was recorded by the software in 
form of histograms. Intracellular quantification was done on Ad images (without 
dystrophin), images were changed to 8-bits on Image and the arbitrary intensity was 
calculated as mean intensity per area.
Western blot analysis
Control and DEX-treated HUVECs, and L6 or H9C2 cells treated with HUVEC-conditioned 
medium and soleus skeletal muscle were lysed in sample buffer (80 mMTris-HCl (pH 6.8), 
2% (w/v) SDS, 20% glycerol, 3.3% (v/v) β-mercaptoethanol 0.01% w/v bromophenol blue) 
containing protease and phosphatase inhibitors (3 mM EDTA, 10 uM E64, 1 mM Na3VO4, 1 
μMleupeptin, 1 μMpepstatin A, 1 μMokadaic acid and 200 μM PMSF). Apical and 
basolateral HUVEC-conditioned media collected from Ad flux experiments were 
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concentrated with Amicon Ultra-4 Centrifugal Filter Units with Ultracel-30 membranes 
(EMD Millipore, Billerica, MA, USA) and subjected to nondenaturing, nonreducing 
conditions to allow the analysis of the different forms of Ad (HMW >250 kDa, MMW ~180 
kDa, and LMW ~90 kDa). Primary antibodies specific for the following proteins: T-cadherin 
(1:1000, R&D Systems), occludin (OCLN, 1:3000), tricellulin (TRIC, 1:3000), claudin-7 
(CLDN-7, 1:500), CLDN-10 (1:800), CLDN-11 (1:1000), phospho-AMPKα (Thr172) 
(1:1000), phospho-p38 MAPK [pT180/pY182] (1:1000), Ad (1:1000),β-actin (1:1000). 
OCLN, TRIC, CLDN-7, CLDN-10 and phospho-p38 MAPK [pT180/pY182] antibodies 
were obtained from Life Technologies, CLDN-11 and Ad antibodies were purchased from 
EMD Millipore and Signalway Antibody (College Park, MD, USA) respectively, and 
phospho-AMPKα (Thr172) and β-actin antibodies were obtained from Cell Signaling 
Technology (New England Biolabs Ltd., Whitby, ON, CA). Protein detection using 
enhanced chemiluminescence (Bio-Rad) and quantification by densitometry using ImageJ 
analysis software. TJ protein expression was normalized to β-actin, Tubulin protein 
abundance.
Statistical analysis
All data are expressed as mean values ± SEM. A one-way analysis of variance (ANOVA) 
followed by a Student-Newman-Keuls test was used to determine significant differences (P ≤ 
0.05) between groups. When appropriate, a Student’s t-test was also used. All statistical 
analyses were conducted using Prism 5, Excel SigmaStat 3.5 softwares.
Results
Dexamethasone induces endothelial tightening and inhibits Ad movement across 
endothelial cell monolayers
We first investigated the effect of dexamethasone (DEX), a synthetic glucocorticoid, on 
tightness of an endothelial monolayer of HUVECs. Addition of DEX to culture media 
significantly elevated TEER (Fig. 1A) and correspondingly reduced the endothelial 
permeability of the paracellular transport marker [3H]PEG-4000 (Fig. 1B). Similar trends 
regarding permeability were observed in microvessels of DEX-treated rats. DEX treatment 
(n = 4) did not cause a significant reduction in baseline Lp compared to normal control 
group (n = 6), but lowered the mean value from 1.5 ± 0.1 to 1.1 ± 0.2 (× 10−7 cm/s/cm 
H2O). When each vessel was exposed to platelet activating factor (PAF, 10 nM) that is 
known to cause transient increases in Lp(Zhou and He 2011), microvessels in DEX-treated 
rats showed significantly attenuated Lp response. The mean peak Lp value was reduced from 
11.1 ± 1.8 (normal control) to 6.0 ± 0.4(× 10−7 cm/s/cm H2O, Figure 1C). We then assessed 
flux of Ad from the apical to basolateral side of HUVEC monolayer and found a reduced 
total amount of Ad in basolateral media after DEX treatment (Fig. 1D–F). When monitoring 
absolute flux rates in control cells, Ad flux rate was 4.4 ± 0.12 cm s−1 × 10−9 which 
significantly decreased after DEX treatment to 3.2 ± 0.30cm s−1 × 10−9 (Fig. 1D). Following 
a 24 h flux period, Ad levels detected in basolateral media were 64.8 ± 5.7 ng/mL. Using 
Western blotting to examine various oligomeric forms of Ad LMW (~90 kDa), MMW (~180 
kDa) and HMW (>250 kDa), we found that flux of all forms was reduced by DEX (Fig. 
1E&F). Additionally, the functional activity of Ad appearing in basolateral media was 
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confirmed by using this media to treat L6 skeletal muscle cells and H9C2 cells derived from 
rat heart ventricle. In both cell types the media increased AMPK phosphorylation 
(supplementary Figure 1A–B).
Dexamethasone treatment alters transcript and protein abundance of select TJ proteins in 
HUVEC monolayers
A tissue expression profile of transcripts encoding 26 TJ proteins in HUVECs revealed the 
presence of 15 (Fig. 2A). The most abundant transcript was found to be CLDN-11, while 
CLDN-7, CLDN-12 and ZO-1 exhibited relatively high abundance and OCLN, TRIC, 
CLDN-10 and CLDN-15 exhibited moderate levels of abundance (Fig 2A). Transcripts not 
detected in HUVECs included CLDN-3, −4, −5, −8, −9, −16, −17, −18, −19, −23 and −25 
(Fig. 2A & Supplementary figure 1C). Human kidney cDNA was used as a positive control 
for transcripts that were not detected in HUVECs (Supplementary figure 1C). To explore the 
response of TJ proteins to DEX- treatment, we first compared mRNA abundance of 
expressed target genes in HUVECs. DEX increased CLDN-6 mRNA abundance while 
CLDN-2, −20, −22, −24 and ZO-1 mRNA showed significant decreases (Fig. 2B). DEX 
treatment had no significant effect on mRNA encoding OCLN, TRIC, CLDN-1, −7, −10, 
−11 −12 and −15(Fig. 2B). Following DEX treatment, the protein abundance of CLDN-1, 
−7, −11 and ZO-1 was examined and found to be significantly upregulated following DEX 
treatment when compared to the control group (Fig. 2C, D). On the other hand, CLDN-10 
protein levels were significantly decreased when compared with the expression in control 
conditions (Fig. 2C, D). In order to validate the functional significance of Dex-induced 
changes in expression of tight juntion proteins we used shRNA to target claudin-7 and this 
effectively reduced its expression by 71% on average (Fig. 3A). Furthermore, HUVEC with 
reduced levels of claudin-7 showed reduced TEER and a small but significant increase in 
flux of adiponectin from apical to basolateral side (Figs 3B–D).
Examination of changes in transcellular endothelial flux
The possible contribution of transcellular receptor-mediated Ad movement across HUVEC 
monolayers was then investigated by analysis of expression levels of three identified Ad 
receptors. Intracellular Ad content in these cells was detected, although at low level, and 
expression levels did not change significantly with DEX treatment (Fig. 4A). However, DEX 
significantly increased T-cadherin protein abundance (Fig. 4B), but had no effect on protein 
abundance of AdipoR1 and AdipoR2 (Fig. 4C).
Skeletal muscle Ad content in a rat model of exogenous glucocorticoid-induced diabetes
We then examined whether the increased endothelial cell barrier tightness observed after 
DEX treatment would be paralleled in a diabetic rodent model of chronic glucocorticoid 
exposure. As expected based on previously published work (D’Souza A et al. 2012; 
Shikatani et al. 2012; Shpilberg et al. 2012), two weeks of exogenous corticosterone (CORT) 
treatment resulted in severe fasting hyperinsulinemia and impaired glucose tolerance (Supp 
Fig 2A). In addition, CORT treatment caused mild/moderate elevations in fasted blood 
glucose concentrations (5.12± 0.2 mM to 8.3 ± 1.88 mM, Supp Fig 2B) despite the 
significantly increased fasted insulin concentrations (0.76±0.25 ng/ml to 4.68±0.72 ng/ml , 
Supp Fig 2C). CORT treatment also caused a change in skeletal muscle fibre type 
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composition; a switch from predominantly slow to fast-twitch skeletal muscle fibers, within 
the tibialis anterior muscle (Supp Fig 2D).
To explore whether CORT-treatment affects circulating Ad levels, we measured plasma Ad 
levels in these animals before CORT pellet implantation and at 7 days post pellet 
implantation, at 0800h. Circulating Ad levels were unaffected by CORT treatment (Fig 5. 
A). Interestingly, there was an apparent elevation in skeletal muscle Ad mRNA levels (Fig 5. 
B), yet Ad protein content was significantly reduced (Fig 5. C&D). Upon 
immunohistochemical analyses, we also observed that the total amount of Ad was decreased 
in skeletal muscle from the COR-treated rats versus control rats (Fig 5. E–H). Dystrophin, 
was used to assess the structural integrity of the skeletal muscle and was unaffected by 
CORT treatment. Representative images are shown (Fig 5. E) with quantification of the total 
and intracellular Ad signal (Fig 5. G–H). Since CORT-treatment is known to preferentially 
target fast-twitch skeletal muscle (Beaudry et al. 2015), representative images accordingly 
depict smaller IIb/x fiber area (Fig. 4D) within the CORT-treated rats. CORT-treatment was 
also found to cause a significant reduction in individual myocyte size (Fig. 5F).
AdipoR abundance in a rat model of exogenous glucocorticoid-induced diabetes
Both Ad receptor isoforms (AdipoR1 and AdipoR2) genes were expressed in rat soleus 
skeletal muscle and although an apparent increase in AdipoR1 mRNA abundance was seen 
in the diabetic rat model, neither was significantly altered (Fig. 6 A,B). However, a 
significantly increased level of ADIPO-R1 protein (approximately 3.4 fold compared to the 
control) was seen (Fig. 6F). There were no changes in ADIPO- R2 nor in T- Cadherin 
protein levels (Fig. 6E, G).
CORT treatment altered Tight Junction genes in rat soleus skeletal muscle after 2 weeks
We then measured changes in mRNA abundance of tight junction, Cldn-1, −2, −3, −4,−5, 
−6, −7, −9, −10, −11, −12, −24,−14, −15, −19, −20, −22, −23 and Ocln, Tricand Z0–1 were 
found to be no significant changes with in diabetic rat skeletal muscle (Fig. 6C), with only 
Cldn −5, −10, −11, −22 significantly decreased (Fig. 6D).
Discussion
Glucocorticoids are potential mediators of endothelium permeability. Our study was 
designed investigate the its influence on endothelium permeability and consequently the 
changes in Ad movement across the endothelium barrier and the underlying mechanism. 
More recently, a similar proposed mechanism for regulation of Ad action was suggested 
both by us and others (Rutkowski et al. 2014; Yoon et al. 2014). To the best of our 
knowledge, the regulation of this process by glucocorticoids had not been studied before. 
Our vitro model using DEX treated HUVEC and CORT treated rats to integrate the 
established observations that glucocorticoids can restrict paracellular transport across 
various endothelia (Keaney and Campbell 2015; Rao, et al. 2015; Rochfort and Cummins 
2015) with the fact that glucocorticoids, commonly prescribed medications, have numerous 
side effects, including insulin resistance and diabetes (Beaudry et al. 2015). Furthermore, we 
examined whether the emerging phenomenon that transendothelial movement of Ad may 
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regulate the anti-diabetic effects of this hormone and whether this was regulated by 
glucocorticoids (Rutkowski et al. 2014; Yoon et al. 2014). Specifically, our approach 
involved the use of endothelial cell monolayers and individually perfused intact microvessels 
to examine whether glucocorticoid altered Ad flux was through reduced microvessel 
permeability. We also used a rat model of diabetes induced by exogenous glucocorticoid 
treatment to determine changes in Ad content in muscle as well as peripheral insulin 
sensitivity.
As indicated in the introduction, strong rationale for this work comes from previous studies 
with other circulating hormones, most notably insulin. Concentrations of insulin at the cell 
surface have been shown to be very different from those observed in plasma in microdialysis 
experiments (Herkner et al. 2003; Sjostrand, et al. 1999), direct interstitial sampling 
(Bodenlenz, et al. 2005) and lymph measurements (Chiu, et al. 2008; Yang et al. 1994). It 
was noted that insulin-mediated glucose uptake lagged behind the increase in plasma insulin 
(Freidenberg, et al. 1994), whereas in cultured skeletal muscle cells, insulin-mediated 
glucose uptake occurs within 10 min (Somwar, et al. 2001). The time delay seen in vivo 
(Freidenberg et al. 1994) reflects a delay in insulin access to the myocyte which is mediated 
in part via altered paracellular or transcellular endothelial transport. Thus, modification of 
access to skeletal muscle can have major effects on insulin action and metabolism, 
suggesting that reaching the interstitial space is the limiting factor for insulin-mediated 
glucose uptake (Kolka and Bergman 2012). Indeed, delivery of insulin to the interstitial 
space has been shown to be altered by diet (Kubota, et al. 2011).
We confirmed the ability of the synthetic glucocorticoid DEX to alter endothelial transport 
properties, in this case of HUVEC monolayers, as indicated by changes in TEER and 
PEG-4000. Similar effects were observed in DEX-treated rats, where we saw a significant 
reduction of permeability in rat mesenteric venules. We then showed that DEX reduced Ad 
flux across cultured endothelial monolayers by ELISA detection of total Ad content. 
Western blotting of Ad isoforms indicated that all three oligomeric forms of Ad (trimer, 
hexamer and oligomer) were reduced in basolateral media from DEX-treated cells, and 
although the magnitude of change was more evident in the case of LMW adiponectin, all 
isoforms were significantly altered and we do not believe this data infers a preferential 
restriction of LMW flux. This demonstration of restricted flux is important to establish from 
several perspectives. First, many studies have suggested that oligomeric high molecular 
weight complexes of Ad are most tightly correlated with insulin resistance (Liu, et al. 2007; 
Pajvani, et al. 2004). Second, the concept that endothelial transport regulated Ad action was 
also proposed by a recent study which estimated the size of different Ad forms by 
calculating a Stokes radius (Rutkowski et al. 2014). The Stokes radii were 3.96 nm for 
trimeric Ad, 6.01 nm for hexameric Ad and 10.1 nm for various HMW oligomeric forms 
(Rutkowski et al. 2014) and these sizes are likely to be in the range that can be physically 
obstructed or facilitated by changes in endothelial cell tight junction size. Indeed, it was 
concluded that Ad bioavailability and action in target cells was attenuated under stressed 
conditions due to reduced trans-endothelial transport (Rutkowski et al. 2014). We concur 
that regulation of Ad flux across endothelium is particularly relevant since the target tissues 
where Ad mediates its physiological effects have a wide-range of endothelial permeability. 
Liver, for example has highly fenestrated endothelium that may permit the passage of HMW 
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Ad, which has potent effects on hepatic metabolism. In contrast, the central effects of HMW 
Ad may be limited by its transport across the comparatively tighter blood brain barrier (Yoon 
et al. 2014).
The well-established effect of glucocorticoids to restrict endothelial transport has been 
proposed to be mediated via regulation of TJ and adherens junction (AJ) proteins (Blecharz, 
et al. 2008; Felinski and Antonetti 2005). Strands of transmembrane and cytosolic proteins 
form TJ and AJ complexes that regulate permeability between endothelial cells (Gunzel and 
Fromm 2012). Functional characteristics of the vertebrate TJ complex are dependent on the 
variable assemblage of TJ proteins such as occludin (OCLN), tricellulin (TRIC) and in 
particular, claudins (CLDNs) which directly establish the TJ barrier and form the backbone 
of TJ strands, while cytosolic ZO-1 and other cortical TJ proteins provide structural support 
to the TJ complex (Gunzel and Fromm 2012). The CLDN superfamily consists of at least 27 
isoforms in mammals and the incorporation of specific CLDN isoforms in TJs can modulate 
TJ barrier function by making the paracellular pathway tighter or leakier (Gunzel and Yu 
2013). The main observations in our study were increased CLDN-7 and decreased CLDN-10 
protein abundance in HUVEC in response to DEX and these changes may underlie the 
functional properties of paracellular transport limiting Ad flux. Little is known about 
CLDN-7, although CLDN-7 knockout is lethal in murine models and it seems that CLDN-7 
most likely facilitates anion movement across vertebrate epithelia. CLDN-7 was previously 
found to form a complex with the epithelial cell adhesion molecule (EpCAM) which 
enhanced cell-cell interaction (Krug, et al. 2012; Verma and Molitoris 2015) . We suggested 
that the functional role of CLDN-7 in our model is tightening of the endothelium in 
association with an increase in abundance, and that this may help to explain, in part, the 
restricted movement of Ad in DEX-treated HUVEC as well CORT-treated rats. Further 
supporting this idea, a reprevious studies which have found that CLDN-7 (−/−) can cause 
colonic inflammation and enhance the paracellular flux of small organic solutes (Tanaka, et 
al. 2015), as well as observations that CLDN-7 (−/−) results in the presence of intercellular 
gaps below TJs and cell matrix loosening (Ding, et al. 2012). Thus, we used shRNA to target 
claudin-7 in HUVEC and observed that this caused a decrease in TEER and increase in 
adiponectin flux across monolayers, further indicating an important mechanistic role for 
Dex-mediated changes in claudin-7 expression. Interestingly, another group found that 
NLRP3 inflammasome promoted endothelial disruption via production of HMGB1 to 
disrupt the junctions and increased paracellular permeability (Chen, et al. 2015). Finally, 
(Tatum, et al. 2010) reported that urine Na(+), Cl(−), and K(+) were significantly increased 
in CLDN-7(−/−) mice compared with that of CLDN-7(+/+) mice. Taken together, the studies 
outlined above and our data indicate an important functional consequence for CLDN-7 
reduction and compromised epithelial permeability as the result of tight junction disruption, 
and this supports the view that increased CDLN-7 abundance, as seen in these experiments, 
may contribute to endothelial tightening and reduced Ad flux.
In contrast, CLDN-10 isoforms in vertebrate epithelia have been described to impart both 
charge and size selective properties to the paracellular pathway. Previous studies investigated 
the role of CLDN-10 deficient mice using Cre-Lox found that serum phosphate 
concentration was 28% higher and serum Mg2+ concentration was almost two-fold higher in 
cKO mice compared with controls. However, the same study also found that CLDN-10 
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transports molecules in a charged selective manner (Breiderhoff, et al. 2012). To the best of 
our knowledge, Ad is uncharged. Therefore, the transport of Ad is less likely to be affected 
by CLDN-10. Nevertheless, it would be very interesting to explore whether the consistent 
decrease in CLDN-10 observed in this study has a functional role in the modulation of Ad 
transport across the endothelium barrier.
In the glucocorticoid-induced diabetic rodent model used here, a decrease in CLDN-10 
mRNA expression in skeletal muscle was also observed. Although changes in expression 
profiles of other tight junction proteins do not entirely match the changes in HUVEC treated 
directly with DEX, this is not entirely surprising since there are multiple factors impinging 
upon tight junction protein expression in skeletal muscle tissue in vivo.
We believe that reduced paracellular transport is the main mechanism of reduced Ad flux 
observed, yet we also tested possible indicators of altered transendothelial flux (Yoon et al. 
2014). In DEX-treated endothelial cells, there was no major change in ADIPO-R1 or 
ADIPO-R2 mRNA and protein expression, although in skeletal muscle homogenates, 
ADIPO-R1 protein expression levels increased significantly in CORT-treated animals. This 
may reflect a compensatory mechanism to reduced Ad availability in order to increase 
sensitivity to available Ad. We also observed that DEX increased expression of T-cadherin in 
HUVEC. T-cadherin has been identified as a non-functional receptor for Ad (Hug, et al. 
2004). This is in agreement with a previous study showing that DEX enhanced T-cadherin 
expression in human osteosarcoma cells (Bromhead, et al. 2006). One possible interpretation 
of our finding is that binding to endothelial T-cadherin may trap Ad in the vasculature, as 
has recently been proposed (Matsuda, et al. 2015).
We also investigated potential alterations in endothelial transport of Ad in a rodent model of 
glucocorticoid-induced diabetes (Shpilberg et al. 2012). In these rats, we found normal 
circulating Ad levels but significantly reduced total Ad protein content within skeletal 
muscle without an accompanying decrease in muscle Ad gene expression. This suggests less 
flux of Ad from circulation could be a contributory mechanism. Indeed, upon 
immunohistochemical analysis we found reduced Ad content in the interstitial space. 
Although not a direct comparison to the in vitro studies we used here, it suggests that 
skeletal muscle Ad availability, and thus action, may be limited in this animal model 
possibly contributing to its diabetic phenotype (Beaudry et al. 2013; Beaudry et al. 2015; 
Beaudry, et al. 2014; Shpilberg et al. 2012; Yoon et al. 2014).
In conclusion, our study indicates that glucocorticoid-mediated tightening can reduce flux of 
Ad across endothelial monolayers, and that this may be due to alterations in the expression 
profile of tight junction proteins. Furthermore, in a rat model of diabetes induced by 
exogenous glucocorticoids, we observed reduced interstitial and intracellular levels of Ad in 
skeletal muscle. Thus, we propose that reduced Ad action in target tissues, as a consequence 
of reduced endothelial flux from circulation to interstitial space, may contribute to the 
diabetic phenotype occurring after glucocorticoid treatment. Since glucocorticoids are one of 
the most commonly prescribed medications, our discovery of reduced Ad transport in 
response to glucocorticoids is a particularly important and novel finding with potentially far-
reaching consequences.
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Figure 1: 
Effects of DEX on permeability. HUVECs (Human Umbilical Vein Endothelial Cell) were 
seeded onto permeable polyethylene terephthalate (PET) filters and treated with or without 
1µM of DEX every other day in both top and bottom of compartments. Tightness of the 
monolayer was measured on the 5th day of DEX treatment. A) Transendothelial Electrical 
Resistance (TEER). B) [3H]PEG-4000 permeability across HUVEC monolayer. C) 
Measurements of hydraulic conductivity (Lp) in individually perfused mesenteric 
venulesfrom normal (n = 6) and Dex-treated(n = 4) rats. DEX treatment significantly 
attenuated the Lp responses to PAF that was known to cause transient increases inLp. D–F) 
10 µg of full-length Ad was added onto the apical side. After 24 hrs, the medium on 
basolateral was collected. D) Total Ad amount was quantified using ELISA. E) The 
collected basolateral medium was concentrated and separated by PAGE. 3 forms of Ad are 
labeled as LMW (~90 kDa), MMW (~180 kDa), HMW (>250 kDa). F) Representative 
Western blot for full-length Ad flux across control and Dex-treated monolayers. Data are 
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expressed as mean values ± SEM (n = 4–8). *Significant difference (P ≤ 0.05) from control 
(Con) group.
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Figure 2: 
Effect of DEX on Tight Junction Components. A) mRNA abundance by qRT-PCR analysis. 
HUVECs grown to confluence on permeable PET inserts. Total RNA was isolated from 
control cells on the 5th day. Transcript abundance was normalized to GAPDH and each gene 
examined was expressed relative to OCLN transcript abundance. B) TJ transcript levels in 
DEX-treated cells were normalized to GAPDH, and expressed relative to the control group 
(Blue - increasing compared to control; Green- decreasing compared to control). Data are 
expressed as mean values ± SEM (n = 3–5). C) Protein abundance in HUVECs grown on 
cell culture inserts. Protein abundance were normalized toβ-ACTIN, and expressed relative 
to the control group. D) Representative Western blots of CLDN- 1, −7, −10, −11, −15, TRI, 
OCC, Z0–1. Data are expressed as mean values ± SEM (n = 3–8). * indicates significant 
difference (P ≤ 0.05) from control (Con) group.
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Figure 3: 
Knockdown of claudin-7 alters transendothelial electrical resistance and adiponectin flux. 
We used shRNA to reduce levels of claudin-7 in HUVEC and average efficiency of 
knockdown was 71% with a representative Western blot shown in A. In cells transfected 
with scrambled (Control) or claudin-7 shRNA we then tested TEER (B) and flux of 
adiponectin with representative Western blot shown in C and quantitation in D. In B and D 
values are mean ± SEM (n = 3) and *indicates significant difference (P ≤ 0.05) from control 
group.
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Figure 4: 
Expression of Ad and its receptors in HUVEC. A) Ad expression in HUVECs treated with 
DEX after 5 days. B) T- CADHERIN expression in HUVECs with DEX treatment. C) 
ADIPO -R1/ -R2 expression in HUVECs. Data are expressed as mean values ± SEM (n = 3–
6). *indicates significant difference (P ≤ 0.05) from control (Con) group.
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Figure 5: 
Ad level in CORT treated animals. A) Using ELISA, circulating Ad was calculated in 1 
week treated rat serum. B) Ad mRNA expression after 14 days of CORT. C&D) 
Representative Western blotting and quantitation of reduced Ad (~30 kDa) in soleus skeletal 
muscle. E) Immunohistochemical detection of dystrophin (green), Ad (red) in skeletal 
muscle isolated from rats after 2 weeks of CORT treatment, together with quantitation in F. 
G) Quantification of changes in intracellular Ad levels and H) cell number. Quantification of 
Ad shown as the intensity expressed per cell in arbitrary units and are expressed as mean 
values ± SEM (n = 3–5).* indicates significant difference (P ≤ 0.05) from control (Con) 
group.
Dang et al. Page 21
J Endocrinol. Author manuscript; available in PMC 2018 November 12.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Figure 6: 
Ad receptor expression in skeletal muscle. Rats were treated with CORT for 2 weeks. A,B) 
mRNA expression of Ad and its receptors after 14 days of CORT. Data are expressed as 
mean values ± SEM (n = 4–5). C–D) mRNA profile of tight junction in soleus skeletal 
muscle isolated from 2 weeks CORT- treated rats. mRNA abundance by qRT-PCR analysis. 
Transcript abundance was normalized to GAPDH mRNA abundance, and mRNA abundance 
for each gene examined was expressed relative to control group transcript abundance. 
Control group gene transcript were normalized to 1. C) mRNA profile of TJ that are 
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increased after 2 weeks CORT treatment compared to control. Blue- CORT- treated, Red- 
Control. D) TJ genes that are decreased after 2 weeks of CORT treatment. . E–G) Protein 
expression in soleus. E) T- CADHERIN. F) Ad receptor 1. G) Ad receptor 2. Data are 
expressed as mean values ± SEM (n = 3). * indicates significant difference (P ≤ 0.05) from 
control group.
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Altered Transendothelial Transport of Hormones as a 
Contributor to Diabetes
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Department of Biology, York University, Toronto, ON, Canada 
The vascular endothelium is a dynamic structure responsible for the separation and regulated movement of biological material 
between circulation and interstitial fluid. Hormones and nutrients can move across the endothelium either via a transcellular or 
paracellular route. Transcellular endothelial transport is well understood and broadly acknowledged to play an important role in 
the normal and abnormal physiology of endothelial function. However, less is known about the role of the paracellular route. Al-
though the concept of endothelial dysfunction in diabetes is now widely accepted, we suggest that alterations in paracellular trans-
port should be studied in greater detail and incorporated into this model. In this review we provide an overview of endothelial 
paracellular permeability and discuss its potential importance in contributing to the development of diabetes and associated com-
plications. Accordingly, we also contend that if better understood, altered endothelial paracellular permeability could be consid-
ered as a potential therapeutic target for diabetes.
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INTRODUCTION
Structure and function of endothelium
A monolayer of endothelial cells lines the entire circulatory 
system of the body. This endothelium acts as a barrier which 
regulates the exchange of hormones, proteins and small mole-
cules between the vascular compartment and the interstitial 
space [1,2]. The actions of a hormone or nutrient on a target 
tissue is implicitly dependent upon the ability of these factors 
to gain access to the target and numerous studies have indicat-
ed that hormone and nutrient concentrations in blood differ 
from those surrounding cells on the tissue side of the blood 
vessel endothelium [3-11]. In this regard, it is our contention 
that the significance of the endothelium as a regulator of hor-
mone and substrate access to target tissues is often underap-
preciated. Endothelial permeability can be regulated by two 
distinct pathways: 1) the transcellular pathway where solutes 
are actively transported across the endothelium, primarily via 
caveolae-mediated transcytosis; or 2) the paracellular pathway 
where solutes passively move through the intercellular space 
between adjacent endothelial cells (Fig. 1). 
TRANSCELLULAR TRANSPORT
The transcellular movement of solutes involves energy-depen-
dent trafficking of vesicles across the endothelium [2]. This of-
ten requires their recognition by receptors in caveolae on the 
luminal surface of the endothelium, may involve vesiculo-vac-
uolar organelles or occur via transcellular channels [2]. Caveo-
lae, cholesterol- and sphingolipid-rich non-clathrin-coated 
pits, are abundant in endothelial cells. After ligand binding to 
receptors in caveolae, dynamin-mediated endocytosis occurs 
followed by vectorial transport and fusion of the vesicle with 
basolateral membrane, resulting in the release of contents by 
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exocytosis [2]. As a general concept, transcellular vesicle traf-
ficking is important in the transport of larger macromolecules 
across the endothelium since the paracellular route is typically 
capable of restricting passage of solutes larger than 3 nm in ra-
dius [12,13].
PARACELLULAR TRANSPORT
The paracellular mode of transport across endothelia depends 
upon concentration gradients between blood and interstitial 
fluid. One regulatory mechanism of paracellular movement 
involves tight junctions (TJs) which are composed of strands 
of transmembrane and cytosolic proteins that closely control 
paracellular flux and have been established to be important in 
regulating hormone transport [4,12,14]. As a component of 
the cell-cell junction of endothelia, the TJ provides a selective 
barrier to solute movement between cells [13]. The permselec-
tivity of the TJ barrier is dependent on the variable assemblage 
of TJ proteins that comprise the complex. Proteins such as oc-
cludin, tricellulin, and claudins directly establish the TJ barrier 
and form the backbone of TJ strands while the cytosolic pro-
teins, such as ZO-1, provide structural support to the TJ com-
plex. The incorporation of specific TJ protein isoforms can en-
hance TJ barrier function (i.e., make TJs tighter) or form chan-
nels to increase TJ permeability (i.e., make TJs leakier) [13]. 
Importantly, skeletal muscle and heart vasculature have con-
tinuous endothelium with TJs between cells (Fig. 2) [15,16]. 
However, the liver and spleen have a discontinuous endotheli-
um with large holes, which allow rapid equilibration of plasma 
with the underlying tissue [15,16]. It was suggested that this 
expedited exposure of the liver to plasma solute changes may 
partly explain its earlier susceptibility to insulin resistance [17]. 
Indeed, the precise architecture of TJs varies between different 
vascular beds, with TJs being either dominant at the apical point 
Paracellular transport
Features
• Movement between cells
• Passive
• Driven by gradients
•  Regulated by tight and 
adherens junctions
Transcellular transport
Features
• Movement across cells
• Driven by active processes
•  Involves transport proteins, 
pumps, receptors
Various molecules
Blood ve
ssel
Fig. 1. Routes of transendothelial transport. A schematic repre-
sentation of paracellular and transcellular routes for transport 
of blood-borne hormones and solutes to interstitial space of 
underlying tissue.
Fig. 2. Diversity of paracellular transport characteristics in different vascular beds. The size and structure of tight junctions varies 
significantly between different tissues and in this figure we summarize this by defining three arbitrary categories of leaky, moder-
ately tight and tight endothelia. The typical resistance values associated with these definitions and examples of tissues where each 
category of endothelium is characteristic is shown. N/A, not applicable.
Tight endothelium
>100 Ωcm2
Moderately tight endothelium
40-100 Ωcm2
Leaky endothelium
<40 Ωcm2
• Tissue types: Blood brain barrier
• Pathological condition: Inflammation, vasodilation
• Tissue types: Skeletal muscle, heart
• Pathological condition: N/A
• Tissue types: Liver
• Pathological condition: Hypertension, other
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of intercellular space or intermingled with adherens junctions 
(AJs). Therefore, there is no doubt that transendothelial para-
cellular flux in certain vascular beds is more susceptible to 
changes in TJ composition and structure. Furthermore, chang-
es in paracellular transport leading to endothelial hyperper-
meability is a significant problem in vascular inflammation as-
sociated with diabetes, cancer, ischaemia-reperfusion injury, 
thrombisis, trauma, sepsis, and adult respiratory distress syn-
drome [18]. Importantly, despite the tremendous interest in 
adipokines over recent years very few studies have examined 
the critical step whereby and factors secreted by adipose tissue, 
or other tissues, must enter the circulation via capillaries or 
lymph. Paracellular movement is very likely to be a major reg-
ulatory step in this process. Indeed, it has been demonstrated 
that lymph/capillary partitioning of adipokines is dependent 
upon their molecular size and proposed that this will have im-
portant ramifications for their regional and systemic distribu-
tion and subsequent physiological effects [19].
 It is also important to realize that crosstalk exists between 1) 
transcellular and paracellular routes of transport across endo-
thelia and 2) TJs and AJs of endothelia. An example of the for-
mer is that in caveolin-1 knockout mice, or upon siRNA-me-
diated reduction of caveolin-1, altered TJ assembly in small 
capillaries and veins increased paracellular transport of albu-
min [20-22]. In the latter case, it has been shown that vascular 
endothelial (VE)-cadherin mediated signaling can regulate 
the expression of TJ proteins and consequently alter barrier 
function [2]. 
 Indeed, evidence suggests that AJs also play a crucial role in 
regulating vascular permeability. They are comprised of calci-
um-dependent VE-cadherin in complex with a range of inter-
acting partners, such as β-catenin and p120-catenin [2] and 
the expression of VE-cadherin is a specific early developmen-
tal marker for endothelial lineage. Deletion of the VE-cadherin 
gene induces embryonic lethality due to early collapse of the 
vasculature [23]. Increased vascular permeability occurs when 
VE-cadherin homophilic binding is inhibited. AJ stability is 
also critically regulated by phosphorylation [2]. More specifi-
cally, phosphorylation of VE-cadherin at catenin binding sites 
induced internalisation and thus alterations in vascular per-
meability. Interestingly, recent work demonstrated that phos-
phorylation of these residues (tyrosine 658 and 685 of VE-cad-
herin) occurs constitutively in veins but not arteries, correlat-
ing with enhanced leakiness in venous vessels [24]. Further-
more, single point mutations in VE-cadherin (Y658F and 
Y685F) reduce paracellular permeability by blocking internal-
isation of VE-cadherin [24].
ENDOTHELIAL DYSFUNCTION IN 
DIABETES
The concept of endothelial dysfunction in diabetes is well es-
tablished [25]. However, this typically refers to vascular func-
tions independent of transendothelial solute flux. The endothe-
lium is also a dynamic interface that responds to various stimu-
li and synthesizes and liberates vasoactive molecules such as ni-
tric oxide, prostaglandins and endothelin. Accordingly, vascu-
lar complications in diabetes include outcomes occurring in 
large (atherosclerosis, cardiomyopathy) and small (retinopathy, 
nephropathy, neuropathy) vessels [26]. We believe that diabe-
tes-induced deleterious alterations in paracellular solute move-
ment also represents a form of endothelial dysfunction which 
should be fully characterized to establish its physiological sig-
nificance.
STUDIES ON TRANSENDOTHELIAL 
TRANSPORT OF HORMONES
Transport of insulin has been perhaps the best studied exam-
ple. Insulin concentration at the target cell surface has been 
shown to be very different from that in plasma by approaches 
including microdialysis [7,8], direct interstitial sampling [9], 
and lymph measurements [5,6]. Furthermore, early temporal 
studies have demonstrated that insulin-mediated glucose up-
take in muscle lags behind increases in plasma insulin [27], In 
contrast, when using cultured skeletal muscle cells, the addi-
tion of recombinant insulin has been shown to stimulate glu-
cose uptake almost immediately (maximal at~10 minutes) 
[28]. The time delay seen in vivo has led to the suggestion that 
reaching the interstitial space is the limiting factor for insulin-
mediated glucose uptake [14]. Thus, modification of access to 
skeletal muscle can have major effects on insulin action and 
subsequent metabolism [14,29]. Indeed, the efficiency and ex-
tent of insulin delivery to the interstitial space can be inhibited 
physiologically by diet [30]. The mechanism via which insulin 
crosses the endothelium is at least in part via the paracellular 
pathway and for more information on this topic readers are 
referred to recent excellent review articles by Kolka and Berg-
man [14,31].
 Recent years have seen great interest in the role of adipo-
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nectin in the pathophysiology of diabetic complications [32-
34]. Numerous studies have now established that adiponectin 
can act on various targets to mediate antidiabetic, anti-inflamma-
tory, antiatherosclerotic, and cardioprotective effects [32,34,35]. 
Thus, enhancing adiponectin action is considered as a therapeu-
tically beneficial strategy. Adiponectin circulates in the blood as 
three multimeric complexes; low molecular weight (LMW; 
trimer), medium molecular weight (MMW; hexamer) and 
high molecular weight (HMW; oligomer), and in obese and 
diabetic patients reduced circulating levels of adiponectin 
have been observed. In addition, cleavage of adiponectin by 
leukocyte derived elastase generates a C-terminal globular 
fragment of adiponectin which mediates important functional 
effects. It is likely that delivery of adiponectin to the interstitial 
space is a major, yet underestimated, determinant of its func-
tion. Given the size range of the biologically active forms of 
adiponectin (16 kDa for globular form and >500 kDa for 
HMW) there is considerable potential for selective paracellu-
lar transport of adiponectin, particularly in different vascular 
beds. HMW adiponectin is often considered to be the most 
biologically active and most relevant form with respect to the 
metabolic syndrome, and we speculate that given the large size 
of the HMW form, transendothelial movement may prove to 
be a significant rate-limiting step in its physiological actions 
(Fig. 3). Indeed, it has been proposed that HMW adiponectin 
mediates beneficial metabolic effects primarily by acting on liver 
[34], whereas the globular form is thought to have more potent 
metabolic effects in skeletal muscle [33]. These observations 
could be explained by the leaky and moderately tight paracellu-
lar barriers present in vascular beds of these respective tissues, 
although this is likely an oversimplification (Fig. 3). As far as we 
are aware, no studies have directly examined the paracellular 
movement of adiponectin in skeletal muscle and liver.
 Studies of adiponectin movement across the blood-brain 
barrier (BBB) have indicated that only LMW and MMW, but 
not HMW forms were found in cerebralspinal fluid [36-38]. 
Surprisingly, there are only a few studies examining interstitial 
adiponectin levels. One found that interstitial concentrations 
of adiponectin in human adipose tissue were ~25-fold lower 
than plasma [39] while the other found that exercise increased 
interstitial adiponectin levels, which were around 20% of plas-
ma concentration [40]. We hypothesize that the magnitude of 
gradient between plasma and interstitial levels of adiponectin 
in skeletal muscle may be higher due to existence of a tighter 
endothelial barrier within the muscle vasculature. Indeed, this 
may be highly significant as it has been shown that hyperinsu-
linemia differentially affects the compartmental (interstitial 
and circulating) distribution of the adiponectin complexes in 
lean and insulin-resistant, obese individuals [41]. We have re-
cently shown that adiponectin moves across cultured endothe-
lial monolayers via a paracellular route and that this movement 
was reduced by hormonal or physical manipulation of TJs.
TJ COMPOSITION AND PROTEIN 
EXPRESSION IN DIABETES
Studies examining changes in TJ composition and protein ex-
pression in diabetes have not been extensive but have so far 
yielded numerous consistent observations in the study of dia-
betic complications. For example, reductions in ZO-1 have been 
observed in kidney glomeruli, the retina, BBB and intestine of 
various diabetic models [42-46]. Localization of ZO-1 in glom-
eruli was also investigated by electron microscopy and found 
to redistribute from the podocyte membrane to the cytoplasm 
in the diabetic kidney [47]. Several reports have indicated that 
both occludin and claudin-5 were reduced in diabetic retina 
or BBB [44-46,48,49]. Hence, expression or localization of TJ 
proteins appear to be susceptible to a diabetic environment and 
contribute to complications such as retinopathy and nephrop-
athy. More widespread analysis is now needed, particularly in 
metabolically active tissues. Knockout mouse models have 
TJ tightness
Target tissue
fAd
gAd
Interstitial 
fluid
Fig. 3. Paracellular movement of adiponectin. A conceptual 
model showing the potential significance of paracellular tran-
sendothelial movement of adiponectin. When vascular endo-
thelium is leaky (left side) there is significant flux of all forms 
of adiponectin from bloodstream to interstitial space. Howev-
er, as endothelium becomes tighter there is likely to be a gradi-
ent of decrease in high molecular weight or other multimeric 
forms of adiponectin whereas the smaller globular fragment 
of adiponectin may still be able to access underlying target tis-
sue such as skeletal muscle. TJ, tight junctions; fAd, full length 
adiponectin; gAd,  globular adiponectin.
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been generated for various TJ proteins, including occludin and 
claudin-1, 2, 4, 5, 7, 9, 11, 14, 15, 16, 18, and 19 [50-63]. Little 
to no information was given regarding their metabolic pheno-
type, however in one study using Cldn2−/−Cldn15−/− double-
knockout mice the animals died from malnutrition related to 
defective absorption of glucose, amino acids and fats [63]. 
These models may prove valuable in elucidating the significance 
of alterations in transendothelial hormone flux in determining 
metabolic dysfunction in diabetes.
THERAPEUTIC POTENTIAL OF TARGETING 
ENDOTHELIAL TRANSPORT
Based on the above description of the importance of endothe-
lial transport in diabetes, it is evident that developing thera-
peutic strategies which manipulate paracellular flux may prove 
useful. Indeed, a literature review indicates that various agents 
are already available; such as peptides which bind to integral 
TJ proteins, siRNA and antisense oligonucleotides targeting TJ 
proteins, various toxins, lipids, and activators or inhibitors of 
kinases and phosphatases that regulate junction assembly and 
function have all been shown to regulate paracellular permea-
bility [64]. Nevertheless, there is an innate risk in therapeutics 
which globally alter transendothelial permeability and so it 
will be desirable to elicit changes in a localized or tissue-spe-
cific manner, or to targeting specific components of TJs which 
allow more controlled and selective changes in permeability 
[65]. One example of a current therapeutic approach targeting 
TJs is the use of glucocorticoids as a locally applied treatment 
for diabetic retinopathy. The mechanism of action is thought 
to involve, at least in part, restoration of barrier function in the 
retinal vasculature by modifying TJ composition and structure 
[66]. Therefore, it is attractive to speculate that controlled ma-
nipulation of paracellular transport may be applicable to im-
proving metabolic dysfunction in diabetes.
CONCLUSIONS
The endothelial monolayer is an important rate-limiting de-
terminant of hormone and substrate access to target tissues. 
Previous studies focusing on insulin suggest that impaired de-
livery of insulin from plasma to interstitial space in obesity 
may contribute to metabolic insulin resistance and diabetes. 
Since adiponectin is known to mediate beneficial antidiabetic 
effects, and the molecular weight of biologically active forms 
of adiponectin ranges widely, we propose that paracellular 
transport may be a major determinant of transendothelial adi-
ponectin flux. In particular, the research community has often 
accepted that fact that the HMW oligomeric form of adipo-
nectin targets liver and not muscle whereas the small globular 
portion has ‘more potency’ in skeletal muscle. This was initial-
ly attributed to the higher binding affinity of globular fragment 
of adiponectin to skeletal muscle cell membranes which were 
thought to express more adiponectin receptor AdipoR1 iso-
form. However, such data are not consistent and easier access 
of the smaller globular adiponectin across the relatively tight 
endothelial monolayer found in skeletal muscle vasculature, in 
comparison with liver, may be significant. Thus, TJ-mediated, 
or AJ-mediated, alterations in adiponectin access to tissues 
from the vasculature are likely to be of important functional 
significance. Numerous studies in kidney and retina have in-
dicated that expression of various TJ proteins is altered in dia-
betes; however, the changes in metabolic target tissues of adi-
ponectin and their physiological significance still need to be 
established. The principal mechanisms responsible for altered 
TJ composition and structure in diabetes must also be eluci-
dated, with likely mediators including hyperglycemia, hyper-
insulinemia, free fatty acids or tumor necrosis factor-α. 
 Overall, the paracellular permeability of the endothelial bar-
rier is a tightly regulated process which can be dynamically 
adjusted in response to various mediators. The potential con-
tribution to metabolic dysfunction in diabetes is apparent yet 
the precise significance has likely been somewhat underesti-
mated. We believe that further investigation of TJ-mediated 
changes in hormone or substrate flux in diabetes and charac-
terization of their functional significance will shed additional 
light on the pathophysiology of disease and identify potential 
therapeutic opportunities.
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